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To determine the role of candidate gene polymorphisms in patients who 
sustained myocardial infarction at a young age and examine their relationship, 
if any, to risk factors. Since angiotensin IT is known to play a 
pathophysiological role at the myocardial and vascular level, the genes to be 
studied are those regulating the renin angiotensin system and tissue 
metabolism. 
Design: 
The risk factors and genetic profile is described in 117 young Indians with 
myocardial infarction recruited over a period of thirty months (Dec 1997 -Jun 
1999). Controls comprised 80 normal subjects with no clinical evidence of 
coronary heart disease (CHD) and with a normal effort response. 
The key features of this study are the selection of young subjects with 
myocardial infarction, (mean age 43 ± 6.8 years) in whom the possibility of a 
genetic basis for the disease was felt to be more likely since the confounding 
effect of age as a risk factor was reduced. 
viii 
Setting: 
Patients recruited 3 -12 months after myocardial infarction from Addington 
Hospital, Durban. This hospital subserves the Indian community in the north 
of Durban. The majority of patients were from the Phoenix settlement area. 
Results: 
1 The clinical profile of the young Indian with myocardial infarction is a young 
man, slightly overweight with a high prevalence of risk factors, particularly 
smoking and diabetes, coupled with sedentary behaviour and risk-prone 
dietary patterns characterised by high red meat intake and low fruit and 
vegetable consumption, resulting in increased BMI and W IH ratios. 
2 There were no differences in the patterns of gene polymorphism in the renin-
angiotensin system between the study and control groups. This fmding 
extended across all candidate gene loci studied i.e. those involving 
aldosterone, G-protein, TGF-~ and homocysteine metabolism. Serum 
triglycerides, haemoglobin Al C and urine microalbumin levels were elevated 
in the probands together with low HDL-C levels (p = 0.001). 
3 A striking fmding of this study was the substantial proportion of patients found 
to have diabetes mellitus, totalling 47% of the proband group. Of the 53 
diabetic patients, (45 males and 8 females) four (3 males, 1 female) had 
impaired glucose tolerance. Cigarette smoking, a positive family history of 
hypertension/diabetes and a family history for premature CHD emerged as 
IX 
important risk predictors for MI. 
Conclusion: 
This study, the ftrst to report candidate gene polymorphisms in young Indians 
with coronary heart disease, has shown no obvious association between the 
genetic loci studied and acute myocardial infarction. Instead a high prevalence 
of risk factors, particularly smoking and diabetes mellitus, coupled with 
coronary-prone behavioural patterns was observed. 
In the light of these fmdings, genome-wide screening of unaffected siblings of 
subjects with early onset CHD cannot be recommended in this population until 
common polymorphisms can be clearly identified as risk factors. Indeed this 
study again supports the dire need for early, school level, education in 
behavioural lifestyle patterns and disease predisposition. The Indian 
community is a very high-risk group who should be targeted, not for 
secondary, but for primordial disease prevention measures. 
The study does not rule out the role of other candidate gene polymorphisms in 
the pathogenesis of CHD in these subjects. The high prevalence of diabetes 
and insulin resistance suggests that studies of genes regulating glucose and 
lipid metabolism should be pursued. Such candidate genes should include 
genes for lipoprotein lipase and Paraoxonase polymorphisms which may 
explain the dyslipidaemia patterns in this group. 
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1. Pathogenesis of Coronary Artery Disease: 
In recent years great strides have been made in elucidating the pathogenesis of 
coronary heart disease (CHD). Although the role of cardiovascular risk factors has 
emerged as central to the development of CHD (Kannel et aI, 1976) it is now 
known that atherosclerosis is a disease of multiple aetiology resulting from a 
complex series of molecular and cellular changes that begin in the intima of the 
arterial wall. Furthermore, it is now recognised that the function and activity of 
cellular components within the plaque are a more important determinant of acute 
events (unstable angina, myocardial infarction) than the degree of stenosis of the . 
arterial lesion (St Clair, 1997). Thus, while risk factors undoubtedly contribute to 
disease development, other trigger factors at a cellular level, precipitate acute 
coronary events in patients with atherosclerotic coronary disease. 
Furthermore, differences in the prevalence of the established atherogenic 
cardiovascular risk factors such as hypertension, smoking and 
hypercholesterolaemia do not fully account for the variations in geographical 
prevalence, the severity of CHD, the age at presentation or ethnic predisposition to 
disease development (Whitty et ai, 1999, HelIer et ai, 1984). 
2. Epidemiology in South Asians 
Of all ethnic groups people of Indian origin have been shown to have one of the 
highest mortality rates for CHD (Balarajan, 1991). CHD has now become a major 
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public health problem in South African Indians (Seedat et aI, 1990, 1993). Local 
studies show that there is an alarming increase in the younger age group (20-39 
years), affecting men more than women (Sewdarsen et aI, 1990, 1991). 
Risk factors for CHD have been well documented in the South African Indian 
(Seedat et aI, 1990, Sewdarsen et aI, 1991). Smoking, diabetes and a family 
history have been identified as important risk factors in this community (Seedat et 
aI, 1990). A prevalence rate of 15,3% for CHD has been linked to the presence of 
at least one major risk factor in half the number of patients. In addition, 
hypertension was present in 19% of a house-to-house survey of 1000 Indians and 
in another study almost half of 620 male survivors of myocardial infarction had 
abnormal cholesterol levels > 6.5 mmolll (Sewdarsen et aI, 1991). Smoking was 
the commonest risk factor (79%) in young males. 
The rate of premature CHD has been documented to be up to 3 times higher in 
Indians when compared with subjects of similar age in the Western world (Lowry 
et ai, 1991). Epidemiological observations suggest that environmental factors play 
a significant role in the pathogenesis of premature CHD in Indians (Rajadurai et 
ai, 1992). Urbanisation as well as the westward migration of Indians appear to be 
associated with increased prevalence of CHD in Indians (Klatsky et aI, 1993, Enas 
et ai, 1992). A variety of environmental factors in the Western world might play a 
potential role in increasing the risk of CHD among the migrant Indians. It has 
been demonstrated that Indians living in the Western world have an increased 
incidence of obesity, diabetes, hypertension and emotional stress (McKeigue et ai, 
1991). Although the precise reasons for these metabolic abnormalities are not 
entirely clear it has been suggested that dietary habits (generally rich in 
calories/carbohydrates) in association with a lack of physical activity might be 
responsible for some of these findings. 
Recent studies have demonstrated that serum HDL cholesterol levels are generally 
low and serum triglyceride levels are high among Indians with premature CHD 
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(Krishnaswami et aI, 1989). There is evidence that these patients have insulin 
resistance which is manifest by the presence of hyperinsulinaemia (Seedat et aI, 
1993, Mckeigue et aI, 1993, Bhatnager et aI, 1995) glucose intolerance, and 
truncal obesity. In addition, some studies have suggested that increased levels of 
lipoprotein (a) [Lp(a)] might also play a role in premature CHD (Scanu, 1992, 
Lowry et aI, 1991). A direct link between the metabolic abnormalities, the lipid 
levels and the increased risk of premature CHD in Indians, has not been 
established; and whether these abnormalities are genetically modulated has also 
not been shown. 
3. Pathogenesis of Premature Coronary Atherosclerosis: 
The hypothesis that atherosclerosis is a 'response to injury' is now generally 
accepted and can be summarised as follows: 
a) Many factors damage and activate the endothelium of the vessel wall. These 
are the major risk factors for atherogenesis i.e. hyperlipidaemia, hypertension, 
diabetes, smoking and ischaemia. 
b) Endothelial dysfunction leads to increased permeability so that lipids (low 
density lipoprotein particles) and circulating cells (monocytes and 
lymphocytes) enter the subendothelial space and form the initial characteristic 
lesion of atherosclerosis, the fatty streak. 
c) As cell numbers increase together with lipid accumulation there is increased 
endothelial disruption leading to thrombogenic surfaces to which platelets 
adhere. 
d) The cellular elements within the plaque can themselves release growth 
modulatory factors leading to proliferation of smooth muscle cells and 
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fibroblasts (fibrous plaque) and finally to the complex advanced lesion - the 
atherosclerotic plaque. Ross (1993) has described atherosclerosis as an 
'inflammatory fibroproliferative process'. It is thought that lesions with large 
amounts of lipid are particularly unstable and liable to rupture leading to 
thrombosis and vessel occlusion, causing ischaemia and manifesting as a 
clinical event, the acute coronary syndrome (ACS) (Fuster et al, 1999). 
These syndromes (ACS) include unstable angina, non-q wave myocardial 
infarction, ST-segment elevation, myocardial infarction and sudden death. 
Unstable angina and non-q wave MI generally result from rupture of 
atherosclerotic plaque in the coronary arteries. The term, acute coronary 
syndrome, is therefore a misnomer, when one considers that the process is a 
chronic syndrome with exacerbations leading to the formation of occlusive 
thrombus on minor as well as on critically stenotic lesions. Such episodes are 
temporary or clinically silent but incorporation of thrombus contributes to the 
development of a complex plaque. In q wave myocardial infarction larger 
plaque fissures result in the formation of a persistent thrombus. Abrupt 
cessation of blood flow for more than an hour results in transmural recrosis 
(Fuster et al, 1999). Myocardial infarction therefore usually results from 
thrombotic events triggered by rupture of advanced atherosclerotic lesions. 
The composition of a plaque influences the likelihood of rupture, as fatty 
lesions are more likely to rupture than more fibrous lesions. Rupture 
frequently occurs at edges of these lesion, which are fatty in nature and contain 
foam cells, suggesting that some of the same factors that contribute to early 
atherosclerosis may also promote rupture (Fuster et al, 1990). Thus, both local 
and systematic thrombogenic factors may influence the degree and duration of 
thrombus. In addition to the degree of plaque disruption and the severity of 
stenosis at the site of injury, smoking, level of cholesterol, Lp( a), fibrinogen, 
PAl-I, factors VII and von Willebrand factor contribute to vasoconstriction and 
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thrombotic complications (Koenig, 1998). 
Although the process of atherosclerosis is the same, little is known about the 
pathogenesis in patients who develop atherosclerosis and premature CHD at a 
young age (less than 55 years). Evaluation of major coronary risk factors in 
Indian patients undergoing coronary arteriography has shown that more than 
one third of patients with CHD have few or no major risk factors (Kaul et aI, 
1986). There is a relatively low prevalence of traditional coronary risk factors 
such as high cholesterol levels, cigarette smoking and hypertension in patients 
with premature CHD (Krishnaswami et aI, 1989, Enas et aI, 1992, Klatsky et 
aI, 1993, Stampfer et aI, 1991). A review of the family history in South 
Africans with CHD has indeed suggested that there may be a strong genetic 
element in risk predisposition (Seedat et aI, 1996). In contrast, HLA typing 
has shown no evidence of genetic susceptibility in this ethnic group 
(Sewdarsen et aI, 1987). Whether factors other than environmental and/or 
metabolic abnormalities predispose to early onset of atherosclerosis and to 
what extent genetic factors interact with these stimuli are not known. 
Among genes likely to influence the composition of atherosclerotic plaques are 
those involved in matrix production, lipid metabolism, as well as the 
coagulation and fibrinolytic pathways. Lesion stability may also be influenced 
by haemorrhage from small vessels that grow into the lesions from the media 
and factors contributing to coagulation influence thrombus formation. 
Variations of haemostatic factors, such as fibrinogen, PAI-I and factors XIII 
have been associated with CHD (Koenig, 1998). In the past few years, 
evidence has emerged that angiotensin 11 plays a significant role in 
atherogenesis and interacts with these pathways at various levels in the 
pathological process ranging from the influence of risk factors to 
haemodynamic changes and alterations in tissue metabolism and endothelial 
function (Fig 1). (see 1.2) Early onset of disease with such a multifactorial 
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aetiology is suggestive of a strong genetic component that may become 
unmasked in the presence of appropriate environmental stimuli. Thus, the 
documented high incidence of early CHD in the migrant Indian population 
might indicate a greater degree of genetic predisposition among them as 
compared to Europeans. The genetic distance between these two ethnic groups 
makes the presence of differential disease-allele frequencies plausible, 
supporting the postulate that genetic differences contribute to the observed 
differences in disease patterns among Indians and Europeans. 
Background 
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B) EPIDEMIOLOGICAL EVIDENCE OF HERITABILITY 
OF 
CARDIOV ASCULAR DISEASE 
1. The Framingham Heart Study: 
In the Framingham Heart Study, death due to CHD in parents was associated 
with a 30% increase in the risk of coronary artery disease in the offspring 
(Myers et aI, 1990). This effect was stronger for early onset of coronary artery 
disease with age adjusted relative risks of 1.5 for early (occurring at under 60 
years of age) and 1.2 for late (in patients older than 60 years) coronary artery 
disease. No evidence was found for a significant interaction between any of 
the known risk factors and family history of CHD. In examining persons with 
a low risk for coronary artery disease as suggested by their risk factor profile 
(normotensive, non-smoking, non-obese individuals), more than two-thirds of 
those who experienced coronary artery disease were found to have a positive 
family history. These findings suggest that primary genetic factors may play a 
significant role in the pathogenesis of CHD. 
2. Segregation studies: 
The observation of a familial aggregation of a number of cardiovascular 
diseases, such as CHD (Schildkraut et aI, 1989), hypertension (de Faire et aI, 
1975) and left ventricular hypertrophy (Beilen et aI, 1990) lends support to the 
role of primary genetic factors in the pathogenesis of cardiovascular disease. 
A "positive family history" may be the result of shared genes: studies among 
monozygotic and dizygotic twins and adaptation studies comparing incidence 
among natural versus adopted siblings of parent-child pairs have consistently 
shown a greater degree of disease concordance among more closely genetically 
related individuals, thus distinguishing the effects of genetic and 
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environmental variables, and supporting the role of hereditary factors (de Faire 
et aI, 1975, Feinleib et ai, 1977). In addition, a number of segregation studies 
in a large number of families have yielded additional evidence for the 
importance of genetic predisposition in the occurrence of cardiovascular 
disease. 
C) GENETIC STUDIES OF HERITABILITY 
Coronary heart disease shows strong family aggregation, especially when it 
presents at an early age and when many relatives are affected. Several 
cardiovascular sequelae including left ventricular hypertrophy, are potentially 
shared by family members of affected individuals (Schunkert et ai, 1994). 
Because familial clustering of risk factors is insufficient to explain the high 
risk of disease in a sibling of an affected parent, genetic factors are strongly 
suspected to play a significant role in susceptibility to premature CHD. 
1.1 Monogenic Disorders: 
As important as the established risk factors are for predicting disease, only a 
fraction of those subjects who have one or more of these risk factors will 
actually develop a cardiovascular event; even some with no known factors will 
experience an event. Epidemiological studies suggest that CHD may have an 
environmental as well as a genetic basis, which in the latter instance does not 
follow simple Mendelian patterns of inheritance. Very little is known thus far 
about the actual genes, or their allelic variants that contribute to the pathogenesis 
of CHD. In only a small proportion of cases do rare monogenic disorders 
account for the expression of disease, e.g. familial hypercholesterolaemia 
(Brown et aI, 1986). 
Although the dyslipidaemias form a well known risk factor for CHD, only a 
small percentage of CHD patients have recognised mutations in lipoproteins or 
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their related genes. In the South African Afrikaner, familial 
hypercholesterolaemia (FH) is highly prevalent and has been diagnosed to be 
due largely to the LDL receptor gene defect (Kotze et ai, 1991, Rubinsztein, 
1994). Mutations in the LDL-C receptor gene produce familial 
hypercholesterolaemia; an autosomal codominant disorder characterised by 
raised plasma LDL cholesterol (LDL-C), tendon xanthomas and premature 
CHD. 
CpG hotspot mutations at the LDL receptor locus have been described in South 
African Indians (Kotze et ai, 1997) but the majority of premature CHD sufferers 
do not have this clinical picture, suggesting some other mode of a genetically 
determined predisposition to atherosclerosis, probably acting at a cellular level 
in the intima of the vessel wall. 
1.2 Renin-Angiotensin System: 
1.2.1 Role of the Renin-angiotensin System (RAS) III the Pathogenesis of 
Atherosclerosis: 
Since hypertension is a major risk factor for CHD, (Kannel et aI, 1976) 
attention has been focussed on the RAS and its major component angiotensin 
n, a potent vasoconstrictor and mediator of vascular events, in the 
pathogenesis of CHD. The activity of the RAS depends on the availability of 
angiotensin, renin, angiotensin converting enzyme (ACE), and Ang 11 receptor 
activity. Angiotensin converting enzyme generates the vasoactive Ang 11 and 
inactivates bradykinin. It is widely distributed in endothelial and epithelial 
cells. Each of these components of the RAS may play a contributory role in 
disease pathogenesis. 
Alderman et al (1991) followed up 1717 subjects with mild-moderate 
hypertension for 8,3 years and provided the best epidemiological evidence for 
the link between the RAS and the risk of subsequent myocardial infarction. 
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They showed that the risk of Ml was increased over 5 fold among subjects 
with high- compared to those with low-renin profiles, and this effect was 
independent of other cardiovascular risk factors. This relationship between 
plasma renin and risk for myocardial infarction has not been shown in 
normotensive subjects (Meade et al, 1993). 
The RAS may contribute to the process of atherogenesis VIa several 
mechanisms. Angiotensin II, an octapeptide, represents the biologically active 
product of the RAS. It is generated by precursors, which are cleared by 
enzymes. Besides its involvement in blood pressure regulation, Ang 11 acts as 
a growth factor and contributes to vascular remodelling in most vascular 
organs, including the heart itself. There is experimental evidence that local 
Ang 11 formation is increased in atherosclerotic lesions, and that chymase is 
primarily responsible for this increase (Ihara et al, 1999). Angiotensin has also 
been shown to play an important role in regulating the production of 
plasminogen activator inhibitor-l (PAl-I) (Vaughan et al, 1995, van Leeuwen 
et al, 1994). This biological role of angiotensin suggests that regulatory 
changes in the RAS may also influence the development of thrombosis in 
subjects with coronary atherosclerosis. 
There is also increased expression of ACE in atherosclerotic lesions, leading to 
local production of Ang II and ultimately stimulation of vascular superoxide 
production (Diet et al, 1996). These findings suggest a pathogenetic role for 
the RAS in the early stages of atherosclerosis. This hypothesis is supported by 
the fact that ACE inhibition has been shown to promote regression and even 
prevention of atherosclerosis (Becker et al, 1991). Recently, Mancini et al 
(1996) showed that patients with coronary artery disease treated with an ACE 
inhibitor developed markedly improved coronary vasomotor function. This 
study, the Trial on Reversing Endothelial Dysfunction (TREND) demonstrated 
that quinapril 40mgldaily given for six months improved acetylcholine _ 
provoked vasoconstriction in patients with CHD. There is now substantial data 
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from experimental and clinical trials to support the role for ACE inhibition 
retarding atherosclerosis at a tissue level (Naidoo, 1996). There is also 
evidence of a link between the RAS and lipid levels in vascular biology. 
Hypercholesterolaemia is associated with AT/ receptor upregulation and 
increased vascular production of superoxide, secondary to activation of 
vascular NADH oxidase. This results in attenuation of endothelium-dependent 
coronary vasodilatation which is demonstrable early in the atherosclerotic 
process (Zeiher et aI, 1994). AT] receptor blockade has been shown to 
normalise the activity of NADH oxidase, reduce plaque area and macrophage 
infiltration and in parallel improve endothelial function (Warnholtz et aI, 
1999). 
These data suggest that: the RAS may be playing an important role in both the 
initiation and acceleration of the atherosclerotic process. 
1.2.2 Gene Polymorphism and the RAS: 
1.2.2.1 
Allelic association studies have suggested that polymorphism in genes 
involved in lipid metabolism, coagulative and fibrinolytic pathways, as well as 
the renin-angiotensin system may be associated with coronary atherosclerosis. 
The role of polymorphisms in genes that regulate the RAS in the pathogenesis 
of CHD has recently come under scrutiny (Tiret et al 1995, Beohar et aI, 1995, 
Arbustini et al 1995, Ohishi et aI, 1993). Although the genetic basis of CHD is 
still unfolding, many studies have suggested several putative genes (Table 1). 
A widely studied example is the angiotensin converting enzyme (ACE) gene on 
chromosome 17. 
A CE Gene Polymorphism: 
Recently an insertion/deletion polymorphism has been described which is 
based on the presence (insertion: I) or absence (deletion: D) of a 287-base pair 
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alu-repeat DNA domain, resulting in three genotypes: homozygous (DD) 
heterozygous (ID) and homozygous (II). This polymorphism is co dominantly 
associated with the plasma ACE activity, with the DD genotype having about 
double the value of the II genotypes (Rigat et aI, 1990). Both circulating 
(Rigat et aI, 1990) and local cardiac (Danser et aI, 1995) activity of ACE are 
higher in the presence of the deletion polymorphism, which might increase the 
conversion of Ang I to the highly active Ang II. Local ACE activity could thus 
promote the development and progression of atherosclerotic plaque in the 
vessel wall. ACE could be involved in the pathogenesis of atherosclerosis by 
several biological mechanisms. In addition to activating Ang I (resulting in 
decreased tissue perfusion), Ang 11 is involved in vascular smooth muscle cell 
growth (Daemen et ai, 1991) and the stimulation of plasmogen-activator 
inhibitor type I (Ridker et ai, 1993). 
Since Rigat et al (1992) identified an insertion/deletion (liD) polymorphism 
within intron 16 of the A CE gene, several studies have reported an association 
between the D allele and an increased risk for coronary artery disease, 
myocardial infarction, (Cambien et aI, 1992) restenosis after angioplasty 
(Kaski, 1994 Ramon et ai, 1998), ischaemic and dilated cardiomyopathy 
(Raynolds et ai, 1993) as well as left ventricular hypertrophy (Iwai, 1994, 
Schunkert et ai, 1994). 
Cambien et al (1992) was the first to report the association of the D allele for 
an increased risk of MI, especially in a low risk group defined by body mass 
index and serum apo B levels. It is possible that the effect of the A CE DD 
genotype is strongest when no other causative factors are present. In a large 
case-controlled study Etude Cas-Temoins sur L'lnfarctus du Myocarde 
(ECTIM) an increased risk of MI and an increased frequency of parental MI 
was demonstrated in subjects carrying the D allele. In this study the 
relationship between the ACE DD genotype and MI was much stronger in 





ACE Gene Polymorphism and Premature Atherosclerosis: 
Variations in the ACE gene have also been associated with early changes of 
carotid atherosclerosis (Kauma et ai, 1996). The gene effect, however, may be 
masked by stronger effects of environmental factors such as smoking. The D 
allele has been shown to be a risk factor for MI (Cambien et ai, 1992, Mattu et 
ai, 1995), even in patients with non-insulin dependent diabetes mellitus (Ruiz 
et ai, 1994). Angiotensin converting enzyme gene polymorphism has also 
been shown to be associated with a parental history of MI (Tiret et ai, 1993, 
Badenhop et ai, 1995) and may explain the premature development of CHD 
and MI in low risk patients (Gardemann et ai, 1995, Evans et ai, 1994, Ludwig 
et ai, 1995, Takahashi et ai, 1995). The underlying mechanism maybe related 
to impaired endothelial function since increased coronary vasomotor tone has 
been demonstrated in patients with CHD who possess the D allele (Prasad et 
ai, 2000). 
1.2.3 Angiotensinogen (Agt) Gene: 
1.2.3.1 Agt M235T Polymorphism: 
Recent studies suggest that the M235T variant of the Agt gene is associated 
with the development of hypertension in Caucasians. This mutation consists of 
a nucleotide transition in exon 2 leading to an exchange of methioine for 
threonine in the M235 position, and is linked to a family history and an early 
onset of hypertension (Winkelmann et ai, 1996). It was found to be more 
frequent in hypertensive patients in studies in Utah and in Paris, (Jeunemaitre 
et ai, 1992) and correlated with arterial wall thickness (Castellano et ai, 1995) 
measurements. It has been estimated that mutations at the Agt locus might be a 
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predisposing factor in 3-6% of hypertensive individuals younger than 60 years 
of age (Jeunemaitre et aI, 1992). Although a large European study has not 
shown any evidence of linkage in 630 affected sibpairs, we decided to evaluate 
polymorphisms at the Agt locus because frequency of the Agt T235 allele 
varies strongly according to ethnic groups. It is more frequent in the Asian 
population (about 0.75) than in the White population (about 0.40) (Niu et aI, 
1998) and is associated with early onset of familial hypertension (Schimidt et 
aI, 1995). Furthermore, Shunkert et aI, (1997) found that the T235 allele was 
associated with higher systolic and diastolic blood pressure. In a meta-anlysis 
involving 5493 patients Kunz et aI, (1997) showed that the Agt T235 allele was 
significantly associated with hypertension, mainly in studies with a positive 
family history of hypertension and that the contribution of the T235 allele may 
also be dependent on interacting risk factors such as gender, BMI, and 
menopause. The Agt M235T polymorphism has also been shown to be 
associated with CHD, both independently (Katsuya et aI, 1995) and also 
synergistically with the ACE insertion-deletion (I/D) polymorphism (Kamitani 
et aI, 1995). 
1.2.4 Core Promoter Element of Agt Gene: 
In 1997, Inoue et al identified a common variant in the proximal promoter of 
the Agt gene: the presence of adenine, instead of guanine (G-6A) 6 bp upstream 
from the initiation site of transcription. The G-+A substitution located at 
position -6 base region upstream of the initial transcription site is of the same 
frequency and in almost complete linkage disequilibrium with the T235 allele 
(Jeunemaitre et aI, 1997). After an extensive investigation Jeunemaitre et al 
(1997) concluded that, with the exception of G-6A, no other known biallelic 
polymorphism is associated with hypertension. Also, he showed that the G and 
A alleles are synonymous with the M235T M and T alleles respectively. 
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Since tests of promoter activity showed that G-6A nucleotide substitution 
affects the basal transcription rate of the gene and is in very tight linkage 
disequilibrium with M235T, it marks the original form (in evolutionary terms) 
of the gene. Both polymorphisms (M235T and the G-6A) are associated with 
an increased plasma angiotensinogen level, (Jeunemaitre et aI, 1992) which 
could result in an increased formation rate of Ang II, especially in tissues 
where these proteins are rate limiting for Ang II generation. Since variants in 
the Agt gene have been associated with an increased risk of CHD (Katsuya et 
aI, 1995, Ishigami et ai, 1995, Kamitani et ai, 1995) we investigated the G-6A 
polymorphism in the core promoter region of the Agt gene in patients with 
premature MI. 
1.2.5 Angiotensin II Type I Receptor (AT]R) Polymorphism: 
Angiotensin II is the biological active peptide of the RAS that produces 
vasoconstriction, release of aldosterone and catecholamines as well as the 
development of cardiac hypertrophy. Most of the actions of Ang II are 
mediated through the angiotensin II subtype I receptors (AT]) (Goodfriend et 
ai, 1996). 
This receptor is the mam effector of the RAS and mediates the growth-
promoting effect of Ang 11 in humans (Goodfriend et ai, 1996). 
It is now known that several pathways exist for the production of Ang 11 in 
addition to the effects of ACE on Ang 1. Since the main effector of the RAS is 
the AT] receptor, which also mediates the growth promoting effect of Ang II in 
humans, variations in the gene for the AT] receptor may account for a variable 
response to Ang 11 stimulation and its possible interaction with risk factors. 
Little is known about the effect of major risk factors such as 
hypercholesterolaemia on RAS gene expression. The interaction between 
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lipoproteins and the RAS does have some pathogenetic significance and may 
explain why ACE inhibitors attenuate hypercholesterolaemia - induced 
atherosclerosis in animal models (Chobanian et al, 1990). This may have a 
genetic basis since hypercholesterolaemia has been shown to enhance AT] 
receptor gene expression and in this way it accentuates the vasoconstrictive 
effect of Ang 11 (Nickenig et al, 1997). More recently macrophages trapped in 
the vessel wall have been shown to upregulate AT] receptors and contribute to 
increased production of reactive oxygen radicals (Yanagitani et al, 1999). The 
resultant effect of Ang 11 will therefore be instability of the atherosclerotic 
plaque leading to plaque rupture. 
The gene for the human AT] receptor has recently been cloned and sequenced 
(Furuta et al, 1992). Several biallelic polymorphisms have been detected in 
the coding and 3' untranslated regions of this gene (Bonnardeaux et al, 1994). 
Of these, the Al166C gene polymorphism has been shown to be associated 
with resistant essential hypertension and synergistically increases the effect of 
ACE genotype on the risk of MI (Szombathy et al, 1998). A lower frequency 
of the C allele has been reported in patients with CHD and hypertension (Saku 
et ai, 1998). 
It is possible that AT] receptor polymorphism may cause alterations in the 
activity of this receptor and in this way contribute to a more pronounced 
potentiation of the effects Ang 11, explaining the strong cardiovascular risk 
associated with hypertension (Graves et ai, 1992). There is also evidence that 
the AT] receptor is a risk marker for arterial stiffness and could modulate the 
effects of hypertension, aging, and lipids on large arteries (Benetos et ai, 
1995). It has also been associated with decreased aortic wall compliance and 
could modulate the effect of lipids on large arteries (Benetos et al, 1995, 
Kauma et al, 1996). Blockade of this receptor has been shown to correct the 
endothelial dysfunction of peripheral resistance arteries from hypertensive 
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patients (Schiffrin et aI, 1999). 
We therefore investigated the role of a common polymorphism (A1166C) of 
the AT} receptor gene (A-+C transition at position 1166) in our patients. 
Although this polymorphism is not functional it might be in linkage 
disequilibrium with an unidentified variant and may reflect a relationship 
between this 'variant and the risk of premature MI. 
1.2.6 Aldosterone Synthase: 
The trophic effects of neurohormones modulate cardiac growth and function. 
Angiotensin II contributes to an increase in L V mass by promoting myocyte 
growth as well as by stimulating vascular smooth muscle cell growth and 
proliferation. In addition, increase in myocardial collagen may occur via 
aldosterone activation (Weber et aI, 1991). Thus, the combined effect of the 
renin-angiotensin-aldosterone system is to increase LV mass through several 
mechanisms. Angiotensin 11 is a potent fibrogenic factor (Brilla et aI, 1993). 
Besides its well-known effect of stimulating aldosterone production from the 
adrenal cortex, a reciprocal interaction between the hormones has been 
reported. F or instance, an increase in Ang II receptor density has been 
observed in the heart of aldosterone salt-treated rats. (Sun et aI, 1998) There 
is also experimental evidence that aldosterone - salt induces cardiac fibrosis 
through Ang 11 acting on the AT} receptor (Roberts et aI, 1988). 
In addition to regulating renal sodium reabsorption and thus intravascular 
volume, aldosterone may have direct effects on the cardiovascular system. It 
has been shown to stimulate the growth of cardiac myocytes and accumulation 
of extracellular matrix proteins (Weber et aI, 1991). Angiotensin 11 is also an 
important regulator of noradrenaline release from sympathetic nerve endings 
and may modulate cardiac sympathetic activity and ischaemic events 
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(Zimmerman et ai, 1995). This may explain the salutary effects of the ACE 
inhibitors as well as aldosterone antagonists in reducing event rates in heart 
failure studies (Lonn et ai, 1994). These data support a role for all components 
of the renin-angiotensin system in the pathogenesis of CHD and as trigger 
factors for cardiovascular complications and event rates. 
The genes encoding aldosterone synthase (CYP 11 B2) and 11 P-hydroxylase are 
very similar at the nucleotide level, sharing 95% homology (Fisher et ai, 
1998). Altered activity of these enzymes may be important in the pathogenesis 
of hypertension and atherosclerosis. Genetic variations within or near the 
aldosterone synthase gene are associated with aldosterone and 11-
deoxycortisol production in males. This may modulate the activity of the RAS 
and thereby contribute to blood pressure regUlation. Two biallelic 
polymorphisms, one in the promoter (C344T) and the other in the second 
intron have been identified in the gene encoding aldosterone synthase, the 
enzyme catalyzing the steps of aldosterone biosynthesis (White et ai, 1995). 
Preliminary data suggests that genetic variations in CYP 11 B2 are associated 
with variation in baroreflex sensitivity. The TT genotype was strongly 
associated with baroreflex sensitivity as measured by the Valsalva manouevre 
(yitalo et ai, 1998). Amongst the genetic loci studied we therefore included 
polymorphism in the promoter region of the aldosterone synthase gene which 
is known to affect the binding of the steroidogenic factor-transcription factor 
and so influence gene expression. This pathway may not only explain the 
direct effects of aldosterone on the cardiovascular system, but also support the 
association between renin levels and MI (Alderman et ai, 1991). 
Aberrations in these genes can lead to changes in arterial pressure and are 
responsible for a monogenically inherited form of hypertension (Fisher et ai, 
1998). There is evidence that a polymorphism (C344T) in the promoter of the 
CYP 11 B2 gene is strongly associated with left ventricular size and decreased 
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baroreceptor sensitivity in healthy individuals (White et aI, 1998). This 
polymorphism may be associated with an increased risk of MI in dyslipidaemic 
patients (White et aI, 1998). As altered activity of CYP 11 B2 has been 
proposed as an intermediate phenotype in essential hypertension, we also 
evaluated gene polymorphism in this gene in our subjects. 
1.2.7 11~-Hydroxysteroid Dehydrogenase 2 Polymorphism: 
1.2.7.1 
Aldosterone exerts its effects through the binding and activation of the 
mineralocorticiod receptor (White, 1998). Since cortisol binds to this receptor 
with the same affinity as aldosterone the enzymatic conversion of cortisol to 
cortisone by l1~-hydroxysteroid dehydrogenase 2 (llBHSD2) ensures that 
aldosterone gains access to this receptor. 
The gene encoding this enzyme is located on chromosome 16q22. Mutations 
in the 11BHSD2 gene results in loss of the activity of the encoded enzyme, 
causing severe hypertension due to mineralocorticoid excess (Stewart et aI, 
1996). Therefore, anomalies in either of the genes encoding the enzymes 
11 BHSD2 and CYP 11 B2 can lead to important changes in arterial pressure and 
are responsible for several monogenically inherited forms of hypertension 
(Ulick et aI, 1979, Mune et aI, 1995) but these are rare. 
A single such polymorphism has been identified in exon 3 of the 11 ~HSD2 
gene characterised by the GAG to GAA transition at codon 178 (Smolenicka et 
aI, 1998, Brand et aI, 1998). Since common polymorphisms in these genes or 
their regulatory regions could contribute to genetic variation in the 
susceptibility to hypertension and its cardiovascular sequelae, we investigated 
this polymorphism in patients with premature myocardial infarction. 
Other candidate genes: 
Background 
20 
The interplay between gene polymorphism and newly identified risk factors for 
CHD such as hyperinsulinaemia (Despres et ai, 1996) and abnormalities in 
apolipoprotein metabolism may also contribute to premature coronary 
atherosclerosis (Tas et ai, 1994, van Bockxmeer et ai, 1992). Therefore, 
extending the genetic analyses to other candidate genes may explain how 
insulin and fibrinogen contribute to a procoagulant state, (Robins on et ai, 
1994, Akimova et ai, 1994) impaired fibrinolysis and altered levels of growth 
factors and in this way predispose to early onset CHD. Among the candidate 
genes that have been investigated to date, gene polymorphisms in 
homocysteine metabolism, G-protein and TGF-fJ may provide supportive 
evidence for a genetic basis to transcriptional changes predisposing to 
atherosclerosis (Cambien et ai, 1996). 
1.2.8 Homocysteine and CHD: 
The sulphur-containing ammo acid homocysteine is formed during the 
metabolism of methionine. Methylenetetrahydrofolate Reductase (MTHFR) 
catalyses the reduction of 5,l0-methylenetetrahydrofolate to 5, 
methylenetetrahydrofolate. This is the predominant circulating form of folate 
and is a methyl donor for the remethylation of homocysteine to methionine. 
Reductase activity of MTHFR or defects in the MTHFR gene itself may lead to 
raised homocysteine levels. 
Homocysteine concentration IS elevated in up to 30% of patients with 
atherosclerosis (Clarke et ai, 1991). Hyperhomocysteinaemia is known to be 
an independent risk factor for the development of CHD, (Clarke et ai, 1991, 
Murphy-Chutorian et ai, 1994, Amesen et ai, 1995, Robinson, 1994) MI, 
(Stampfer et ai, 1992) particularly in young women (Schwartz et ai, 1997), 
cerebrovascular disease and venous thrombosis. The serum homocysteine 
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level is influenced by environmental as well as genetic factors. A high plasma 
concentration of homocysteine may predispose to atherosclerosis by injuring 
the vascular endothelium. In a meta-analysis Blom et al (1991) estimated that 
the risk associated with a 5 IJ,mollL elevation in total plasma homocysteine was 
equivalent to a 0.5 mmollL rise in the serum cholesterol. Levels only 12% 
above the upper limits of normal (15 IJ,mollL - mild hyperhomocysteinaemia) 
are associated with a three-fold increase in MI (Nygard et aI, 1997). 
The exact mechanisms by which raised homocysteine levels promote 
atherosclerosis are not clear but postulates include endothelial damage (Woo et 
aI, 1997), platelet dysfunction, (Lentz et aI, 1991) and LDL-C oxidation 
(Reinhardt et aI, 1998). Acute elevation in homocysteine concentration, 
similar to levels found in MI, is associated with endothelial dysfunction 
(Chambers et aI, 1999), and can be prevented by pre-treatment with vitamin C 
suggesting that the effects are mediated via oxidative stress. 
A further report (Tsai et aI, 1996) has shown that homocysteine inhibits 
endothelial cell proliferation and stimulates vascular smooth muscle cell 
proliferation. In addition homocysteine enhances endothelial cell-associated 
factor V activity (Rodger et aI, 1986) and inhibits thrombomodulin surface 
expression (Lentz et ai, 1991), protein C activation (Rodger et aI, 1990) and 
tissue plasminogen activator binding (Hajjar, 1993). These findings suggest 
that homocysteine may be involved in the thrombotic and atherosclerotic 
process by promoting prothrombotic activities as well as modulating vascular 
cell proliferation in the vessel wall. 
Homocysteine concentrations are determined to some extent by genetic factors. 
Genetic aberration in the gene coding for 5,10-methylenetethydrofolate 
reductase (MTHFR) may account for reduced enzyme activity and elevated 
plasma homocysteine level. (Kang et aI, 1991). Reduced activity of MTHFR 
and elevated plasma homocysteine levels may be seen in individuals with a 
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thermolabile variant of MTHFR. This phenotype results from a C to T 
mutation at nucleotide position 677 in the cDNA (Goyette et ai, 1995). It 
predicts the replacement of 222 Ala by Val and reduces the basal activity of the 
enzyme by 50%, leading to decreased thermostability in homozygote 
individuals (Frosst et ai, 1995). This mutation is frequent: about 12% of 
Caucasians are mutant homozygotes. They have lower mean serum folate 
levels and 25% higher plasma homocysteine concentrations than normal CC 
homozygotes. Up to 17% of patients with CHD are reported to express the 
thermolabile phenotype. 
Since the effects of high plasma homocysteine levels have not been shown to 
be mediated by the known coronary risk factors (Tonstad, 1997), we 
hypothesized that the MTHFR mutation might be a candidate gene for coronary 
heart disease, particularly in younger patients with few risk factors. 
1.2.9 Transforming Growth Factor Beta (FGF-jJ): 
Excessive proliferation and migration of several vascular cell types (e.g. 
vascular smooth muscle cells, endothelial cells, myofibroblasts) are important 
components of the vascular remodelling and the atherosclerotic processes 
(Ross, 1993, Schwarz et ai, 1997). In the normal artery cell growth and 
migration are closely regulated processes: there is a balance of paracrine 
growth factors, vasoactive factors and circulating hormones that control tissue 
homeostasis. For instance, endothelial cells produce nitric oxide and other 
factors that reduce smooth muscle cell proliferation. When the endothelium is 
damaged, the expression of these factors is altered resulting in enhanced 
proliferation and/or migration of vascular smooth muscle cells which 
contribute to neointimal proliferation and the atherosclerotic process. 
Transforming growth factor-13 is a member of a larger family of growth factors 
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and cytokines and has a wide spectrum of biological activities (Wahl, 1994) 
which include regulation of cell growth, differentiation and matrix production 
(Roberts et at, 1988). It is secreted by peripheral blood monocytes, endothelial 
cells and vascular muscle cells, and induces fibrosis in the kidney, heart and 
blood vessels (Border et at, 1994). 
In animal models angiotensin 11 has been shown to act by the induction of 
proto-oncogenes efos, c-myc and c-jun, and induces expression of several 
growth factor genes, (Campbell et ai, 1997, Lonn et ai, 1994) including the 
genes encoding for PDGF and TGF-fJ. Early activation of these proto-
oncogenes followed by sequential activation of growth factor genes ultimately 
result in vascular smooth muscle cell growth. In addition to these trophic 
effects Ang 11 has been shown to release an endothelial neutrophil 
chemoattractant, leading to neutrophil accumulation. All these mechanisms 
probably contribute to the genesis and progression of the atherosclerotic plaque 
as well as endothelial function (Bell et at, 1990). 
At a cellular level the trophic effects of the Ang 11 on smooth muscle cells of 
blood vessels are therefore determined by the expression of TGF-f3] (Gibbon et 
at, 1992, Campbell et at, 1997). Elevated plasma levels of TGF-f3f have been 
described in diseases that involve modification of extracellular matrix 
particularly Type 11 diabetes mellitus (Pfeiffer et at, 1996). Furthermore, 
several G-protein coupled receptor agonists including Ang 11 and a-thrombin 
are potent mitogens that induce extracellular matrix formation (Weber et ai, 
1994). Data also exists that TGF-f3] and Ang 11 regulate the expression of each 
other (Border et at, 1989). Overproduction of TGF-f3] mediated in part by Ang 
11, has been linked to L VH and vascular remodelling in hypertension (Villareal 
et ai, 1992, Sarzani et ai, 1989). Recent evidence suggests that TGF-fJ] is a 
key inhibitor of atherogenesis and increased plasma levels of TGF-fJf are seen 
in early atherosclerosis but levels are severely depressed in the advanced stages 
of the disease (Blann et ai, 1996). 
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Transforming growth factor-~ is therefore a multi-functional cytokine which 
regulates cell proliferation and is a potent inducer of extracellular matrix 
production and fibrogenesis. There is experimental evidence that proteoglycan 
accumulation in atherosclerotic lesions depends on the proximity of platelet 
derived growth factor (PDGF) and TGF-fJ (Evanko et ai, 1998). Its exact role 
in human atherosclerosis is unknown but elevated plasma levels have been 
found in type II diabetes mellitus, correlating with retinopathy, neuropathy and 
HbA1C levels. Three mutually compatible hypotheses have been put forward 
to explain the development of atherosclerotic lesions. The 'response to 
retention' hypothesis emphasizes the importance of atherogenic lipoprotein 
accumulation in the sub-endothelial region (Williams et ai, 1995), whereas the 
oxidation hypothesis (Witztum, 1994) emphasises the role of the oxidative 
process in the recruitment of macrophages. The 'response to injury' 
hypothesis proposes vascular smooth muscle cell proliferation as the key event 
in the formation and progression of the atherosclerotic lesion (Ross, 1993). 
Transforming growth factor-~l could be the missing link that promotes lipid 
accumulation through increases in proteoglycan synthesis and deposition in the 
fatty intima. In the human aorta TGF-fJ participates predominantly in the 
pathogenesis of the lipid-rich atherosclerotic lesion and contributes to specific 
stages of lesion progression. Studies of human aorta atherosclerotic plaque 
and restenotic lesions after angioplasty have documented TGF-fJl expression 
by vascular cells within the lesions. Similarly, TGF-J31 expression within the 
vasculature is upregulated in the context of diabetes and hypertension in 
animal models of vascular disease (Han et ai, 1995). Transforming growth 
factor-~l in the arterial wall promotes vascular cell differentiation, vascular 
wall remodelling, arterial lesion growth and regression through apoptotic 
mechanisms (Schulick et ai, 1998). It is postulated that vascular structure and 
lesion formation is determined in part by a balance between cell proliferation 
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and cell death and by apoptosis (Isner et aI, 1995, Geng et aI, 1995, Han et aI, 
1995). Transforming growth factor-~ is an inducer of endothelial cell death 
and it also prevents vascular smooth muscle cell death. All evidence points to 
it being a proatherogenic cytokine (Bobik et aI, 1999). 
Furthermore f3eta ig-h3 a TGF-Prinducible gene, is over-expressed in ig-h3 
restenotic human vascular lesions (O'Brien et aI, 1996). Recent evidence 
suggests that genetic factors may play a role in TGF-pj expression, the gene 
for which is located on chromosome 19q3 and comprises seven exons, of 
which exon 5, 6 and 7 encode the active TGF-pj. Since five polymorphisms 
have been identified in the TGF-~l gene we hypothesized that gene 
polymorphism might regulate the expression of TGF-pj and therefore studied 
Thr 263 Ile polymorphism in patients with premature MI. This gene mutation, 
a C to T transition at position 76 in exon 5 results in a change from threonine 
to isoleucine in position 263 (Thr 263 lIe) of the propeptide. 
1.2.10 G-Protein Polymorphism: 
In addition to the regulatory effect of RAS genes in blood pressure homeostasis 
and vascular remodelling, genes encoding the components of the transport 
system that regulate salt and water homeostasis are also potential candidates 
for influencing blood pressure. 
The pH-regUlating ion transport system (Na+1I-t exchanger [NHE]) which 
swaps extracellular Na + for intracellular H+ is one such system. Of the five 
isoforms have been isolated in human tissues one has been associated with 
hypertension but variations in its transcripts have not been detected (Diez et aI, 
1995). 
Since cell lines that display enhanced NHE-l activity have also shown 
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increased activity of pertussis toxin-sensitive G-proteins, Siffert et aI, (1998) 
have located a C ~ T polymorphism at position 825 of cDNA that encodes the 
P3 subunit of the pertussis-toxin-sensitive G-protein (GNfJ3). There is 
preliminary data to suggest that the response to UT adrenergic stimulation in the 
coronary arteries is genetically determined: patients with GNf33 T825 allele had 
augmented flow reduction compared to CC homozygotes (Baumgart et aI, 
1998). The 825T allele was significantly associated with hypertension. Since 
hypertension is a major risk factor for CHD we extended our genetic analysis 
to include GNf33 subunit as a candidate gene related to NHE activity and salt 
and water homeostasis on the basis that enhanced intracellular signal 
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Fig I: Putative Mechanisms for Angiotensin 11 in Relation to Risk Factors in 
Atherogenesis 
In response to angiotensin II monocytes release cytokines and growth factors which 
cause inflammation of the vessel wall, leading to further release of angiotensin II, as 
well as a direct effect on vascular smooth muscle cells. 
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1.3 Arterial Stiffness and Pulse Wave Velocity: 
As one ages the arteries become progressively stiffer. This is due to 
degeneration in the elastic fibres in the media and as a result stress is 
transferred to the collagenous element in the arterial wall. A further 
consequence of arterial stiffening is a higher systolic and lower diastolic blood 
pressure, thereby causing increased afterload and altering coronary perfusion. 
The principal outcomes of these changes are left ventricular hypertrophy, 
aggravation of coronary ischaemia and increased fatigue of arterial wall tissues 
(cyclical stress). Higher systolic blood pressure, pulse pressure and lower 
diastolic blood pressure and left ventricular blood pressure have been 
identified as independent risk factors for cardiovascular mortality (Dame et aI, 
1989, Levy et aI, 1990). Increased stiffness of the central arteries not only 
reflects the presence of hypertension but also risk factors (diabetes, obesity and 
hyperlipidaemia) that are associated with coronary artery disease and may 
prove to be a composite measure of risk. 
CHD is thought to be associated with a generalised process that begins in the 
large arteries. Since coronary artery perfusion occurs mainly in diastole, the 
elastic recoil of the aorta is necessary to produce the energy for the retrograde 
flow through the coronary arteries. Furthermore, reduced arterial distensibility 
is responsible for a disproportionate increase in systolic BP, which is an 
important component of left ventricular stress leading to the development of 
hypertrophy (Bouthier et aI, 1985). 
A consequence of arterial stiffness IS early return of the pressure wave 
reflection from the periphery leading to summation of the reflected wave with 
the systolic pressure, generating a higher and later systolic peak. Elevated 
systolic blood pressure has been shown to correlate with the development of 
atherosclerosis (Witteman et aI, 1994). Whether enhanced arterial stiffness is a 
risk factor contributing to the development of cardiovascular disease has been 
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debatable (Blacher et aI, 1999) but several markers do suggest this. As a 
determinant of pressure load, aortic stiffness correlates with left ventricular 
mass and wall thickness to radius in essential hypertension (Boutyrie et aI, 
1995). Increasing arterial stiffness occurs with ageing and correlates with the 
prevalence of atherosclerosis (Wada et at, 1994) and end-stage renal disease 
(London et at, 1992). In addition, there is evidence that morphological and 
structural changes in the aorta may be influenced not only by environmental 
but also by genetic factors such as AT 1 receptor gene expression (Benetos et 
aI, 1995). Therefore, in the absence of risk factors, assessment of arterial 
compliance in subjects with early onset atherosclerosis may reflect arterial 
stiffness due to a genetic predisposition in these subjects (refer to 1.2.5). 
Several methods have been used to measure compliance/distensibility of large 
blood vessels (change in vessel volume per mmHg change in pressure) but 
simultaneous measurements of volume and pressure at a point in the vessel are 
technically difficult. In recent years it has become increasingly possible to 
measure arterial stiffness easily and accurately, through determination of pulse 
wave velocity (PWV). An increase in arterial stiffness increases the speed of 
aortic pulse travel along the walls of the aorta and the major arteries (increased 
arterial pulse wave velocity). According to the Moens-Korteweg equation, 
PWV, which is related to the square-root of the elastic modulus, rises in stiffer 
arteries. Since the elastic properties of the aorta and central arteries are 
important determinants of cardiovascular coupling, PWV is clinically relevant 
to cardiovascular risk. 
PWV measurement offers a simple, reproducible, indirect and non-invasive 
evaluation of regional arterial stiffness. PWV determined from foot-to-foot 
transit time in the aorta eliminates the influence of arterial wave reflections and 
closely approximates PWV measurements determined from phase velocity 
studies (Nichols et aI, 1998). Correlation of PWV measurements with left 
ventricular mass have not been studied previously and may indicate early 
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arterial changes outside the coronary vasculature. 
In addition to age and high BP, local hormonal factors may play a role in the 
modification of the arterial wall, mainly by modifying cell growth. Among 
these factors Ang 11 plays a critical role, since it induces hypertrophy of 
vascular smooth muscle cells and increases collagen production by fibroblasts. 
Most of the actions of Ang 11 are mediated by its effects on the AT] receptor. 
Furthermore, the interaction between lipoprotein and the RAS may explain why 
ACE inhibitors attenuate hypercholesterolaemia-induced atherosclerosis in 
animal models. The identification of polymorphic DNA markers on the AT] 
receptor gene offers a good opportunity to study the interaction of this gene 
with lipoproteins and its effects on arterial rigidity as measured by PWV. The 
genetic background may influence large artery function in many ways. The 
association of genetic and environmental factors may contribute to the 
development of hypertension, dyslipidaemia, salt-sensitivity and type 11 
diabetes. In addition the genetic make-up of an individual may determine the 
response of the arterial wall to risk factors such as hypertension, aging, 
cholesterol and smoking. Identification of such genetic markers may have 
clinical implications in the detection of high-risk subjects. Polymorphisms of 
genes coding proteins implicated in cardiovascular regulation are therefore the 
logical candidates for study. 
Thus, in summary, clinical risk factors account only in part for the high 
propensity to eHD in the Indian population. On their own these risk factors 
are insufficient to explain the seemingly high prevalence in younger patients, 
particularly men. Since family history studies suggest that there may be a 
strong genetic element in risk predisposition and since HLA typing has not 
shown any evidence of HLA predisposition in these patients, a study of 
candidate gene polymorphism seems warranted. To date there have been no 
published studies of gene polymorphisms in Durban Indians, as have recently 
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been described in the Caucasian population. The Indian population in Natal is 
an inbred population with a high prevalence of coronary disease. This 
constitutes a suitable group for analysis of candidate genes by restriction 
fragment length polymorphism (RFLP). 
Patients with CHD comprise a heterogeneous group, ranging from subclinical 
silent ischaemia to chronic severe, often advanced, yet stable, triple vessel 
disease. The transition from subclinical cardiovascular disease to overt clinical 
disease is often precipitated by acute coronary events such as unstable angina 
or MI. Of all patients with acute coronary syndromes, those with MI form a 
well-defined, relatively homogeneous group suitable for study. Furthermore 
the pathogenesis of this condition is now well described, involving thrombotic 
factors against a background of changing metabolic milieu leading to altered 
lipid dynamics within unstable atherosclerotic plaques. Since the diagnosis of 
CHD is clearly established without the need for invasive procedures such as 
coronary angiography in patients with proven MI and given the high 
prevalence of CHD in relatively young Indian subjects, we prospectively 
evaluated a well-defined homogeneous cohort of Indians with early onset MI 
to determine whether candidate genes regulating the renin-angiotensin system 
were associated with premature CHD as manifested by MI. 
The initial report which implicated the angiotensin converting enzyme gene, 
was made by Cambien et aI, (1992) and confirmation of this finding was 
replicated in many but not all subsequent studies. Therefore, we also focussed 
on other candidate genes involved in cardiovascular homeostasis as described 




The primary objective of this study is to prospectively evaluate the genetic 
polymorphisms that might be responsible for premature atherosclerosis in 
Indians who sustained MI at a young age. The focus of this study is on the 
candidate genes that are components of mediator systems involved in the 
regulations of vascular tone, cell growth and proliferation (Table I). 
The aims can be summarised as follows:-
i) To ascertain the role of candidate gene polymorphisms pertaining to the 
angiotensin pathway. These include the A CE gene, Agt gene and the AT] 
receptor gene. 
ii) To ascertain the role of candidate gene polymorphisms pertaining to 
aldosterone metabolism. These are genes for aldosterone synthase (CYP llB2) 
and IIp-hydroxysteroid dehydrogenase 2 (l1f3-HSD2). 
iii) To ascertain the role of gene polymorphisms of the MTHFR gene and correlate 
these with homocysteine levels. 
iv) To ascertain the role of polymorph isms in the G-protein and TGF-f3] genes. 
v) To establish a correlation, if any, between genetic polymorphisms, risk factors, 
PWV, microalbumin and left ventricular mass. 
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TABLE I: CANDIDATE GENE POLYMORPHISMS STUDIED 
PUTATIVE GENE CHROMOSOME LOCUS DESIGNATION 
Angiotensin Converting 17q Intron 16 I/D 
Enzyme (ACE) 
Aldosterone Synthase 8q22 Promoter C344T 
(CYP11/32) 
1q Core promoter G6-)A 
Angiotensinogen (5' region, Exon 1) 
(Agt) 
Ang 11 Type 1 Receptor 3q (5' end of 3' C1166T 
(AT1) untranslated region) 
11 P-hydroxysteroid 16q 22 Exon 3 G534A 
dehyd rogenase (Glu 178/Glu) 
(11j3-HSD) 
Transforming Growth Factor 19q 13 Position 76 Exon 5 C263T 
(TGF-/3) (Thr263 lie) 
G-Protein CDNA Nucleotide position C825T 
(GN/33) 825 (P3 Subunit) 
Methylenetetrahydrofolate CDNA Nucleotide gosition G677T 
Reductase 677 (Ala2 2Nal) 
(MTHFR) 
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Informed consent was obtained from all subjects (see Appendix J). A detailed 
clinical questionnaire including family history, patient's history, risk factors, 
current medical and a physical examination were obtained for each patient. 
The data were validated with reference to hospital records and dialogued with 
family members. From all participants, data on medical history, medication 
and smoking or drinking behavior were obtained by interviews, which 
included a family history and three-day dietary recall. 
The study population was selected from Addington Hospital, Durban. This 
hospital provides a feeder service to districts north of Durban and most 
probands came from Phoenix area, which is almost exclusively an Indian 
littoral district. This popUlation is extremely homogeneous with respect to 
ethnicity, dietary habits, lifestyles and environmental factors. Only unrelated 
probands and controls were utilised in the present study. Screening of 
probands occurred at least 3 months after the index MI. 
The diagnosis of MI was confirmed from hospital records on the basis of at 
least two out of three criteria: typical chest pain, electrocardiographic features 
showing ST elevation and/or raised cardiac enzymes greater than two times the 
upper limit of normal. 
2.1.1 Controls Subjects: 
~ The study included 80 unrelated subjects without clinical evidence of CHD. 
Normalcy was determined by clinical history, examination, electrocardiogram 
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and a normal effort test. It was originally planned to use the spouse as a 
control subject. However, since the majority of the probands were male and 
since the spouse was therefore a much younger female subject, it was decided 
to select older male subjects as controls. They were randomly selected from 
Indian volunteers who met the matching criteria of sex, age (± 5yrs.) and time 
from selection of probands. 
Sub-clinical atheroma was not excluded in these subjects since the tests 
employed i.e. history of angina, abnormal q-waves on the electrocardiogram 
and a negative stress test, do not exclude sub-clinical atherosclerosis. In order 
to be absolutely certain that control subjects had no sub-clinical disease, 
coronary angiography would need to be performed, raising an ethical 
consideration in performing an invasive procedure in a normal subject. 
Subjects referred for coronary angiography and shown to have a normal study 
were not selected because microvascular angina could not be excluded in these 
patients. Therefore, control subjects who were older (+ 5 years) were selected 
in order to be more certain of the absence of symptomatic premature coronary 
heart disease in this group. 
Samples from cases and controls were stored for the same duration and were 
handled together, identically. 
The presence of hypertension, diabetes mellitus, hypercholesterolaemia or 
smoking was determined by history taking, previous medical records, (if any) 
current medication and by the results of blood tests and examination. 
2.2 Procedures: 
This included taking an updated medical history and obtaining informed 
consent. After sampling of fasting venous blood for biochemistry, blood 
pressure determination, anthropometric measurements, resting 
electrocardiogram (ECG) and combined echo-doppler ultrasound examination 
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of the heart were performed, followed by pulse wave velocity determination. 
Resting blood pressure (BP) was measured before echocardiography in the 
right arm with the subject supine for at least 10 minutes and was recorded with 
a validated automated device (Dinamap) using a cuff of suitable size. The first 
reading was discarded and the mean of two subsequent readings taken. 
Hypertension was defined as BP values equal to or above systolic 160mmHg 
and/or diastolic 95mmHg, or as being present in subjects chronically taking 
antihypertensive medication. 
2.3 Examination and Anthropometric Measurements: 
After clinical examination body height was measured in cm with a statometer. 
Subject's body height and weight were measured in light clothing and without 
wearing shoes, and the body mass index (BMI) was computed as weight in 
kilograms divided by height in metres squared (kg/m2). As body weight 
measures not only fat, but other components of the body, and BMI is a 
measure of muscloskeletal mass as well as of body fat, waist and hip 
measurements were obtained by standard criteria in order to estimate intra-
abdominal fat. Obesity was defined as BMI ~ 26 kg/m2. Waist and hip 
measurements were taken in cm at the level of the umbilicus and at the level of 
the anterior superior iliac spine respectively. The data are presented for waist 
circumference as well since this may provide a better measurement of visceral 
adiposity (Pouliot et ai, 1994). 
2.4 Venous Blood Sampling: 
Informed consent was obtained from probands and controls prior to screening. 
Subjects were instructed to fast for 12-14 hours and compliance of fasting was 




examined in the morning and underwent the same procedure. 
After a period of 10 minutes of supine rest approximately 20ml antecubital 
venous blood was 'collected in serum separator tubes, citrate and EDTA tubes 
and immediately kept on wet ice. Further processing began within 30 minutes. 
The plasma was separated by centrifugation at 2500 rpm for 20 minutes and 
stored at -70° for special biochemistry. Serum for lipid analyses was stored at-
40C and assayed within 24 hours. A Sml sample ofEDTA was lyzed, (sucrose 
lysis technique - Appendix II); the white cells were then separated and stored 
as a pellet at -70°C for subsequent DNA extraction. 
Each individual provided a random urine sample for determination of 
microalbumin level. After the initial blood sample subjects underwent a 
modified 2-hour glucose tolerance test, with blood samples taken at 1 and 2 
hours. Known diabetic patients did not participate in this part of the screening. 
2.5 Evaluation of Risk Factors: 
2.5.1 Biochemistry: 
We evaluated risk factors that were considered standard in the Framingham 
Study. (Kannel et ai, 1976). We measured serum cholesterol levels with the 
use of standard enzymatic methods to determine total and HDL-C cholesterol 
levels after precipitation of apo-p containing lipoproteins (LDL-C and VLDL) 
by phosphotungstic acid and magnesium chloride. Subjects with diseases 
causing secondary hypercholesterolaemia were excluded from the study. We 
evaluated lipid levels 3-9 months after a MI since total cholesterol and HDL-C 
levels fall with a rise in triglycerides in the first 24 hours and return to baseline 





Fasting glucose (intra-assay co-efficient of variation 1.9% at 6.7mmollL), 
cholesterol, triglyceride and HDL-C were carried out by enzyme tests using 
the Beckman CX7 autoanalyser. LDL-C was calculated by the Friedwald 
equation provided total triglycerides did not exceed 4.0 mmollL (Friedewald et 
aI, 1972). Apolipoprotein (a) was quantified by radio-immuno assay using 
antisera from Mercodia (Uppsala, Sweden) .. HbA1C was estimated by ion 
exchange chromatography. 
2.5.2 Glucose Tolerance Test: 
The criteria of the Wodd Health Organisation, based on fasting levels and 
plasma glucose values measured two hours after a standard oral 75-g glucose 
load (2-h plasma glucose) were used to diagnose diabetes. Diabetes mellitus 
was considered to be insulin dependent type I (IDDM) if it was diagnosed 
before the age of 30 years and treatment with insulin began within one year 
and continued thereafter. On this basis, no subject in this study was classified 
as insulin dependent (Type I) diabetes. 
2.5.3 Insulin Estimation: 
Fasting insulin was used as a measure of insulin resistance based on the 
observation that fasting insulin level is a good marker of insulin resistance in 
population studies (Olefsky et ai, 1973, Laakso et ai, 1998). In subjects who 
underwent a glucose tolerance test (GTT) the 2 hour insulin was also 
measured. 
A commercial radio-immunoassay kit was used for measuring plasma 
immuno-reactive insulin level (Phadeseph - Pharmacia & Upjohn). This assay 
has 41 % cross-reactivity within pro insulin, which is disproportionately low in 
non-diabetic patients, and less than 0.1 % cross-reactivity with C peptide. The 
detection limit of insulin was 2.5 /-lU/ml. The intra and inter-assay coefficients 
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of variation for this test are 5.3 and 7.6%. 
2.5.4 Homocysteine Estimation: 
Fasting blood samples were drawn and separated within 1 hour. Plasma total 
homocysteine was measured by high performance liquid chromatography 
using the modified method of Ubbink et al (1996). 
2.6 DNA Extraction and Genotyping: 
Genomic DNA was extracted from the white cell pellet by the standard 
method of phenol and chloroform extraction and this was followed by 
isopropanol precipitation of the DNA (Appendix 11). 
For each candidate gene an appropriate set of primers, designed to encompass 
the polymorphic region was used. In each analysis the PCR reaction contained 
100 ng DNA template, 0,1 IlM of each primer, 1,25 IlM of 4DNTPs, 0.5 units 
of Taq DNA polymerase, and 1,5 mM MgCh. DNA was amplified for 35 
cycles, each cycle comprising denaturation at 94° C for 3 minutes, annealing at 
60°C for 40 seconds, extension at 72°C for 2 minutes. The PCR products were 
digested where necessary with the appropriate restriction endonuclease and 
then separated by electrophoresis on 2% agarose gels containing ethidium 
bromide. After the gels were run and photographed, genotyping was 
performed by a trained laboratory technologist who was blinded to the 
subjects' clinical data (Appendix Ill). 
In the case of the ACE gene, 4-5% of samples with the ID genotype were 
misclassified as DD when only the flanking primer pair was used. To prevent 
mistyping of ID as DD genotype a second PCR, with an insertion-specific 
primer, was performed in all samples classified as homozygous DD in the first 
PCR (Lindpaintner et aI, 1995) with 67°C as the annealing temperature. 
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2.7 Echocardiographic Measurements: 
Two dimensional-guided M-mode echocardiograms were obtained from each 
subject with a Toshiba SSH 270HG (Toshiba Corporation, Tokyo, Japan) 
phased-array scanner connected to a 2.5 MHz transducer. Left ventricular 
internal dimensions were measured at end-diastole and end-systole according 
to the Penn convention just below the tip of the mitral valve as recommended 
by the American Society of Echocardiography. (Sahn et ai, 1978) Only 
tracings that demonstrated optimal visualisation of the left ventricular 
interfaces were accepted for analysis. Each recording was also saved on 
video-tape for subsequent review. Left ventricular mass (LVM) was 
calculated according to the formula of Devereux et al (1977). 
LVM (grams) = (1.04 [EDD + SWT + pWT]3 - EDD3) -13.6 
where EDD = internal end-diastolic diameter, SWT + PWT = septal 
and posterior wall thickness, respectively. 
Partition values for the diagnosis of L VH were taken from the 
Framingham study, with 125 glm2 used as the cut-off for both men and 
women as suggested by Casale et ai, (1985). 
Immediately after M-mode recordings, pulsed Dopper echocardiography was 
performed. Transmitral flow velocity waveforms were obtained form the 
apical view in the four-chamber projection with the sample volume placed at 
the level of the mitral annulus and at the tip of the mitral valve leaflets. The 
angle between the Doppler beam and the assumed direction of the transmitral 
flow was less than 10° in all subj ects. The peaks of the early diastolic velocity 
wave (E) and late diastolic wave (A) were measured in metres/second and the 
E/ A ratio determined. The whole scanning procedure was recorded on 
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videotape and a hard copy print of the tracing taken. Imaging was performed 
blinded to the result of the genetic analysis. To assess reproducibility of the 
LV mass determination imaging was repeated 7-14 days later in ± 10 subjects. 
The intra-observer variation was < 10%. 
2.8 Pulse Wave Velocity (PWV): 
After 15 minutes of rest in the supine position aortic PWV was evaluated 
transcutaneously with the use of two pressure probes (Ty 306, Fukuda, Tokyo, 
Japan). This method has been extensively analysed previously (Asmar et aI, 
1995). Briefly, two pressure waves were recorded simultaneously at two sites 
(at the base of the neck for the common carotid artery and over the right 
femoral artery). Pulse transit time was determined as the average of 30 
consecutive beats in order to cover 5 respiratory cycles. The distance travelled 
by the pulse wave was measured over the body surface as the distance between 
the two recording sites. Aortic PWV was calculated as the ratio of distance to 
transit time. The reproducibility of the measurement for aortic PWV 
(expressed as percent variation of the mean value) has been found 5,3 ± 3,6% 
(Asmar et aI, 1995). The variation coefficient of two consecutive 
measurements of PWV by the same examiner was previously found to range 
from 8-9,7%. 
2.9 Statistical Analysis: 
For all statistical analysis we used the computer software SPSS package for 
Windows '95 software (Version 9.0). Comparison between groups was done 
with student's unpaired t-test for continuous variables. Univariate regression 
analysis was performed according to Pearson. For some parameters log 
transformation was necessary to obtain a Gaussian distribution which is 
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necessary for the parametric tests. Multiple regression analysis was performed 
stepwise on all indicated parameters. 
The results for categorical data are expressed as percentages and continuous 
variables as means ± standard deviation if the distribution was symmetric. 
Plasma triglycerides, apolipoprotein (aJ, fibrinogen and urinary protein values 
were also log-transformed for statistical analysis because of their skewed 
distribution. Since microalbumin levels were below detection limits in a 
considerable number of subjects, this parameter had to be analysed by U-test 
and Spearman's test. Categorical data were analysed by chi-square tests. A p 
value < 0.05 was considered statistically significant. 
The relationship between genotypes and classical risk factors for CHD was 
assessed by one-way analysis of variance (ANOVA). Statistical significance 
was again taken at the 5% level. Analysis of covariance (ANCOV A) was used 
to examine the relationship between genotype, blood pressure (systolic and 
diastolic) and L VMI. Again, to account for the non-normal distribution of 
L VMI, the analysis was done using log transformed data. 
Alle1es and genotype frequencies in cases and control subjects were compared 
by chi-square (X2) tests and by stepwise logistic regression analysis using the 
SPSS program. Since the genotypes constituted a biallelic marker, 
comparisons of genotype distributions and allelic frequencies were assessed by 
t-test with two and one degrees of freedom respectively. Deviation from the 
Hardy-Weinberg equilibrium was tested by X2 test with one degree of freedom. 
The analysis was also carried out by means of an explorative bivariate logistic 
regression analysis to assess the independent role of the different factors using 
MI as the dependent variable and homocysteine, apolipoprotein (aJ, smoking, 
BP, lipids, diabetes, family history and genotype as independent variables. 
Analysis of genetic polymorphisms are sensitive to the allelic frequencies of 
the gene in the population studied. To date very few studies have been 
performed in Asian Indian subjects so that allelic frequencies in these groups 
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are not known. Furthermore, the few studies to date in Asian Indians have 
included subjects with a tremendous degree of heterogeneity in the study 
sample i.e. age range, angina vs MI, geographical area and gender mix (Saha 
et aI, 1996, Ramasawmy et aI, 1996). The number of probands in these 
studies did not exceed 85 and controls, 108. Furthermore, in the original study 
reported by Cambien et al (1992) the Toulouse sample was not in Hardy-
Weinberg equilibrium. This law is relatively robust and deviations from it 
could be explained by the size of the study sample. 
It was therefore decided to include a homogeneous study sample i.e. young 
age, myocardial infarction, cadastral district, time from index event of at least 
50 probands and controls. The number of probands was increased to 100 
when the results of glucose tolerance tests revealed a high prevalence of 
diabetes in this group. Both proband and control groups satisfied Hardy-
Weinberg statistical requirements. 
Methods 
3.1 Assessment of Risk Factors: 




There were 117 probands and 80 controls. In keeping with selection criteria the 
mean age in the proband group was under 50 years (43,1 ± 6.8). The majority 
of pro bands were males (105 males and 12 females). In the control group there 
were 64 males and 16 females. By selection subjects in the control group were 
slightly older (46.4 vs 43.1 years). None of the subjects exhibited clinical 
characteristics of familial hyperlipidaemia i.e. premature arcus, xanthelasma or 
tendon xanthomas. 
The infarct territory in the probands was anterior in 59 (50%), inferior in 48 
(41 %) and two patients had a lateral and posterior (1) infarct. The remaining 
eight patients had anterior infarction with inferior extension. Most patients 
received thrombolytic therapy and during follow up were on aspirin and statin 
therapy. Three had a very low ejection fraction and were receiving in addition 
diuretic therapy. A substantial number of patients received ACE inhibitors (n = 
33 (28%), P-blockers n = 44 (38%) and twenty-four (20%) were referred for 
interventional therapy. 
Details of the patients and control groups are summarised in Table 11. Since 
gender did not play an important role in our study objectives and because there 
were so few females data were combined for males and females in further 
statistical analysis. 
3.1.2 Patient Morphometry: 
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The allometric data revealed significant differences in waist and waist-hip 
measurements as well as body mass index in the two groups. Probands had 
higher waist-hip ratios (0.98 vs 0.94) and wider waists (92.2cm vs 87.8cm) than 
controls (p < 0.05). 
Table IT 
DEMOGRAPHIC DATA AND ANTHROPOMETRY 
PROBANDS CONTROLS 
n=117 n=80 p 
Age 43.l±6.8 46.4±8.5 .006 
GenderMIF 105/12 64/16 
BMI,Kglm2 26.4±4.0 25.1±4.0 .015 
Waist, cm 92.2±10.8 87.8±9.l .002 
WaistlHip 0.98 (0.78-1.12) 0.94 (0.78-1.08) .001 
Values are mean ± SD except for waist/hip (median + range) 
3.1.3 Blood Pressure: 
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were similar 
in both groups. Many probands had nonnal blood pressure but all were taking 
therapy (cardioprotective ACE inhibitors ± P-blockers) which would have 
lowered the blood pressure. Measurements were made after an overnight fast 
so that unifonnly trough levels were recorded in all subjects. Subjects were 
diagnosed as hypertensive if their blood pressure was elevated (> 
160/95mmHg) or they had a diagnosis of hypertension and were taking 
antihypertensive therapy. On this basis 31% of the probands were deemed 
hypertensive (cf.: controls 5%). 
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3.1.4 Behavioural Risk Factors (Table 11): 
3.1.4.1 Smoking: 
Table III shows the percentages of subjects in each group who smoked and 
consumed alcohol. Among the probands only 21 subjects (18%) had never 
smoked and almost half had not taken alcohol. There was a higher percentage 
of current smokers among probands, among whom only 10% made attempts to 
quit the habit completely. 
3.1.4.2 Type A Personality: 
3.1.4.3 
3.1.4.4 
Measurements of lifestyle were assessed by simple questions regarding drive, 
motivation and social interaction and revealed that 54% of probands had Type 
A personality as compared to 16% in the control group (p < 0.05). 
Employment/Education: 
Eighty-five probands (73%) had a low level employment and educational level 
(under standard 9) compared to 50 controls (63%) (p = ns). 
Exercise: 
The level of physical activity in all subjects was assessed by questioning them 
about regular exercise of any sort. Only 26% of probands performed a regular 
exercise routine i.e. 20 minutes at least twice a week. However, almost half the 




RISK FACTOR CATEGORIES 
PRO BANDS CONTROLS P 
% % 
Total Cholesterol> 6.2 mmol/l 26 25 0.919 ns 
Diabetes 47 21 
Impaired Glucose Tolerance 5 7 
Cigarette Smoking 82 26 
Blood Pressure 31 5 
Family History CHD 80 24 
Family History Premature CHD 48 8 
Family History of Diabetes 44 6 
Family History of Hypertension 41 3 
Overweight, > 25 kg/m2 62 49 
Waist> 96 cm 36 14 
Waist /Hip> 1.0 30 16 
Type A Behaviour 54 16 
t Serum Triglycerides > 2.3 mmolll 42 15 
J,. Serum HDL-C < 1.0 mmolll 53 30 
HDLITC<20% 56 34 
t Alcohol Intake 57 30 
Sedentary Lifestyle 74 54 
Microalbumin > 2.8 mg/mmol creatinine 40 19 
3.1.4.5 Diet: 
Of the 117 probands, only 3 patients were vegetarians (cf.: control 5 p = ns). 




















shortly after the index event (myocardial infarct), only to revert to their former 
dietary patterns. After a short while many found it difficult to make the 
lifestyle adjustment required because this meant a change in dietary patterns for 
the whole family. Only those in the higher income bracket managed to 
maintain lifestyle changes. Across the group, and except for the vegetarians, 
diet consisted mainly of curry dishes cooked in sunflower oil. The average 
meat consumption was similar, approximately three times per week, with only a 
low intake of fruit and vegetables. Half of the probands and a third of the 
controls ate fruit and vegetables only once a week. 
3.1.5 Metabolic Risk Factors: 
3.1.5.1 Diabetes Mellitus: 
The proband group had a significantly higher prevalence of diabetes (47%), 
glucose intolerance (4%: WHO definition) and family history of diabetes 
(44%). When this became apparent early in the recruitment phase, the number 
of probands was increased from 50 to 100. All probands had type 11 diabetes 
and most were on oral hypoglycaemic agents except for two who were taking 
insulin. Thirty-two probands and six controls were known diabetics. Diabetes 
was diagnosed for the first time in 33 subjects (21 probands, 12 controls). 
3.1.6 Lipid Profile: 
The lipid profile for the two groups showed important differences. Whereas 
total cholesterol and LDL-C levels, were similar in both groups, significantly 
elevated triglyceride levels and lower HDL-C levels were present in the 
probands (p < 0.05) (Table IV). The likely explanation was that almost all 
probands were receiving lipid-lowering therapy in the form of statins. There 
was however, failure of concomitant attempts at diet-modifying behavioural 
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changes. In order to assess lipid levels independent of treatment effects it was 
decided to assay Lp(a) on a stored sample (at -70°C) of plasma. Lp(a) 
measured as apolipoprotein (a) is essentially unaffected by therapy and 
correlates well with a genetic predisposition to early onset CHD. This assay 
did not reveal any striking changes between probands and controls (p = 0.102). 
However, there was a correlation between the apolipoprotein (a) level and a 




DESCRIPTIVE STATISTICS: BIOCHEMISTRY 
PROBANDS CONTROLS p (m-w) 
Total Cholesterol 5.4 ± 0.12 5.5 ± 0.13 0.384 
LDL-C 3.2 ± 0.10 3.46 ± 0.11 0.074 
HDL-C 1.1 1.3 0.000 
HDL/TC 0.21 0.24 0.005 
Triglycerides 2.8 ± 0.26 1.77 ± 0.18 0.000 
Plasma Glucose (0 hr) 7.44 ± 0.33 5.81 ± 0.25 0.000 
Plasma Glucose (2 hr) 9.10 ± 0.59 7.5 ± 0.52 0.09 
Serum Insulin (0 hr) u/l 19.4 ± 1.85 14.6 ± 1.8 0.799 
Serum Insulin (2 hr) u/l 54.9 ± 5.5 52.3 ± 8.7 0.271 
Ins/glucose (0 hr) 2.38 ± 0.3 2.4 ± 0.3 0.27 
Ins/glucose (2 hr) 8.7 ±2.2 8.7 ± 2.2 0.93 
Haemoglobin AIC (%) 7.08 ± 0.2 6.21 ± 0.2 0.021 
Plasma Fibrinogen (gll) 3.4 3.2 0.106 
Plasma Homocysteine J.lmmolll 18.9 ± 1.0 17.53 ± 0.89 0.511 
Apolipoprotein (a) J.l/l 354.9 ± 25.8 279.0 ± 26.8 0.102 
Microalbuminuria mglmmol creat 7.47 ± 0.97 3.55 ± 0.81 0.000 
Values are Mean ± SE 
3.1.7 Summary of Risk Factors: 
The distribution of the common risk factors in probands and controls are shown 
in Table III and reflects common differences in the risk profile of the two 
groups. Total cholesterol levels were similar in probands and in controls, 
probably reflecting the higher frequency of lipid-lowering drugs in the former. 
None of the risk factors shown in Table III differed according to ACE genotype 
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data. (Refer to 3.2) 
When the probands were divided according to the presence/absence of diabetes 
and other risk factors it emerged that almost of all young Indians (113/117) 
with MI had at least one major risk factor, and that in almost half of them 
diabetes was a major contributor to risk. When a positive family history was 
used as an indicator of heritability, 48% of the probands and 8% of the controls 
had a family history of premature coronary heart disease. A regression analysis 
was performed with family history of cardiovascular disease (hypertension, 
diabetes, CHD, stroke). A family history of premature CHD, hypertension and 
smoking emerged as strong predictors of risk of MI. 
3.2 Angiotensin Converting Enzyme Gene Polymorphism: 
(Fig 2-7 Appendix) 
The ACE genotype distributions in probands (l = 0.03) and controls (X2 = 
0.69) were in the Hardy-Weinberg equilibrium. The relative allelic frequencies 
of the A CE genotypes in controls did not differ from frequencies in the whole 
proband group (l = 1.81), as well as when the probands were subdivided into 




GENOTYPE FREQUENCIES IN PROBANDS (n = 117) & CONTROLS (n = 80) 
HOMO 0/0 HETERO 0/0 HOMO m % 
ACE Gene p 44 38 55 48 16 14 
C 25 33 34 45 17 22 
Agt Core Promoter p 44 39 50 45 18 16 
C 32 43 32 43 11 14 
AT 1 Receptor p 100 86 16 14 0 0 
C 65 81 15 19 0 0 
Aldosterone Synthase P 48 41 54 46 15 12 
C 29 36 44 55 7 9 
I1J3-HSD2 P 115 98 1 1 1 1 
C 76 97 1 1.5 1 1.5 
MTHFR P 94 80 21 18 2 2 
C 64 81 14 18 1 1 
TGF-J3 P 114 98 1 1 1 1 
C 78 98 1 1 1 1 
G-Protein P 61 52 47 40 9 8 
'" 
C 42 53 32 40 6 7 
See Appendix for Hardy-Weinberg Determination and Allelic Frequencies 
P = proband 




GENOTYPE FREQUENCIES IN NON-DIABETICS 
HOMO 0/0 HETERO 0/0 HOMO m 
ACE Gene p 17 27 34 56 10 
C 21 36 24 41 13 
Agt Core Promoter P 22 36 30 49 9 
C 23 40 25 44 9 
AT 1 Receptor P 54 86 9 14 0 
C 50 83 10 17 0 
Aldosterone Synthase P 26 42 30 50 5 
C 23 37 35 56 4 
1113-HSD2 P 60 98 1 2 0 
C 57 98 1 2 0 
MTHFR P 50 82 11 18 0 
C 49 80 11 19 1 
TGF-13 P 61 0 0 0 0 
C 78 0 0 0 0 
G-Protein P 6 10 26 43 29 
C 4 7 27 45 29 
PRO BANDS VS CONTROLS: Monte Carlo Sig. (2-sided) p = ns 
P = Probands 
C = Controls 
Further analysis to identify a group at low risk of CHD was not performed 
since almost all subjects had risk factors . None of the recognised risk factors 
differed according to ACE genotype data. Thus, in this Indian cohort of 
premature MI the ACE genotype was not associated with a significantly 
increased risk of MI. This finding persisted across subgroups without diabetes, 
as well as in groups with putative genetic risk factors i.e. elevated 




















clinical and laboratory variables were compared among genotypes ill the 
control group, no significant differences were noted with regard to 
biochemistry variables. 
3.3 Angiotensinogen Core Promoter Polymorphism: 
(Fig 8-10 Appendix) 
The genotype frequencies in both probands (X2 = 0.35) and controls (i = 0.41) 
were compatible with Hardy-Weinberg equilibrium. There was no differences 
in the genotype frequencies between controls and probands (i = 0.22 : p = ns). 
The allelic frequencies were similar in both groups (X2 = 0.22; P = 0.72). The 
mutant homozygote was present in 18/112 (16%) probands and 11175 (15%) 
controls. There were no differences in the risk factor profile of the two groups. 
The study showed no association between the Agt G-6A polymorphism and 
premature MI in this cohort of patients. 
3.4 Angiotensinogen II Type I Receptor Polymorphism: 
(Fig 11-13) 
The genotype distribution in the proband (i = 0.27) and control group (X2 = 
0.06) was compatible with the Hardy-Weinberg equilibrium. There were no 
differences allelic distribution (X2 = 0.80; p = 0.48) between the two groups. 
The mutant homozygote (1166C) was not seen in probands or controls in this 
study. The frequency of the A allele was 93% in probands and 91 % in controls. 
3.5 Aldosterone Synthase Polymorphism: 
(Fig 14-16 Appendix) 
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The genotype distribution in both case-patients ("l = 0.02) and controls (X2 = 
4.91) were in Hardy-Weinberg equilibrium. The genotype was TT in 15 cases 
vs 7 controls, CT in 54 vs 42 and CC in 48 vs 31 (X
2 = 1.16). The allelic 
frequencies were similar in both groups (X
2 
= 0.03; P = 0.97). 
3.6 IIp-Hydroxysteroid Dehydrogenase 2 Polymorphism: 
(Fig 18-20 Appendix) 
The polymorphism did not exhibit significant deviation from Hardy-Weinberg 
equilibrium in the proband (X2 = 1.31) or control (l = 1.29) groups. No 
significant differences in the allelic frequencies (Fisher's exact; p = 0.69) was 
found between cases and controls. There was only a sample each of the 
mutated genotype in cases and controls, and one each of the heterozygote 
genotype. 
3.7 Transforming Growth Factor-p Polymorphism: 
(Fig 20-22 Appendix) 
The genotypes were similar in both groups (X2 = 0.14). The polymorphism did 
not exhibit deviation from the Hardy-Weinberg equilibrium in cases (X2 = 1.31) 
and in controls (X2 = 1.30). The allelic frequencies were almost identical in 
both groups (Fisher's exact; p = 0,69). No individuals homozygous for the rare 
allele (TT) were identified, nor were there any heterozygotes in this sample. 
These results were confirmed with known heterozygotes identified previously 
and used as positive controls. 
Results 
3.8 Methylentetrahydrofolate Reductase Polymorphism: 
(Fig 22-26 Appendix) 
3.8.1 MTHFR Genotype Distribution: 
56 
The distribution of the genotypes in both probands (l = 0.02) and controls (X2 
= 1.26) was compatible with the Hardy-Weinberg equilibrium. There were no 
differences in the genotype (X2 = 0.85) or allelic (l = 0.18) frequencies in the 
two groups. The allelic frequencies were almost identical: C allele 90% vs 
89%, T allele 10% vs 11 % in probands and controls respectively (X
2 = 0.18; p = 
0.83). 
Homozygosity for the MTHFR polymorphism Val/val (TT) genotype was found 
in one proband (1%) and 2 controls (2.5%). There was therefore no significant 
difference between patients and controls in the prevalence of the TT genotype 
(p = ns). The prevalence of the T allele in the small number of patients with a 
strong family history of CHD was higher than in controls but this difference 
was not significant. 
3.8.2 Homocysteine Concentrations: 
No substantial differences existed in the homocysteine level among the 
genotypes. Patients with the TT genotype did not have elevated homocysteine 
levels. The results of this study do not confirm that MTHFR genotype is an 
important determinant of plasma homocysteine levels in this cohort: TT 
genotype carriers have significantly higher levels than carriers of the other 
genotypes, but this mutation was not common. If homocysteine were indeed a 
cardiovascular risk factor, especially for premature MI, then one would expect 
a higher prevalence of the TT genotype which would predispose carriers to 
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accelerated atherosclerosis. 
3.9 G- Protein Polymorphism: 
(Fig 26-28 Appendix) 
57 
The genotype frequencies were in Hardy-Weinberg equilibrium in both 
probands (X2 = 0.00) and controls (X2 = 0.00). The distribution of the allele (X
2 
= 0.00: p = 0.09) and genotype (X2 = 0.00) frequencies did not differ 
significantly between probands and controls. 
The 825 T allele frequencies were 0.93 in probands and 0.91 in controls. The 
results of this study suggest that it is unlikely that the GNp3 C825T 
polymorphism contributes to the risk for premature MI in this cohort. 
3.10 Pulse Wave Velocity: 
The average PWV was 10.7 ± 0.17 m/sec in probands and 12.2 ± 1.33 mlsec in 
controls. PWV was higher in the controls but the differences was not 
significant (p = 0.393). There was a significant correlation between PWV and 
age (p = 0.001), pulse pressure (p = 0.000), WIH ratio (p = 0.006), and a 
weaker correlation with triglycerides (p = 0.05) and HbAl C (p = 0.045). 
Amongst the controls only age, W IH ratio and systolic blood pressure showed 
correlation with PWV (Table VII). There were significant differences in the 
echocardiographic parameters in the two groups. In keeping with the previous 
infarct, ejection fraction was lower and LV diameter bigger amongst the 
probands (Table VIII). Although this study observed that significant 
correlation existed between PWV and risk factors particularly BP, diabetic 
status and waist measurement indices. No significant correlation was shown 




SPEARMAN'S CORRELATION BETWEEN PULSE WAVE 
VELOCITY & OTHER RISK FACTORS 
PRO BANDS P CONTROLS P 
Diabetes .298 .001 .232 .038 
Age .569 .000 .054 .634 ns 
Blood Pressure .186 .045 .009 .939 ns 
Haemoglobin AIC .251 .006 .276 .013 
WaistlHip Ratio .228 .013 .232 .038 
Systolic BP .379 .000 .061 .589 ns 
Diastolic BP .536 .000 .020 .858 ns 
Pulse Pressure .290 .002 -0.114 .314 ns 
Triglycerides -0.182 .049 -0.851 .542 ns 




PULSE WAVE VELOCITY AND ECHODOPPLER MEASUREMENTS 
PRO BANDS CONTROLS 
x±SE x±SE P 
PWV, m/sec 10.7 ±..O.17 12.2±1.33 .393 
Systolic Blood Pressure 123 ± 2.5 126 ± 2.0 .661 
Diastolic Blood Pressure 77 ± 1.2 76 ± 1.2 .421 
Pulse Pressure, mmHg 49 ± 1.4 50 ± 1.3 .270 
Septum, mm 10.4 ± 0.35 9.0 ± 0.33 .033 
LVIDD,mm 53.8 ± 0.65 45.0 ± 1.2 .000 
Posterior Wall, mm 6.98 ± 0.48 6.28 ± 0.18 .286 
Ejection Fraction 55.0 ±,,1.22 64.4 ±..1.08 .000 
LV Mass, gm 188±5.83 132±5.9 .000 
L V Mass Index, gm/m2 103±3.23 75±3.7 .000 
Doppler E/A 1.42 1.30 .603 
Results 
4. Discussion: 




Strong familial aggregation of CHD has long been recognised. Statistical 
regression studies suggest that only 30-50% of the observed increment in 
familial risk can be attributed to the classical risk factors: raised cholesterol, 
smoking, hypertension and diabetes, which explain only part of the 
epidemiological features of atherosclerotic coronary heart disease. Other 
factors that increase the risk of myocardial infarction alone or in combination 
with the classical risk factors must therefore be operative. These may involve 
lipid dynamics within the plaque, antioxidative defences, endothelial factors as 
well as hereditary determinants that influence atherogenesis. Recent data 
suggest that these factors may accelerate atherosclerosis in the patient with 
risk factors, giving rise to premature coronary events. 
Evidence for genetically determined predisposition for coronary heart disease 
is derived in particular from migration studies. A marked susceptibility is 
observed in regions such as Great Britain, Singapore and South Africa, 
suggesting that the effect of a changing environment is to unmask the genetic 
factors. More recently the results of the Bogalusa Heart Study have shown 
significant clustering of risk factors in both young parents and their offspring 
(Chen et aI, 1999). Therefore, the risk factor profile of young Indians with 
myocardial infarction was determined by interview and assessment of 
biochemical characteristics in order to define the background risk and compare 
this with their genetic patterns. 
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4.1.1 Premature Myocardial Infarction: 
Among Western series myocardial infarction in young patients <45 years is 
thought to be an unusual occurrence. It is quoted that 2-6% of MI occurs in 
young patients (Jalowiec et ai, 1989). At least 80% of young patients with MI 
have typical atherosclerotic coronary heart disease (Warren et ai, 1979), 
manifesting most often as non-obstructive or single vessel disease 
(Zimmerman et ai, 1995). Multivessel disease appears to be related to the 
number of risk factors (Wagner et ai, 1996), particularly diabetes (Hong et ai, 
1994). 
Myocardial infarction in the absence of atherosclerotic disease accounts for 
only 20% of cases in this age group (Choudhury et ai, 1999). The majority of 
our patients probably had atherosclerosis as the cause of their disease, for 
which underlying risk factors were present to a variable extent. None of the 
patients in our study had clinical evidence to suggest coronary embolism or a 
systemic vasculitis, nor did they have any overt signs of a hypercoagulable 
state or history of cocaine drug abuse. Coronary angiography was performed 
in only those patients who were referred for ongoing pain, so that the number 
who had rare coronary anomalies, if any, is not known. 
Risk factors that account for atherosclerosis in young patients include 
smoking, hypertension, diabetes, dyslipidaemia, a positive family history and 
obesity. In addition, hypercoagulable states associated with increased factor 
VIII activity and reduced fibrinolytic activity as a result of increased PAI-1 
levels, use of the oral contraceptive pill and elevated plasma homocysteine 
levels, have all been reported in patients who sustained MI under the age of 45 
years (Choudhury et ai, 1999). 
The baseline characteristics of our study group confirm that young Indian men 
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and women with MI have significant risk factors, even at a younger age. 
Among young Indian males with myocardial infarction Sewdarsen et al (1987) 
noted that 96% had at least one major risk factor for coronary heart disease. 
Smoking was the commonest and present in 79% of patients and serum 
cholesterol above 6,5 mmollL was found in 50% of patients. These risk factors 
were also present in our control group, albeit to a lesser degree. These 
findings are also in keeping with our survey of medical students which showed 
that young Indian medical students develop risk factors for CHD at an early 
age compared with young Black medical students (Morar et ai, 1998). 
This may explain recent trends which suggest an alarming increase in CHD in 
the South African Indian population (Walker et ai, 1993) (cf. Framingham 
data which indicate a decreasing incidence of M! in younger patients). 
On the Indian subcontinent the major risk factors (hypertension, diabetes and 
hypercholesterolaemia) do not play a significant role while insulin resistance 
appears to be an important risk factor. Abdominal obesity, raised triglycerides 
and low HDL-C were markers of insulin resistance in this group (Vardan et ai, 
1995, Singh et ai, 1995). Only 8.2% of patients with CHD had BMI > 
27kg/m2; CHD was present in subjects with BMI 15 kglm2 upward (Thomas, 
1995), and was related to abdominal obesity. 
4.1.2 Behavioural Patterns: 
4.1.2.l Smoking: 
Together with alcohol consumption smoking was predominant among the men 
in our study. It is the major risk factor among young Indians with myocardial 
infarction regardless of their geographical location (Tambyah et ai, 1996). 
Findings similar to our study have recently been reported in a case-control 
study of 200 Indian patients with myocardial infarction in India (Pais et ai, 




smoking. Fasting blood glucose and abdominal obesity were also strong 
predictors of risk but the lipid profile was not associated with myocardial 
infarction. Smoking contributes to risk via several mechanisms: Hughes et al 
(1998) studied 166 Asian smokers in Singapore and showed that smokers had 
lower HDL-C and higher triglyceride levels as well as higher plasma 
fibrinogen and PAl -1 levels contributing to atherosclerosis and thrombosis. 
Physical Activity and Risk of CHD: 
Mortality from CHD has been reported to be inversely related to the level of 
physical activity and to be reduced in subjects who exercise regularly 
(Paffenbarger et ai, 1993). Physical fitness is a determinant of insulin 
sensitivity (Endre et ai, 1994) and is a long-term predictor of mortality from 
cardiovascular disease in healthy middle-aged men (Sandvik et ai, 1993). A 
recent study in Japanese men has shown that those who engaged in regular 
physical activity (>3 days per week) had fewer risk factors than sedentary 
individuals (Hsieh et ai, 1998). In our study subjects were classified sedentary 
if they did not engage in physical activity at least once per week. There was 
no significant difference in age among the sedentary and physically active 
groups, but there was a high prevalence of physical inactivity in the proband 
group, and this was negatively correlated with the HDL-C level. 
4.1.3 Dyslipidaemia: 
This study confirms previous observations that Indian men and women with 
MI have significantly lower levels of HDL-C than controls with an 
approximate 20% difference in HDL-C levels. The expected inverse 
correlation of BMI and W IH ratio with HDL-C was observed in probands. 
None of the women were recelvmg oral contraceptives; so this does not 
Discussion 
64 
explain lower HDL-C levels in them. In contrast most men were ex-smokers 
and had taken alcohol so that part of the explanation for the lower HDL-C may 
be due to these factors. 
Serum levels of high-density lipoprotein or apolipoprotein A-I (apo A-I) are 
inversely correlated with the risk of CHD (Gordon et ai, 1977). Genetic, 
hormonal and environmental factors determine HDL-C and apo A-I levels 
within distinct populations. In addition, HDL-C levels differ considerably 
among different ethnic groups. Obesity and insulin resistance are associated 
with low HDL-C in many populations, (Reaven et ai, 1994, Despres et ai, 
1996) particularly in Indians in whom a high prevalence of diabetes exists 
(Stern, 1995). In addition to insulin sensitivity, the distribution of body fat is 
an important determinant of HDL-C levels. Intra-abdominal fat is considered 
to be a chief determinant of metabolic complications associated with 
cardiovascular risk and is reflected in measures of central obesity. Waist 
measurement is therefore considered to be a better predictor of CHD than BM! 
(Depres et ai, 1990, Larsson et ai, 1984). WaistlHip ratio showed a strong 
inverse correlation with HDL-C in our study (Table IX). The HDL/TC ratio 
also showed a strong inverse correlation with BMI, WIH ratio and HbAIC 




SPEARMAN'S CORRELATION BETWEEN WAIST-HIP 
RATIO AND OTHER VARIABLES 
PROBANDS CONTROLS 
r p r p 
Diabetes .329 .000 .226 .044 
Microalbumin .281 .002 .092 .416 ns 
SBP .215 .020 .401 .000 
DBP .272 .003 .365 .001 
Pulse Pressure .196 .036 .159 .158 ns 
PWV .228 .013 .232 .038 
LV Mass .323 .000 .240 .032 
HDL-C -0.252 .006 .349 .002 
HDLITC Ratio -0.290 .002 -0.195 .085 ns 
4.1.4 Hyperinsulinaemia and CHD: 
Epidemiologic studies have reported an association between insulin levels and 
cardiovascular events (Haffner et ai, 1998). Although a recent meta-analysis 
has shown that hyperinsulinaemia is a weak indicator of cardiovascular risk 
the relationship appears to be stronger in middle-aged patients (Ruige et ai, 
1998). 
A large trial has shown that there is a negative association between insulin 
sensitivity and carotid intima-media thickness, an indicator of coronary 
atherosclerosis (Howard et aI, 1996). Few studies have examined the effect of 
insulin on arterial stiffness (Salomaa et ai, 1995, Emoto et ai, 1998). In the 
Atherosclerosis Risk in Communities Study (ARIC) the joint effect of 
hyperglycaemia, hyperinsulinaemia and hypertriglyceridaemia contributed 
synergistically to an increase in arterial stiffness. In our study we showed 
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significant correlations between insulin and obesity parameters but no 
correlation with microalbuminuria (Table X). 
Table X 
SPEARMAN'S CORRELATION BETWEEN INSULIN, 
MICROALBUMIN & OTHER VARIABLES 
PRO BANDS CONTROLS 
r p r p 
Insulin (1 hour) BMI .351 .000 .516 0.006 
W .349 .001 .405 0.036 
W/H .305 .003 .249 0.211 ns 
Pulse Pressure .274 .007 .146 0.466 ns 
Insulin (2 hour) BMI .342 .007 .405 0.076 
W 0309 .015 .072 0.763 ns 
W/H .280 .028 .025 0.918 ns 
Microalbumin W/H ratio .092 .416 ns .281 0.002 
Fibrinogen .237 .010 .028 0.807 ns 
Homocysteine .021 .82 ns .386 0.000 
Smoking .249 .007 .254 0.023 
4.1.5 Ethnicity, Diabetes and CHD: 
Type II diabetes carries a strongly increased risk of cardiovascular disease. 
Since hyperinsulinaemia precedes type II diabetes and is associated with an 
adverse cardiovascular risk profile, it is thought that insulin resistance might 
be operative in the pathogenesis of CHD and type II diabetes (Stem, 1996), 
and may be explained on the basis of endothelial dysfunction which is an early 
finding in these patients. Insulin resistance, hyperinsulinaemia and impaired 
glucose tolerance are key components of the metabolic syndrome. Ethnic 
background appears to be a strong determinant of the relationship between 
insulin and CHD (Ruige et at, 1998). This may explain ethnic differences in 
the prevalence of diabetes and the propensity to heart disease. South Asian 
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diabetics have a significantly higher risk of myocardial infarction and death 
from cardiovascular disease than white diabetics (Mather et ai, 1998). 
Hughes et al (1990) reported that the higher mortality for coronary heart 
disease could not be explained by smoking, blood pressure and serum 
cholesterol but he felt that low levels of HDL-C and higher rates of diabetes 
were part of the explanation. He showed that Asian patients with NIDDM had 
higher mean body mass index, waist/hip ratios and abdominal girth. They also 
had a higher prevalence of hypertension, lower HDL-C and higher PAI-l 
levels, components of the metabolic syndrome that increase the risk of 
atherosclerosis and thrombosis. However, he found no differences from 
controls for cigarette smoking and LDL-C, (Hughes et ai, 1998). These 




SPEARMAN'S CORRELATION BETWEEN DIABETES AND OTHER 
RISK FACTORS 
PROBANDS p CONTROLS l.!... 
BMI .433 .000 .254 .023 
Waist .426 .000 .355 .002 
W/H Ratio .329 .000 .072 .524 
BP .193 .037 .161 .153 
Pulse pressure .231 .013 .205 .069 
PWV .298 .001 .232 .038 
LV mass .038 .686 .231 .039 
EtA ratio -0.242 .008 .145 .204 
Triglycerides .235 .002 .160 .155 
Microalbuminuria .276 .003 .355 .001 
As a group Indians have a high genetic risk for diabetes. Adult offspring of 
diabetic parents exhibit hyperinsulinaemia and decreased insulin sensitivity 
long before the development of glucose intolerance (Ramachandran et aI, 
1998). Similarly, our study of risk factors in medical students revealed that 
Indian students exhibited metabolic changes including hyperinsulinaemia 
more frequently than their Black counterparts (Morar et aI, 1998). 
A field survey of South African Indians in Durban, (Seedat et aI, 1990) 
showed that at least two thirds of Indian subjects had a major risk factor for 
coronary heart disease with a high prevalence of insulin resistance. In Britain 
Mckeigue et al (1991) found that the high prevalence of insulin resistance in 
the South Asian popUlation was associated with coronary heart disease and 
obesity. Similar results have been shown for Asian Indians in the USA in 
whom resistance to insulin suppression of free fatty acid levels has been 
shown to be associated with metabolic risk factors (Laws et aI, 1994). In an 
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early report of coronary heart disease in 3 different racial groups in Durban 
diabetes was detected in 47% of Indians with coronary heart disease 
(Thandroyen et ai, 1980). Subsequently, Sewdarsen et at (1991) studied 131 
Indian type 2 diabetic patients 3-4 months after myocardial infarction. He 
found that the diabetic subjects were older and more likely to be hypertensive, 
whilst smoking and a family history of coronary heart disease was common in 
non-diabetic subjects. Amongst women with myocardial infarction he found 
that diabetes mellitus was the commonest risk factor, was present in 78% of 
patients and was associated with a family history of myocardial infarction in 
first-degree relatives (Sewdarsen et ai, 1988). 
4.1.6 Family History: 
A family history of premature CHD in a first degree relative is recognised as 
an independent risk factor for coronary disease (Myers et ai, 1990). 
Epidemiological studies suggest that first degree relatives of coronary patients 
have a 2.5 to 7 fold increase in risk of death from CHD compared to those 
without a family history of CHD (Slack et ai, 1966). In our study, the 
inherited basis of CHD is likely to be represented in the large group with a 
strong family history of premature CHD (48%), although the influence of 
factors such as raised homocysteine and Lp(a) levels cannot be excluded. 
Whilst clustering of risk factors within families suggests that this may be due 
to a genetic influence, particularly in those with diabetes, it is apparent from 
the dietary and behavioural habits that an environmental influence probably 
contributed to their cardiovascular disease. Most interesting in our study was 
the fact that there were hardly any subjects who had no identifiable risk factors 
(n = 4). In most subjects shared environmental influences are likely to have 
had an important effect. Whilst single gene abnormalities such as the LDL 
receptor mutation have been linked to CHD later in life, in most cases the 
development of atherosclerosis is likely to have had a polygenic basis against a 
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setting of environmental risk factors. 
Inherited vascular risk may be mediated by a number of mechanisms. Several 
major risk factors such as diabetes and hyperlipidaemia are known to be 
genetically influenced, including levels of newly identified risk factors such as 
homocysteine, Lp(a) and fibrinogen. In addition, endothelial dysfunction has 
been demonstrated in humans with clinical evidence of atherosclerosis (Vita et 
ai, 1990) as well as in young asymptomatic subjects who have established 
cardiovascular risk factors such as smoking (Celemajer et ai, 1993) and 
diabetes (Clarkson et ai, 1996). It is likely that a variety of genes interact to 
accelerate damage from these risk factors. 
Identification of unaffected siblings at risk therefore becomes an important 
target in the primary prevention of CHD in this high-risk population. A 
marker to select those young people with a strong family history of premature 
CHD who are at risk may lie in determination of genetic patterns, insulin and 
homocysteine levels, markers of endothelial dysfunction (microalbuminuria) 
and arterial stiffness (PWV). 
4.2 ACE Gene Polymorphism: 
The A CE genotype had no influence on the development of MI in this cohort 
of young Indians. Furthermore, no major impact of these polymorphisms on 
blood pressure, patient morphometry and biochemical parameters were 
detected. 
4.2.1 Studies in Asian Indians: 
There are three studies of A CE gene polymorphism in Indian patients with 
coronary heart disease. In Singapore Saha et ai (1996) studied 155 Chinese 
and 72 Indians with myocardial infarction and showed no significant 
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association of the A CE gene with CHD or MI in either race group. In addition 
he showed that the frequency of the D allele was significantly lower than that 
reported in Caucasians. 
In another study, Ramasawmy et al (1996) compared 85 young Mauritian male 
MI survivors with 108 control subjects and found no association between ACE 
liD polymorphism and susceptibility to early onset myocardial infarction. In 
this study the frequency of the D allele was 42% in probands and 43% in 
control subjects. Although Gardemann et ai, (1998) has shown that the D 
allele is associated with coronary heart disease in younger subjects « 61.7 
years) no clear association between A CE genotype and coronary heart disease 
has been demonstrated in the Indian population studies. 
4.2.2 Meta-analyses: 
A meta-analysis of 46 studies, totalling 32,715 subjects has shown that the D 
allele is associated with a 28% increase in plasma ACE activity, a 21% 
increase in the risk of MI and 16% increase in ischaemic heart disease for the 
DD genotype vs. ID and 11 genotypes. However, none of these risks were 
significantly increased when the largest studies were examined separately 
(odds ratio for MI: 0,9, for IHD: 1,09), suggesting that ACE gene 
polymorphism affects plasma ACE activity but not blood pressure and the risk 
of MI (Agerholm-Larsen, 2000). Given the confounding effects of ACE-
inhibitor therapy, which almost all probands received, we did not measure 
renin, aldosterone or ACE activity in our patients. 
In another meta-analysis of fifteen studies totalling 3394 myocardial infarction 
cases and 5479 control subjects Samani et al (1996) provided pooled estimates 
of the association between A CE liD polymorphism and the risk of myocardial 
infarction but the strength of the association was weak. Several important 
limitations have emerged from this meta-analysis that could explain the 
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heterogeneity of results among studies. The studies were carried out in highly 
select groups of cases with less than ideal control subjects. Often cases were 
collected some time after the MI raising the possibility of selection by 
survival. Thirdly, using a funnel plot of sample size vs. odds ratio Samani et 
al (1996) showed that a significant trend towards positive associations were 
reported in the smaller studies, resulting an over-estimation of the true effect 
of the D allele. This reflects the importance of the size of the study needed to 
prove an association. If the risk of MI with the DD genotype is 26% then 
1400 probands and a similar number of controls are required to have 80% 
power to detect a difference between DD and II/ID genotypes at a probability 
ofO,05. 
Subjects similar to ours have been reported in a Norwegian study by Bohn et 
al (1993) who showed that the differences could be due to chance, undetected 
selection bias, different gene-environment interactions, or to preferential loss 
of DD individuals in the high-risk cohort. 
4.2.3 Low Risk and DD Genotype: 
There were too few subjects defined to be at lower risk of MI (by low body 
mass index and low cigarette consumption) and therefore one cannot comment 
on the association of the DD genotypes with MI by this stratification. 
Although a few studies (Cambien et aI, 1992, Ludwig et ai, 1995, Keavney et 
ai, 1995, Gardemann et aI, 1995) have reported that the risk of MI associated 
with the DD genotype is increased in low risk subjects, a large well-designed 
study (Tiret et aI, 1993) did not show this. In another cohort analysis of 388 
Italian patients the D allele showed the strongest association for 
atherosclerosis but the distribution of the risk factors among the three 
genotypes was similar (Arbustini et aI, 1995). 
4.2.4 Mortality and DD Genotype: 
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Cambien et al (1992) reported that the DD genotype was slightly more 
prevalent in 610 patients who survived MI than in 733 controls (32% vs 27%), 
especially in individuals with below average lipids and body mass. In subjects 
at low risk of MI (apo B < I, 25 g/l and BMI < 26 kg / m
2
) the risk ratio of the 
DD vs. ID + II was 2,7 (p < 0,0005). In our study there was no difference in 
the frequencies of the genotypes between probands and controls, even when 
comparing 'low risk' probands to control subjects by this stratification. 
The biological role of angiotensin converting enzyme suggests that the ACE 
gene is a candidate for myocardial infarction. The D allele has a frequency of 
0,53 in Caucasians and is co dominantly associated with higher plasma and 
cellular angiotensin converting enzyme levels. It therefore appears that the 
increased risk associated with the DD genotype may be related to higher 
intracardiac production of Ang 11 leading to coronary vasoconstriction and 
hypertrophy. This may also explain the higher prevalence of restenosis after 
PTCA in subjects with the DD genotype (Ohishi et ai, 1993). In a large case-
control study (ECTIM) an increased risk of MI and an increased frequency of 
parental MI were demonstrated in subjects carrying the D allele (Tiret et ai, 
1993). This relationship was stronger in subjects at low risk of myocardial 
infarction. Further evidence that the D allele could increase the risk of death 
in patients with coronary heart disease comes from the Belfast Monica Project 
which showed an increase frequency of the D allele in autopsy cases of MI 
(Evans et ai, 1994). 
Perhaps the largest study to date with conflicting findings is the prospective 
study of US male physicians by Lindpaintner et al (1995). In this study 1250 
men with CHD were compared to 2340 control subjects according to age and 
smoking history. The presence of the D allele confirmed no appreciable 
increase in risk of coronary artery disease or 'myocardial infarctions' even 
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among low-risk subgroups. 
In a recent analysis Samani et al (1996) prospectively studied 684 patients 
with MI and followed them up to assess the impact of the genotype on 
prognosis. He found that the genotype distribution did not influence the short-
to- medium term prognosis after MI. 
4.2.5 Diabetes Mellitus and ACE Genotype: 
A field survey in Durban (Seedat et ai, 1990) has shown that at least two thirds 
of Indians subjects have a major risk factor for coronary heart disease. 
Diabetes mellitus was strongly associated with a positive history of coronary 
heart disease. This finding is interesting since PIMA Indians have a low 
incidence of coronary heart disease despite a high prevalence of diabetes (Nagi 
et ai, 1998)! It is thought that the lower frequency of the D allele among 
PIMA Indians may underlie their low risk of coronary heart disease. In 
contrast Ruiz et al (1994) found that the DD genotype is an independent risk 
factor for coronary heart disease in type 11 diabetes. The D allele has been 
found be a risk factor for MI in type 11 diabetes mellitus especially in those 
subjects judged to be low-risk. Keavney et al (1995) studied 173 newly 
diagnosed Caucasian type 11 diabetic patients who developed myocardial 
infarction and showed that the D allele was associated with MI in those with 
low plasma LDL-C or low triglyceride levels. We found no difference in the 
genotype frequencies in the diabetic subgroups in our study. In an extensive 
review Kennon et al (1999) performed a meta-analysis and showed that the 
A CE genotype had a significant impact on the progression of diabetic 
nephropathy. Significant odds ratios were shown in individuals with the DD 
genotype for coronary heart disease, myocardial infarction and both diabetic 
and non-diabetic renal disease in his study. 
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4.2.6 Limitations to Genotype Studies: 
4.2.6.1 
4.2.6.2 
Homogeneity of Sample: 
Studies of linkage disequilibrium are highly sensitive to selection of a 
genetically appropriate control sample (Samani et aI, 1996). Case-control 
studies from populations with a heterogeneous genetic background can be 
misleading. For example, in two areas of Finland the prevalence of the DD 
genotype was different in two population-based samples (Perola et ai, 1995). 
In the original study by Cambien et al (1992) the Toulouse sample was not in 
Hardy-Weinberg equilibrium. This law is relatively robust and deviations 
from it could be explained by selection or by the size of the sample. The 
number of subjects in our study is small but few studies have been carried out 
in homogeneous populations including so many subjects (Agerholm-Larsen et 
aI, 1997). Coronary heart disease is a multifactorial disease influenced by 
environmental and genetic factors. The effects of the genotype are determined 
by gene-gene as well as by gene-environmental interactions. Because of 
marked geographical differences in prevalence of risk factors gene 
polymorphisms must be evaluated in the homogeneous samples with the same 
coronary heart disease risk. 
The conflicting results of association studies may also be partially explained 
by the remarkable differences of the allele frequencies in the populations 
investigated. For instance, the frequency of the D allele and the DD genotype 
is significantly increased in the hypertensive African-American population 
(Dum et ai, 1994) compared with normotensives controls. 




Studies reporting an association of the I allele of ACE liD polymorphism could 
be biased by a deficit of the D allele in older subjects, as a consequence of the 
lethality of the D allele (Evans et ai, 1994). In the present study those patients 
who died before admission to hospital or within the first few hours after 
admission were not included. The mean age of our subjects was under 45 
years and we could find no evidence of a 'D allele-dropout' when we stratified 
subjects by age. In addition, there was no significant deviation from the 
Hardy-Weinberg equilibrium for any of the polymorphisms studied. We are 
confident that the genotyping data are accurate since an insertion-specific 
primer was used in the analysis and the gels were read independently by two 
trained observers. Thus these results cannot readily be explained by selective 
loss of DD homozygotes, a finding that has been described previously (Morris 
et ai, 1994). 
In our study the restriction of the inclusion criteria to young patients with 
coronary heart disease who had myocardial infarction could have introduced a 
selection bias. Young patients were chosen to eliminate the confounding 
effect of age as a risk factor, and also to possibly enrich the genetic 
determinant in the study group. Several other pathogenetic, including 
thrombotic, mechanisms could be operative in this group. 
Size of Sample: 
Significant difficulties in the assessment of genetic studies have been the small 
numbers of subjects studied, (resulting in low discriminating power) and the 
presence of mixed genders. In the ECTIM study, an odds ratio of 1.3 was 
observed for those having the V allele in the MTHFR polymorphism. 
Assuming a dominant model and an allele frequency of 0.35 in controls, this 
would imply an allele frequency of 0.37 in cases and to replicate the results of 
the ECTIM study with 80% power, 950 cases and 950 controls would be 
required. The fewer number of subjects investigated may explain the lack of 
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an association of MI with the gene polymorphisms studied. It is therefore 
possible that larger investigations are needed to draw final conclusions. 
Polymorphisms in genes related to cardiovascular homeostasis have often 
required multiple and large studies (ECTIM) to clearly define attributable 
genetic risk. The current study is therefore unable to answer this question and 
anticipates the pooling of data from different regions to achieve numbers 
affording adequate power. Successful application of this type of case-control 
study design, however, is dependent on the ability to identify a group of cases 
and control subjects from the same genetic pool. If allele frequencies of cases 
and control subjects differ for any reason that is not due to the disease process, 
such as population stratification, then false positive, or false negative results 
may occur. 
In order to minimise this problem, cases and control subjects were drawn from 
the same homogeneous popUlation in our study. 
4.3 Angiotensin Core Promoter Element: 
Previous reports suggest that variants of the angiotensinogen gene were 
associated with an increased risk of essential hypertension (Jeunemaitre et aI, 
1992, Brown et aI, 1994, Hegele et aI, 1994, Kamitani et aI, 1994, Caulfield et 
aI, 1994). Another potential mechanism by which angiotensinogen may 
influence susceptibility to CHD may be related to its abundant expression in 
human adipose tissue (Ailhaud, 1997). This may represent a potential link 
between blood pressure and insulin resistance, especially in obese subjects 
(Aubert et aI, 1990). 
4.3.1 MI, Hypertension and Agt Genotype: 
Several gene loci encoding components of the RAS have been implicated in 
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cardiovascular diseases. Whereas there is continuing controversy regarding 
the role of the ACE DD genotype, the angiotensinogen gene has been 
consistently linked to hypertension and also contributes to the risk of CHD 
(Katsuya et ai, 1995). 
Tiret et al (1995) studied two Agt polymorphisms: T174M and M235T in 630 
MI subjects. He found that the T174M and the M235T genotype distributions 
did not differ between MI survivors and controls, but subjects with BMI < 26 
Kg/m2 had a higher prevalence of hypertension if they carried the M174 allele. 
In a recent meta-analysis, Staessen et al (1999) analysed 69 studies totalling 
27,906 subjects and showed that the T allele was associated with an increased 
risk of hypertension in Caucasians, but not in Blacks or Asians. The T allele 
was associated with 7-11 % rise in circulating angiotensinogen levels but was 
not associated with atherosclerosis or microvascular complications. In 
contrast to these findings, Staessen's et al (1997) earlier meta-analysis of 145 
reports on 49,959 subjects showed that possession of the D allele of ACE gene 
polymorphism was associated with an increased risk of atherosclerotic and 
renal microvascular complications. In comparison with the 11 group the excess 
risk in DD homozygotes was 32% for CHD, 45% for MI, 94% for stroke and 
56% for diabetic nephropathy. The corresponding risk in ID heterozygotes 
amounted to 11 % for CHD and 13 % for MI. 
4.3.2 LV Size and Genotype: 
Experimental and clinical data show that the RAS may influence progressive 
ventricular dilatation, ventricular function and outcome after MI. In addition 
to a direct toxic effect on myocardial cells, Ang 11 may induce hypertrophy in 
non-infarcted areas, activate the sympathetic nervous system, stimulate 
fibroblast proliferation, increase ventricular afterload and impair diastolic 
relaxation (Riegger et ai, 1996). Modulating these mechanisms may explain 
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the beneficial effects of A CE inhibition, started early after MI and accounts for 
the reduction in morbidity and mortality for major cardiovascular events in 
clinical trials. 
4.4 ATl Receptor Polymorphism: 
The findings of the present study are at variance with previous reports. We 
have not shown any relation between the AT] receptor genotype and the risk of 
premature MI. This may be related to the low prevalence of severe 
hypertension in our patients. The AT] C allele has been shown to be more 
frequent in patients with severe hypertension and myocardial infarction (Tiret 
et aI, 1994). In an allelic interaction study Hingorani et aI, (1995) has shown 
that both SBP and DBP track with the I allele of the ACE gene and the 1166C 
allele of the AT] receptor gene. Although the AT] receptor genotype has been 
associated with hypertension, in cross-sectional studies this polymorphism has 
not been found to be associated with aortic stiffness. 
In a study of all three RAS candidate gene polymorphisms, (ACE liD, Agt 
M235T, T174M and AT]R Al166C), Riegger et al (1996) found that 
hypertensive patients reporting a parental history of MI before age 60 years 
had a higher prevalence of the ACE D allele. Similar results were obtained in 
patients reporting a parental history of stroke before age 65 years. The Agt 
T235 allele prevalence was higher in male hypertensives and the AT] C1166 
allele higher in females. 
Other studies of RAS gene polymorphisms have shown an interaction between 
the AT] receptor genotype and ACE DD genotype on the occurrence of MI. 
There is also recent evidence of synergism between the ACE DD genotype and 
the AT] 1166 CC genotype that further increases the risk of ischaemic events 
after MI (van Geel et aI, 1998). In addition the interaction between the AT] 
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genotype and the ratio of TC/HDL on aortic stiffness suggests that the AT] 
1166 C allele confers a combined genetic susceptibility to cardiovascular risk 
in association with clinical risk factors. This does not appear to be so in our 
patients and probably applies to Caucasians. 
4.5 Aldosterone Synthase Polymorphism: 
This study does not support a role for eyp IlB2 e344T polymorphism in this 
selected cohort of patients with premature myocardial infarction. The results 
are in keeping with a previous report which showed that genetic variation in 
the promoter of CYP 11 B2 may influence blood pressure regulation but its 
association with CHD is at best weak (Hautanen et ai, 1997). 
Recently, White et al (1998) showed that the -344 e allele eyp Il B2 
polymorphism is strongly associated with increase in L V size (White et ai, 
1998, Kupari et ai, 1998) and decreased baroreceptor sensitivity and could be 
associated with MI in susceptible individuals. Analysis of 2007 participants in 
the MONICA (Monitoring Trends and Determinants of Cardiovascular 
Disease Study), however, did not find any significant effects of this 
polymorphism on serum aldosterone, BP or cardiac size and function 
(Shunkert et ai, 1999). 
4.6 11 ~-Hydroxysteroid Dehydrogenase 2 Polymorphism: 
Decreased activity of IljJ-HSD2, the enzyme that converts cortisol to 
cortisone may be associated with salt sensitivity, hypertension and the 
metabolic syndrome (Sharma et ai, 2000). Although a recent study found an 
association of the 11BHSD2 G534A marker with end-stage renal disease 
(Smolenicka et ai, 1998). Brand et ai, (1998) studied a population of 347 
hypertensive sibling pairs and found no association with hypertension in 
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Caucasians. She concluded that this gene may be relevant in other 
populations. The frequency of the substitution has been reported to be about 
5% (Brand et ai, 1998). In this study we investigated the prevalence of 
llBHSD2 G534A gene polymorphism in premature MI and found no 
association since the genotype frequencies were similar in cases and controls. 
The association was also not significant when comparing subgroups including 
hypertensive pro bands. 
4.7 Transforming Growth Factor-~ Polymorphism: 
The analysis reveals that the !le 263 polymorphism is infrequent in the Indian 
population. To test the validity of our technique we used known positive 
mutant homozygotes as controls from Benjamin Franklin University and were 
able to reproduce the findings. Interestingly we identified no individuals 
homozygous for the rare allele of the gene variants, although this was expected 
with the fewer numbers included in the present study. Given the low 
frequency of the lie 263 variant it is not possible to make any inferences about 
the genetic control of serum levels of TGF-fJl in this cohort. Whether other 
polymorphisms in the promoter region account for this and so predispose to 
cardiovascular pathology is not clear. 
Although increased serum levels of TGF-fJ have been reported in diabetes 
(Pfeiffer et ai, 1996) and atherosclerotic disease (Blann et aI, 1996) studies of 
five polymorphisms in the TGF-fJl gene have not shown any association with 
CHD or hypertension (Syrris et aI, 1998). Further studies have reported not 
only elevated circulating levels of this cytokine in coronary artery disease 
(Wong et aI, 1997, Tashiro et aI, 1997) but also increased expression in heart 
muscle after MI (Sharma et aI, 1999, Fukumoto et aI, 1998, Sun et aI, 1998) 
and on restenotic vascular lesions (O'Brien et ai, 1996). Furthermore, there is 
evidence that many cytokines are upregulated in the intima and there is 
increased responsivity to PDGF and TGF-fJ in medial smooth muscle cells in 
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diabetic patients. These changes lead to proliferation and migration of smooth 
muscle cells into the intima and further accelerate the formation of the 
atherosclerotic lesion (Miyagawa et ai, 1999). 
Seven polymorphisms in the TGF-fJ] gene have been reported in the ECTIM 
study (Cambien et ai, 1996). One of these polymorphisms, the presence of the 
Arl5 allele, was associated with higher blood pressure and a family history of 
hypertension in the normotensive controls compared with individuals with the 
Pro25 allele. The Arl5 allele has also been associated with increased TGF-fJj, 
production and fibrosis. 
4.8 Methylenetetrahydrofolate Reductase Polymorphism: 
This is the first study to report homocysteine levels in relation to MTHFR 
genotype in young Indian MI survivors. An abstract by Kotze et al (1999) has 
shown that the MTHFR gene polymorphisms were more common in Caucasian 
than in Africans in South Africa but she did not report findings in Indians. 
Although raised homocysteine levels were common, our results could not 
confirm that the TT genotype in the MTHFR gene is a strong predictor of 
raised plasma homocysteine since the genotype was infrequent in this cohort. 
The positive results from retrospective studies may reflect a consistent bias 
resulting from measuring homocysteine after the acute vascular events. 
Although the association between homocysteine and atherothrombotic events 
appears to be independent and dose-related it remains to be established 
whether it is causal and modifiable. Due to the close coupling between folate 
metabolism and the methylation of homocysteine to methionine, the plasma 
level of homocysteine is strongly related to serum and red cell folate (Jacques 
et ai, 1996). Because blood levels of folate and B 12 are related inversely to 
homocysteine, nutritional deficiency leads to an increased risk of 
hyperhomocysteinaemia. Although we did not measure serum folate and B 12 
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levels in our patients their nutritional status appeared satisfactory and we did 
not suspect this as a cause of raised homocysteine levels in our patients. 
The mechanism by which homocysteine may cause vascular damage is 
unclear. There is experimental evidence that homocysteine promotes 
atherogenesis by facilitating oxidative arterial injury, so damaging the vascular 
matrix and enhancing vascular smooth muscle cell proliferation. It may also 
promote thromboembolic disease by causing oxidative damage to the 
endothelial lining leading to impaired vasomotion and procoagulant effects 
(Hankey et aI, 1999). 
4.8.1 Homocysteine and CHD: 
An elevated plasma homocysteine is reported to be a risk factor for accelerated 
CHD. As pointed out earlier, the effects of high plasma homocysteine levels 
has not been shown to be mediated by the known coronary risk factors 
(Tonstad, 1997). These findings are in contrast to a study in an Indian 
population with relatively low cholesterol levels in which raised fasting 
homocysteine was an independent risk factor for CHD (Chambers et aI, 1999). 
In our study there was no correlation between homocysteine levels and 
myocardial infarction. Our findings are in keeping with Chacko (1998) who 
studied 56 patients with CHD and found that plasma homocysteine was not a 
major risk factor in the Indian population. 
Recently, a large study of 2453 male Caucasians showed that there was indeed 
no association between MTHFR C677T gene polymorphism and the risk of 
CHD and myocardial infarction (Gardemann et aI, 1999). Carriers of the TT 
genotype with high-risk profiles, however, had higher CHD scores than 
individuals with one allele. 
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4.8.2 MTHFR and Premature CHD: 
Tsai et aI, (1996) studied a patient population of premature CHD, similar to 
our study and showed that 39% of their patients with CHD had elevated 
plasma homocysteine. However, although the TT genotype was more common 
(22.8%) in individuals with raised homocysteine (10.7%) the frequency of the 
TT genotype was not increased in patients with premature CHD (10.6%) as 
compared to controls (14.6%). This finding is agreement with recent 
publications (Ma et aI, 1996, van Bockxmeer et aI, 1997, Brugada et aI, 1997, 
Christens en et aI, 1997, Verhoef et aI, 1997, Gardemann et aI, 1998). Thus, 
data from several studies suggest that the TT genotype is not an important risk 
factor for CHD (Verhoef et aI, 1997). It appears that plasma homocysteine 
may be an innocent bystander or marker rather than be playing a causative role 
in the atherosclerotic process in the vessel wall. Alternatively, the TT 
genotype may be a marker of risk in individuals with low folate levels. 
4.8.3 Limitations to the Study: 
Whereas some investigators have identified the TT genotype as a risk factor 
for CHD others have failed to identify a link between this genotype and 
accelerated atherosclerosis. These discrepancies might be due to differences 
in the study design. This study failed to detect an association of MTHFR gene 
polymorphism with non-fatal myocardial infarction. It should be noted that 
probands constituted survivors of myocardial infarction and not patients with 
fatal outcome of this disease. This bias in selection could explain, in part, 
some of the discrepancy in the findings. It is also not known to what extent 
other gene variations, also postulated to be associated with CHD, might 
interfere with the link between the MTHFR 677T gene polymorphism and the 
risk of myocardial infarction. Potential candidates are polymorphisms of the 
RAS genes, as well as genes involved in lipid and glucose metabolism, since 
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diabetes mellitus was clearly a major contributor to CHD risk in this cohort. 
4.9 G-Protein Polymorphism: 
This study reveals no association between GNp3 (825T) polymorphism and 
premature MI. Although Siffert et aI, (1998) demonstrated a significant 
association of this polymorphism in hypertensive patients a large scale study 
in 681 hypertensive and 564 M! subjects failed to show any association with 
hypertension or M! (Brand et aI, 1999). In the present study the 825T allele 
frequencies were 0.73 in both probands and controls. Because increased 
NHE-l activity is associated with L VB and susceptibility to nephropathy in 
insulin-dependent diabetes, (Siffert et aI, 1996) we also analysed the diabetic 
subgroup separately but found no increase in the frequency of 825T allele 
here. 
There is also new evidence that the G-protein P3 subunit 825T allele is 
associated with high BM! in male Caucasians (Sharma et aI, 2000). Recently, 
Naber et aI, (1998) investigated GNf33 C825T polymorphism in 617 patients 
undergoing coronary angiography. The 825T allele was associated with a two-
fold increase in the risk of CHD and MI. 
4.10 Pulse Wave Velocity: 
Although close correlations have been shown between PWV and 
atherosclerosis in elderly subjects (van Popele et aI, 1998) no study has looked 
at PWV in younger patients « 5 5 yr), so removing the effects of ageing with 
established CHD. Nor has any study attempted to correlate PWV with risk 
factors and gene polymorphism. In this study PWV was measured in all 
fasting subjects (at trough level for all cardiovascular medications) and 




4.10.1 PWV and Gene Polymorphisms: 
In this study polymorphisms of the RAS genes were not related to the 
development of aortic stiffness. Benetos et al (1995) showed no influence of 
ACE gene polymorphism on aortic stiffness but Castellano et aI, (1995) 
showed that medial-intimal thickness of the carotid artery is associated with 
the presence of the D allele. Significant differences in aortic stiffness have 
been found among the AT} genotypes: the presence of the C allele of the 
A 1166-C polymorphism was associated with increased aortic stiffness in 
hypertensive but not normotensive patients. (Benetos et aI, 1995). In a study 
of other RAS genes Pojoga et al (1998) analysed two polymorphisms of the 
aldosterone synthase (CYP 11 B2) gene and found that the presence of the -
344C allele was associated with elevated levels of plasma aldosterone and 
PWV in patients with essential hypertension. 
4.l0.2 Pulse Wave Velocity and Risk Factors: 
In keeping with previous studies (Chanudet et ai, 1989), this study showed that 
age, blood pressure and diabetes were the main determinants of central PWV 
(as measured in the aorta). We also found significant correlations between 
PWV and WIH ratio in keeping with the effect of BMI (Toto-Moukouo et aI, 
1986) and anthropometric measurements (London et aI, 1995) on PWV. 
Surprisingly there was no correlation between PWV and smoking although 
both parameters were independently correlated with micro albuminuria. Active 
smoking deteriorates elastic properties of the human aorta (Nakamoto et aI, 
1989). Numerous studies show that smoking causes a significant increase in 
PWV in both medium-sized and large arteries (Failla et ai, 1997, Levenson et 
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aI, 1987). Our results could be related to the fact that although 80% of 
probands smoked, the smoking consumption was not quantified and PWV was 
not correlated with the degree of exposure to nicotine. 
4.10.3 PWV and Diabetes: 
Studies in Type II diabetes suggest that increased PWV results from an 
underlying diffuse atherosclerotic process, often not detectable clinically, 
(Lehmann et ai, 1992) and related to the duration of diabetes (Tanokuchi, 
1995). Significant alterations have been seen even in younger subjects and 
relate to glycaemic control (Paillole et ai, 1989, Asmar et aI, 1995). 
Significant correlations have also been shown between PWV and the presence 
of microalbuminuria or proteinuria in diabetic patients, suggesting that PWV 
may be a reliable index of vasculopathy in these patients (Takegoshi et aI, 
1991) PWV may be used to detect siblings of diabetic patients who are at high 
risk for CHD (Hopkins et ai, 1996). 
4.10.4 PWV and CHD: 
In the early stages of atheroma infiltration of LDL-C into the intima leads to 
an increase in aortic distensibility. In patients with FH, however, no 
significant correlation has been found between PWV and serum cholesterol 
(A volio et ai, 1985). With advancing age, the 'atherosis' develops a sclerotic 
component in the vessel wall leading to a decrease in aortic distensibility 
(Lehmann et ai, 1992,1995). 
Increased aortic PWV in patients with CHD was first demonstrated by 
Simonson et al (1960) when they showed a mean difference of 1.68 m/s 
between patients with and without CHD. It has been suggested that 
aortic/carotid distensibility might be used as an indicator to distinguish 
between patients with and without CHD (Dart et ai, 1991, Barenbrock et ai, 
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1995). In a study similar to ours, the relationship between arterial compliance 
and risk factors was examined in a group of newly diagnosed patients with 
CHD and controls matched for age, sex, smoking status and serum cholesterol 
levels. The beta stiffness index was significantly higher in the CHD group 
(Cameron et ai, 1995). They found that there was no significant correlation 
shown between compliance and lipid levels, but there was a correlation 
between PWV and microalbuminuria (p = 0.003). 
4.10.5 Limitations of the Study: 
This study showed strong correlations between PWV and major risk factors 
reflecting the vasculopathy associated with this parameter. Although PWV is 
strongly correlated with direct measurements of arterial distensibility and is an 
excellent surrogate evaluation of arterial stiffness, there are limitations in this 
technique: the critical factors are the precise measurements of pulse transit 
time and the length of the vascular segment. The surface vascular length is an 
approximation that might underestimate the true vascular length, particularly 
in the elderly with unfolded aortas. Our patients were young, so that this was 
not a problem and an on-line pulse wave recording by a validated method 
permitted precise measurement of transit time (Asmar et ai, 1995). However, 
our control subjects were slightly older and this may explain the absence of 
any difference between pro bands and controls since PWV increases with age. 
Furthermore, the effects of smoking on PWV need to be re-evaluated taking 
into account the degree of nicotine exposure. 
4.11 Allelic Association Studies: 
Until recently, no study has systematically evaluated genetic polymorphisms 
of all components of the RAS. Tiret et al (1994) was the first to report a 
synergistic effect of angiotensin converting enzyme and AT1 receptor gene 
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polymorphism on the risk of myocardial infarction. He found a significant 
interaction between these polymorphisms. The odds ratio for myocardial 
infarction associated with the angiotensin converting enzyme DD genotype 
was 1.05 without AT] receptor C allele, 1.52 in AC heterozygotes and 3.95 in 
CC homozygotes (test for trend p < 0.02). This interaction was even stronger 
in low risk (Apo B < 1.25 g!L and BMI < 26 kg.m2) subjects. 
Three different genotypes were analyzed in the CORGENE Study 
(Jeunemaitre et ai, 1997): ACE liD, Agt M235T and AT] receptor A 11 66C, but 
no significant association was observed between these polymorphisms and the 
MI (n = 156) and non-MI (n = 307) subjects. Only the Agt 235T allele was 
associated with the extent of the coronary lesions or angiographic score. 
Similarly Biggart et al (1998) analysed ACE, Apo E and TGF-fJ genes ill 
patients with early onset of CHD and found no association. 
More recently Gardemann et al (1998) re-evaluated the evidence for ACEIAT! 
receptor synergism by studying 2244 Caucasians with angiographically-
defined CHD. He found no association for a synergistic effect in patients with 
MI or coronary heart disease. In another case control study Ludwig et al 
(1997) searched for association between the A CE liD and angiotensinogen 
M235T polymorphisms in two different population samples. He found that 
within selected groups in the ARIC sample, ACE D and Agt 235T alleles were 
associated with CHD and MI and that there was a synergistic interaction 
between the two alleles. Comparable tests in the Framingham sample, 
however, failed to support an association of these markers with CHD. 
Another study which searched for interaction between the A CE liD and the 
AT! receptor locus was reported by Berge et ai, (1997) in 235 MI survivors. 
This study found no such interaction but a higher frequency of CC 
homozygotes was found in males in the low risk group. Thus, only few 
studies have examined the potential interaction at the RAS genetic loci and 
these have shown that the association is neither strong nor consistent, and 





5.1 Established Risk Factors and Premature MI: 
5.1.1 Obesity as a Risk Factor: 
Weight gain increases the risks of type 2 DM, premature atherosclerosis and 
hypertension. There is a linear association between weight gain and CHD 
risk: for every 10% increase in weight CHD mortality increases by 17% 
(Rosengren et aI, 1999). 
In this study we took the cut-off point for increased risk as BMI > 25 kg/m2 
which currently defines overweight in Caucasians. At a recent obesity 
symposium (Sharma et aI, 2000) it was pointed out that obesity-associated co-
morbidity may increase rapidly in non-Caucasians when BMI exceeds 18 
g/m2. The cut-off point in our Indian population should therefore be lower, 
probably around 22-23 kg/m2. Using this level at least 80% of our probands 
were classified overweight, as opposed to 66% of the control population (p < 
0.05). 
5.1.2 Dyslipidaemia as a Risk Factor: 
Hypercholesterolaemia is a major risk factor for the development of CHD. 
The interaction between lipoproteins and the RAS may explain why ACE 
inhibitors attenuate the hypercholesterolaemia-induced atherosclerosis in 
various animal models (Sugano et ai, 1996, Chobanian et aI, 1990). Since Ang 
11 exerts its vasoconstrictive and proliferative effects through activation of AT] 
receptors we looked for interaction between hypercholesterolaemia and AT] 
receptor gene polymorphism. 
Although there was no correlation between cholesterol levels (TC and LDL-C) 
and the risk of MI, (probably because patients received treatment), the 
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atherogenic lipoprotein phenotype was especially prominent in probands and 
was characterized by low HDL-C and high triglyceride levels. 
Epidemiologic data indicate a strong inverse correlation between plasma 
HDL-C and CHD (Gordon, 1977, Rhoads et aI, 1976). In fact the most 
frequent lipid abnormality in patients with CHD before the age of 60 years is a 
low HDL-C level. In experimental studies HDL-C administration inhibits the 
development of fatty streaks and induces regression of atherosclerotic lesions 
in cholesterol-fed rabbits (Badimon et aI, 1989,1990). Although the generally 
accepted mechanism for this effect is reversed cholesterol transport (Stein et 
aI, 1997) there is now evidence showing that HDL-C can reduce the 
atherogenicity of LDL-C by inhibiting oxidative modification (Mackness et aI, 
1995). Further evidence of a more direct anti-atherogenic effect ofHDL-C are 
its ability to improve endothelial dysfunction (Cockerill et aI, 1995) inhibit 
platelet aggression (Nofer et aI, 1998) and cholesterol accumulation in foam 
cells (Vifials et aI, 1997). 
5.1.3 Smoking as a Risk Factor: 
In a field survey smoking (> 10 cigarettes per day) was found to be a major 
risk factor for CHD in South African Indians (Seedat et aI, 1999). It was 
present in 40.8% males and 5,7% females. A substantially higher proportion 
of females (33%) smoked fewer cigarettes (> 1 a day). 
Taken together the analysis of major modifiable risk factors, i.e. smoking, 
hypercholesterolaemia, hypertension and diabetes, showed that 68% of the 
Indian population had at least one major risk factor for CHD. Hypertension 
and smoking were the most frequent combination in men, while in women 
hypertension and diabetes frequently occurred together. It is therefore not 
surprising that 82% of probands were smokers in our cohort of premature MI. 
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5.1.4 Insulin as the Intermediate Phenotype: 
In order to establish whether a candidate gene is truly associated with the 
disease the intermediate phenotype i.e. gene product must be shown to be 
related to the genotype. Identification of a key intermediate phenotype for 
diabetes, insulin levels, revealed an association with the metabolic syndrome. 
Better determination of the phenotype in future studies may help in clarifying 
the association of genotype with disease e.g. urinary aldosterone and cortisol 
levels in relation to aldosterone synthase and/or 11 {J-HSD, and plasma renin 
and A CE levels in relation to the RAS genes. This was not performed in this 
study because the majority of patients were receiving ACE inhibitor and beta-
blocker therapy. 
5.2 Molecular Genetics in the Understanding of CHD: 
5.2.1 Gene Polymorphisms in the Promoter Region: 
This study was unable to show that polymorphisms in the RAS genes were 
related to early onset MI in Indians. Since mutations in the coding regions of 
the candidate genes that we studied were uncommon, attention was turned to 
polymorphism in the regulatory (promoter) regions of these genes. Such DNA 
variation may alter gene transcription and is a potential basis for clinically 
important gene-environment interactions. 
Therefore, polymorphisms in the promoter region of the angiotensinogen gene 
and the aldosterone synthase genes were examined and again no genetic 
susceptibility to MI was found. Other newly discovered polymorphisms in the 
promoter regions include genes for the LDL-C receptor, lipoprotein lipase and 
PAl -1, all of which are associated with MI at a young age. These genetic 
components may contribute to the dysregulated extracellular matrix 
metabolism that is so characteristic of atherosclerosis and plaque rupture. 
Common polymorphisms occurring in the promoter region of these candidate 
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genes could account for the substantial differences in the metabolism of 
triglyceride-rich lipoproteins and the ensuing risk of CHD. There is also 
evidence that fatty acids control triglyceride metabolism by modulating the 
transcription of the lipoprotein lipase and Apo C-111 genes through activation 
of peroxisome proliferator-activated receptor (PP AR) gamma (Hamsten, 
1996). 
5.2.2 Genetics and Obesity: 
Identification of genetic determinants of complex disorders such as obesity, 
hypertension and atherosclerosis is a daunting task. In this study we did not 
specifically examine obesity-related genes. However, it appears that the RAS 
is involved in the development of obesity-related hypertension since there is 
convincing evidence (Sharma et ai, 2000) that Ang 11 plays an important role 
in the development of adipose tissue by virtue of its ability to recruit adipose 
precursor cells. 
5.2.3 The Putative Gene for CHD: 
A clinical consequence of genotype-specific regulation of biological 
mechanisms would be that certain individuals are more prone to 
atherosclerosis when exposed to environmental risk factors. Thus, knowledge 
of an individual genotype might be predictive of future atherosclerotic risk. 
Although unidentified, genetic loci probably underlie the variable 
susceptibility to environmental risk factors for CHD in our subjects. 
Individuals identified by genotype may be monitored with special care and 
given specific advice on lifestyle changes geared to their genotype. 
Our study, however, does not show any influence of genotype patterns of the 
polymorphisms we studied on the risk of premature MI. Since gene pools, 
lifestyles and gene-environment interactions differ between populations one 
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cannot assume that a given genetic trait will have similar impact in risk in all 
populations. Recent reports of molecular genetic analyses using allelic 
association studies have suggested that genes involved in lipoprotein 
metabolism and fibrinolytic pathways are also associated with coronary 
atherosclerosis or MI. 
Mild to moderate hypertriglyceridaemia, generally accompanied by low levels 
of HDL-C was present in a substantial number of case-patients with premature 
MI. The molecular genetic pathology of this condition is still ill defined. 
Potential candidate genes include the Apo-A-l , C-III, A-IV cluster and 
lipoprotein lipase which need to be studied in this high risk group. In contrast 
Lp(a) might be a monogenic risk factor for CHD, accounting for a significant 
portion of the familial predisposition to CHD that cannot be explained by other 
established risk factors in low risk groups. 
The strong family history of MI and biochemical parameters suggests that the 
low levels of HDL-C and raised triglycerides may be occurring against a 
background of another major risk factor. This is likely to be a polymorphic 
gene that is directly involved in HDL-C metabolism. Examples of such 
biallelic genes include lipoprotein-lipase, hepatic lipase and cholesterol ester 
transfer protein, which need to be evaluated in future studies in this population 




SUMMARY AND CLINICAL IMPLICATIONS 
6.1 Summary: 
When familial clustering of coronary heart disease was first recognised in the 
1950's it was noted to be especially prominent in families of patients with 
early-onset disease. In most cases the risk associated with a positive family 
history could not be attributed to familial aggregation of established risk 
factors. Until recently little was known of the genetic basis of underlying 
individual susceptibility to coronary heart disease. Since coronary heart 
disease and essential hypertension often overlap genes involved in blood 
pressure regulation became logical candidates for studying susceptibility to 
CHD. To delineate the genetics of this common and multifactorial disease is 
extremely difficult because a host of genes are likely to be contributory 
factors. Furthermore, it is likely that clinical disease results from interactions 
between heritable and environmental factors. 
6.1.1 Clinical Characteristics 
Established major risk factors for CHD could be identified in the present study 
sample. These included lipid parameters, diabetes mellitus, cigarette smoking 
and family history. In addition, coronary prone dietary and sedentary 
behavioural patterns as well as lower educational status were contributory 
factors. Our findings are consistent with those of Hughes et al (1990) who 
found that the higher mortality from CHD to be associated with lower HDL-C 
and higher rates ofDM in this group. 
Markers of insulin resistance: hyperinsulinaemia, increased waist, W IH ratio, 
atherogenic lipoprotein phenotype, diabetes and family history suggested that 
Summary and clinical implications 
96 
some degree of heritability could have predisposed to CHD in the setting of 
risk factors; in this respect genetic variations may have played a significant 
role in pathogenesis. 
6.1.2 Genetic Analysis: 
Analysis of eight candidate gene polymorphisms for CHD showed no 
differences in genotype distribution or allele frequencies in case-patients and 
normal control subjects. Both case-patients and controls showed no deviation 
of genotype distribution from the Hardy-Weinberg equilibrium. The genotype 
frequencies for these eight polymorphisms are different from those described 
in Western series, emphasizing the importance of choosing samples from 
ethnically homogeneous populations in studies of common genetic variations 
(Hamsten, 1996). 
There are very few studies that have evaluated potential interaction of the 
angiotensin converting enzyme gene with other RAS gene polymorphisms on 
the risk of MI. There was also no significant interaction between these alleles 
and those at any of the other loci studied for the presence of CHD. There was 
no relationship of risk factors to the candidate genes studied, nor was there a 
significant association of any of the genetic markers with CHD. 
6.1.3 Newer risk factors: 
In this study Lp(a) and homocysteine levels were elevated in the case-patients 
but the differences were not significant. Larger cohorts are needed to show 
that these risk factors are markers of premature atherosclerosis in this 
population. 
6.2 Conclusion: 
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In conclusion the present study does not support the relevance of the candidate 
gene loci studied to myocardial infarction in young Indian MI survivors. It is 
likely that complex diseases such as CHD are usually not controlled by a 
single disease locus but often involve multiple genetic and/or environmental 
factors that are subject to specific gene environment and gene-gene 
interactions. 
To date, no study has assessed the cumulative effects of several candidate loci 
simultaneously. In the present study polymorphism of five candidate genes of 
the RAS was examined. There was no evidence of any statistically significant 
association between gene cluster polymorphism and MI. There was also no 
association between these polymorphic sites and lipid levels in this cohort of 
predominantly male, young adult survivors. 
The findings of this study therefore reinforce the major contribution of 
behavioural and environmental risk factors in the causation of CHD in this 
ethnic group. The findings do not exclude the role of predisposing genetic 
factors in this group. Indeed diabetes mellitus was a major, probably heritable, 
risk factor and therefore studies of adequate power, designed to investigate 
candidate genes regulating glucose, lipid and tissue metabolism are strongly 
indicated. Potential candidate genes are lipoprotein lipase, paraoxonase and 
PPARy. These gene variations may account for the dyslipidaemia associated 
with insulin resistance and the predisposition to the atherogenic lipoprotein 
phenotype so characteristic of this cohort (Aubo et aI, 2000). 
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APPENDIX I 
Please indicate what you will tell the subjects in simple language and addressed to 
them. The procedure or treatment which will be applied should be described and 
reference should be made to possible side effects, discomfort, complications and/or 
benefits. 
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It must be made clear to the patient that he/she is free to decline participate or to 
withdraw at any time without suffering any disadvantage or prejudice. 
Index case: You have heart disease due to blockage of blood vessels that supply 
blood to your heart muscle. It is not exactly known why you have this 
kind of heart disease at such a young age. We would like to ask you a 
few questions, study your heart and take a sample of blood from your 
vein to find a reason for this. 
You are free to decline and this will not affect your treatment in the 
future. 
APPENDIXII 
DNA Extraction Protocol: 
A) DNA Extraction Method/or Whole Blood (EDTA) 
5-10 ml aliq uot 
1. Add 35 ml reagent 1 to 5 ml EDTA anticoagulated blood. 
2. Rotary mix for 4 minutes, then spin at 3500 rpm for 4 minutes. 
3. Discard the supernatant. 
4. To the WBC pellet, add 2 ml reagent 2 and vortex to resuspend. 
5. Add 500 III reagent 3 and rotary mix for 15 minutes. 
6. Incubate at 65° C for 25 minutes, occasionally mixing by hand. 
7. Add 2 ml ice cold chloroform and rotary mix for 10 minutes. 
S. Spin at 3500 rpm for 5 minutes. 
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9. Aspirate the supernatant, place into a clean tube, add an equal volume of 
phenol: chloroform: isoamyl alcohol (pRS.O) and rotary mix for 5 minutes. 
10. Spin at 3500 rpm for 5 minutes and aspirate the upper phase to a clean tube. 
Repeat the P:C:IAA extraction until the interface is clear of protein deposit. 
11. Add 5 ml cold absolute ethanol to precipitate the DNA. 
12. Pellet the DNA: spin at 4000 rpm for 5 minutes. 
l3. Wash the pellet with 70% ethanol. 
14. Dry the pellet and dissolve in 1 ml 1 x TE buffer (pRS). 
(B) REAGENTS: 
Reagent 1: 
Magnesium chloride hexahydrate (MW 203,3) - 5mM 
Sucrose (MW 342.3) - 320mM 
Tris. HCI (MW 157.56) - 10mM 
Triton X- 100 
• Adjust the pH to 8.0 with 2 M NaOH (MW 40) - 8g in 100ml water. 
Reagent 2: 
Tris. HCI (MW 157.56) - 400mM 
Sodium Chloride (MW 58.44) - 150 mM 











• 1 % SDS to be added after autoclaving the above solution - ie add 50 ml of a 10% 
SDS solution. To make 50 ML 10% SDS, add 5g SDS to 40 ml water, heat to 
68° C and when dissolved, add water to make up to 50 ml. 
• Adjust the pH to 8.0 using 2 M NaOH. 
Reagent 3: 




APPENDIX Ill: PCR CONDITIONS: 
1. Angiotensinogen Core Promoter (Agt-CP) PCR: 
All PCR to detect the Agt-CP mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01. Gene Amp 9600 PCR System 1991) and primers as reported by 
Jeunemaitre et al, (1992). The sense and antisense primers were as follows: 
sense: 
antisense: 
5' TCACT AAgACTTCCTggAAgA-3' 
5' AgACCAgAAggAgCTgAGG-3' 
Samples were amplified for 35 cycles consisting of denaturation at 94°C for 45 
sec, annealing at 56°C for 30 sec and extension at 72°C for 45 sec, followed by 
a final extension step at 72°C for 10 min. Because the nucleotide G-6A 
mutation created a restriction site for Eag I enzyme (New England Biolabs) the 
resulting amplification product (251 bp) after PCR was therefore digested with 
Eag I restriction endonuclease for four hours at 37°C. (New England Biolabs, 
SchwalbachlTs, Germany). Following digestion, restriction fragments (176 bp 
and 75 bp) were sized fractionated on 2% agarose gels. Genotype analysis was 
carried out by two independent investigators (AMS and KS) who were 
unaware of the clinical data. In cases of ambiguity the PCR reaction, Eag I 
digestion and scoring were repeated. 
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2. Angiotensin II Type I Receptor (ATl R) peR: 
All PCR to detect the AT 1 R mutation were carried out with 100 ng of genomic 
DNA as a template, using a DNA thermal cycler (Perkin Elmer Version 2.01 
Gene Amp 9600 PCR System 1991) and primers as reported by Hingorani et al 
(1995). The sense and antisense primers were as follows: 
sense: 
antisense: 
5' gT AAgCTCATCCACCAAgAAgg-3' 
5' gCAAgTgTAgCAgCAgTTgC-3' 
Samples were amplified for 35 cycles consisting of denaturation at 9SoC for 30 
sec, annealing at 60°C for 30 sec and extension at 72°C for 60 sec, followed by 
a final extension step at 72°C for 10 min. Because nucleotide AlC 1166 
mutation created a restriction site for Dde I (New England Biolabs), the 
resulting amplification product after PCR was therefore digested with Dde I 
restriction endonuclease for two hours at 37°C (New England Biolabs, 
SchwalbachlTs, Germany). Following digestion, restriction fragments were 
sized fractionated on 2% agarose gels. Genotype analysis was carried out by 
two independent investigators (AMS and KS) who were unaware of the 
clinical data. In cases of ambiguity the PCR reaction Dde I digestion and 
scoring were repeated. 
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3. Angiotensin Converting Enzyme (ACE) PCR: 
All PCR to detect the ACE gene mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01 Gene Amp 9600 PCR System 1991) and primers as reported by 
Rigat et al (1992). The sense and antisense primers were as follows: 
sense: 
antisense: 
5' CTggAgACCACTCCCATCCTTTCT -3' 
5'gATgTggCCATCACATTCgTCAgAT-3' 
Samples were amplified for 35 cycles consisting of denaturation at 94°C for 45 
sec, annealing at 60°C for 45 sec and extension at 72°C for 60 sec, followed by 
a final extension step at 72°C for 10 min. The PCR product is a 190 bp 
fragment in the absence of the insertion (deletion) and a 490 bp fragment in the 
presence of the insertion. Following PCR, restriction fragments (190 bp and 
490 bp) were sized fractionated on 2% agarose gels. Genotype analysis was 
carried out by two independent investigators (AMS and KS) who were 
unaware of the clinical data. To increase the specificity of deletion 
homozygote (DD) genotyping, a second PCR with the annealing temperature 
at 6SoC and primer pair that recognizes the insertion-specific sequence, was 
performed in all samples classified as DD homozygotes in the first PCR. 
Sense: 5'TgggACCACgCCCgCCACTAC-3' 
Antisense: 5'TCgCCAgCCTCCCATgCCCATAA-3' 
Only the I allele produces a 355 bp amplicon. The reaction yields no products 
in samples of the DD genotype. In cases of ambiguity the PCR reaction-
specific PCR scoring were repeated. 
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4. Aldosterone Synthase Promoter (CYPll-~2) PCR: 
All PCR to detect the CYP II~2 mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cyder (Perkin Elmer 
Version 2.01 Gene Amp 9600 PCR System 1991) and primers as reported by 
White et al (1998). The sense and antisense primers were as follows: 
CYP 304 sense: CAgggCTgAgAggAgTAAAA 
CYP 171 antisense: CAgggggTACgTggACATTT 
Samples were amplified for 35 cycles consisting of denaturation at 94°C for 45 
sec, annealing at 52°C for 45 sec and extension at 72°C for 60 sec, followed by 
a final extension step at 72°C for 10 min. Because nucleotide C344T mutation 
created a restriction site for HaeIII enzyme (New England Biolabs), the 
resulting amplification product (231 bp) after PCR was therefore digested with 
HaeIII restriction endonuclease for two hours at 37°C (New England Biolabs, 
SchwalbachlTs, Germany). Following digestion, restriction fragments (140bp 
and 91bp), were sized fractionated on 2% agarose gels. Genotype analysis was 
carried out by two independent investigators (AMS and KS) who were 
unaware of the clinical data. In cases of ambiguity the PCR reaction HaeIII 
digestion and scoring were repeated. 
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5. peR for l1~-Hydroxysteroid Dehydrogenase 2 (l1~-HSD2): 
All PCR to detect the 11BHSD2 mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01 Gene Amp 9600 PCR System 1991) and primers as reported by 
Smolenicka et al (1998). The sense and antisense primers were as follows: 
HSD 540 A sense: 
HSD 870 B antisense: 
5' ggAAgTTTgCTgCTgggCTgA-3' 
5' AgTggggCAgCTCAgCTTTgg-3' 
Samples were amplified for 35 cycles consisting of denaturation at 940e for 30 
sec, annealing at 630e for 30 sec and extension at 720e for 60 sec, followed by 
a final extension step at 720e for 10 min. Since the nucleotide G534A 
mutation created a restriction site for Alu I enzyme (New England Biolabs), 
the resulting amplification product after PCR was therefore digested with Alu I 
restriction endonuclease for four hours at 37°C (New England Biolabs, 
SchwalbachlTs, Germany). Following digestion, restriction fragments were 
sized fractionated on 2% agarose gels. Genotype analysis was carried out by 
two independent investigators (AMS and KS) who were unaware of the 
clinical data. In cases of ambiguity the peR reaction, Alu I digestion and 
scoring were repeated. 
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6. peR for Transforming Growth Factor-B: 
All PCR to detect the TGF-Bl mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01 Gene Amp 9600 PCR System 1991) and primers as reported by 
Pociot et al (1998) for a mutagenically separated PCR (MC-PCR) assay. In 
this MS-PCR three primers were used in a single reaction mix: 
Sense (1): 
Sense (2): 
5' ACCgCCCCATTCTgCTTCTCATggCCCT -3' 
5'TggCCACCATTCATggCATgAgTCggCCTT-
TCCTgCTTCTCATggACAC-3 ' 
Antisense: 5'AAggCCTCCATC CAg gCT ACA Agg CTC AC-3' 
Samples were amplified for 35 cycles consisting of denaturation at 94°C for 45 
sec, annealing at 68°C for 45 sec and extension at 72°C for 60 sec, followed by 
a final extension step at 72°C for 10 min. The nucleotide Thr 263 !le 
polymorphism does not require a restriction endonuclease. In the presence of 
Thr 263 a PCR product of 150 bp was amplified, whereas a 129 bp fragment 
was amplified in the presence of the !le 263 variant. Following the PCR, the 
amplification products (150 bp and 129 bp) were sized fractionated on 2% 
agarose gels and repeated with Nutrasieve to improve separation of the bands. 
Genotype analysis was carried out by two independent investigators (AMS and 
KS) who were unaware of the clinical data. In cases of ambiguity the PCR 
reaction size fractionation on Nutrasieve gel and scoring were repeated. 
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7. peR for Methylenetetrahydrofolate Reductase Gene Polymorphism: 
All PCR to detect the MTHFR mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01. Gene Amp 9600 PCR System 1991) and primers as reported by 
Frosst et ai, 1995. The sense and antisense primers were as follows: 
sense: 5 'TGAAGGAGAAGGTGTATGAGGGA-3 , 
antisense: 5'AGGACGGTGCGGTGAGAGTG-3' 
Samples were amplified for 35 cycles consisting of denaturation at 94 DC for 
15 sec, annealing at 58 DC for 45 sec, and extension at 72 DC for 45 sec, 
followed by a final extension step at 72DC for 10 min. Because the nucleotide 
C677T mutation creates a restriction site for Hinf I (New England Biolabs,) the 
resulting amplification product (246 bp) after PCR was therefore digested with 
Hinf I restriction endonuclease for 20 hours at 37DC (New England Bioloabs, 
SchwalbachlTs, Germany). Following digestion, restriction fragments (175 bp 
and 71 bp) were size fractionated on 2% agarose gels. Genotype analysis was 
carried out by two independent investigators (AMS + KS) who were unaware 
of the clinical data. In cases of ambiguity the PCR reaction, Hinf I digestion 
and scoring were repeated. 
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8. peR for G-Protein: 
All PCR to detect the G-Protein mutation were carried out with 100 ng of 
genomic DNA as a template, using a DNA thermal cycler (Perkin Elmer 
Version 2.01 Gene Amp 9600 PCR System 1991) and primers as reported by 





Samples were amplified for 35 cycles consisting of denaturation at 94°C for 45 
sec, annealing at 60°C for 45 sec and extension at 72°C for 60 sec, followed by 
a final extension step at 72°C for 10 min. Because nucleotide C~ T mutation 
created a restriction site for BSEDI (MBI Fermentas) the resulting 
amplification product (268 bp) after PCR was therefore digested with BSE DI 
restriction endonuclease for two hours at 60°C MBI Fermentas. Following 
digestion, restriction fragments (152 bp and 116 bp) were sized fractionated on 
2% agarose gels. Genotype analysis was carried out by two independent 
investigators (AMS and KS) who were unaware of the clinical data. In cases 
of ambiguity the PCR reaction, BSEDI digestion and scoring were repeated. 
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ACE-ID-PCR: 
DNA: PRO BANDS 
Mastermix: Dry Liquid Master: For 120 tubes 
Dry Liquid 
Buffer l.0 2 3 min 94° 
MgCI 0.75 90 l.5 45 sec 94°C 
DNTP 1.25M l.0 12T0 l.5 45 sec 60°C 
Taq 0.03 3:4.6 0.03 60 sec nOc 
ACE P 1 (2OIlM) O.l 0.1 10 min nOc 
ACE P 2 (2OIlM) O.l O.l 
DMSO 0.5 0.7 
H2O 6.52 4.07 
DNA-template 0.0 10 
TOTAL 10.0 20 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2 lu IS 26 37 44 63 W 137 159 H2O ISO 
1 2 2 3 2 1 2 2 2 2 0 2 
B 3 11 lIT 27 38 46 65 lW 140 163 172 un 
1 3 2 1 2 1 2 1 2 1 0 1 
C 4 12 20 30 3Y 4Y 77 103 144 164 174 184 
1 1 1 2 1 2 2 2 2 1 1 2 
D H2U 
Jj 21 31 40 54 7'6 105 145 165 175 r&O 
0 2 2 1 2 2 3 2 1 1 2 1 
E 5 14 22 33 H2O 55 85 111 146 H2U 176 187 
3 1 1 2 0 2 1 2 1 0 2 2 
F 7 15 23 34 41 56 87 130 147 167 177 rgg-
2 2 1 2 2 1 2 2 2 2 2 3 
G ::; 16 L4 35 42 57 Y4 133 156 168 17'6 189 
1 3 1 2 2 1 3 1 2 1 0 2 
H 9 17 25 36 4J 6U 93 136 15'6 169 179 190 
2 2 1 1 2 2 2 1 3 1 1 1 
FIG 2: 
(See page 140) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 




FIG 2:ACE-ID-PCR: PROBANDS 
140 
x100 bp 
This peR yielded 2 products: a 190 bp fragment in the absence of the insertion and a 
490 bp fragment in the presence of a deletion. 
141 
ACE-ID-PCR: 
DNA: PROBANDS & REPEATS 
Mastermix: Dry Liquid Master: For 50 tubes 
Dry Liquid 
Buffer 1.0 2 ''" ~ 3 min 94° 
MgCI 0.75 J'6 1.5 7(tOl 45 sec 94°C 
DNTPl.25M 1.0 44 1.5 S6 45 sec 60°C 
Taq 0.03 1.32 0.03 1.§ 60 sec nOc 
ACE P 1 (20J.lM) 0.1 4.4 0.1 $ 10 min nOc 
ACE P 2 (20J.lM) 0.1 4~4, 0.1 !§ 
DMSO 0.5 0.7 
H2O 6.52 4.07 
DNA-template 0.0 10 









1 1 2 1 
FIG 3: 
(See page 142) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-5). The molecular weight marker is a 100 bp ladder. Control samples 











PROBAND & REPEATS 
This peR yielded 2 products: a 190 bp fragment in the absence of the insertion and a 







DNTP 1.25M 1.0 
Taq 0.03 
ACE P 1 (20J.!M) 0.1 





1 2 3 4 5 
A I 9 17 
15 33 
1 2 2 3 3 
B 1 Iu lIS 26 H2O 
2 1 1 2 0 
C 3 11 I~ i.7 
34 
2 1 2 1 2 
D 4 12 lU lIS 35 
0 1 2 1 1 
E 5 13 21 
2l) 36 
1 1 3 3 0 
F 6 14 II jU 37 
2 2 2 2 2 
G 7 15 2J JI 38 
1 2 0 2 0 
H IS 10 14 Ji. J l) 



























































































For 44 tubes 
3 min 94° 
45 sec 94°C 
45 sec 60°C 
60 sec nOc 


















(See page 144) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control samples 
















- - - ... - .... ---- ---- - -- -~~ - -
5 6 ... 
-------- -- - - - ---
8 9 ,--',. 
!! ~ --- -.. x100 bp ------- --
11 • • ::; == 
CONTROLS 
This peR yielded 2 products: a 190 bp fragment in the absence of the insertion and a 
490 bp fragment in the presence of a deletion. 
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ACE-II-PCR: INSERTION SPECIFIC PRIMER 
DNA: PROBANDS 
Mastermix: Dry Liquid Master: For 210 tubes 
Dry Liquid 
Buffer 1 1.3 3 min 94° 
MgCI 0.75 0.9 45 sec 94°C 
DNTP 1.25M 1 1.3 y 45 sec 6SoC 
Taq 0.03 0.03 120 sec nOc 
II P 1 (20~M) 0.13 0.15 3ijl.ci 10 min nOc 
II P 2 (20~M) 0.13 27.3 0.15 31.$ 
H2O 6.96 k.<f~1l~' 3.96 ~ 8~~1;,,6, 
DNA-template 0 3 
TOTAL 10 14 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2 10 
U$ 26 37 44 63 99 137 159 H2O U$U 
I I I 3 I I I I I I 0 I 
B J 11 19 27 38 
46 65 102 140 163 172 HI! 
I 3 I I I I I I I I 0 I 
C 4 12 20 30 39 
49 77 103 144 164 174 1114 
I I I I I I I I I I I I 
D H2O \3 21 
3t 40 54 n 105 145 165 175 IlS6 
0 I I I I I 3 I I I I I 
E 5 14 22 33 H2O 55 85 III 146 H2O 176 187 
3 I I I 0 I I I I 0 I I 
F 7 15 23 34 41 56 87 
-rJ!J 147 107 177 tlSlS 
-
I I I I I I I I I I I 3 
G IS 16 24 J) 42 57 94 133 156 168 in 189 
I 3 I I I I 3 I I I 0 I 
H 9 17 25 36 43 60 93 lJI) 15"8 169 179 I'JO 
I I I I I I I I 3 I I I 
FIG 5: 
(See page 146) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 





FIG 5: ACE-II-PCR: PROBANDS 
This peR used a primer pair that recognises the insertion-specific sequence and 
identifies ID genotypes that have been misclassified as DD when only the flanking 
primer pair was used. Only the I allele produces a 355 bp amplicon, while the 







II P 1 (20).tM) 























































































































































For 210 tubes 
3 min 94° 
45 sec 94°C 
45 sec 68°C 
120 sec nOc 
10 min nOc 
10 11 
Al 1':1 AI61 
I I 














(See page 148) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 





FIG 6: ACE-IT-PCR: CONTROLS 
This peR used a primer pair that recognises the insertion-specific sequence and 
identifies ID genotypes that have been misclassified as DD when only the flanking 
primer pair was used. Only the I allele produces a 355 bp amplicon, while the 
reaction yields no products in samples of the DD genotype: 
ACE-II-PCR: 
DNA: 
INSERTION SPECIFIC PRIMER 





11 P 1 (20I-lM) 











































For 210 tubes 
3 min 94° 
45 sec 94°C 
45 sec 68°C 
120 sec nOc 
'. 10 min nOc 
(See page 150) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-4). The molecular weight marker is a 100 bp ladder. Control samples 
are indicated as water (H20). 
150 
ACE-II-PCR: 
355 bp x100 bp 
FIG 7: ACE-II-PCR: PROBANDS & REPEATS 
This peR used a primer pair that recognises the insertion-specific sequence and 
identifies ID genotypes that have been misclassified as DD when only the flanking 
primer pair was used. Only the I allele produces a 355 bp amplicon, while the 




Mastermix: Dry Liquid Master: For 110 tubes 
Dry Liquid 
Buffer 1 2.3 3 min 94° 
MgCI 0.4 0.75 45 sec 94°C 
dNTP 1.25M 1 1 . 30 sec 56 
Taq 0.03 0.03 45 sec nOc 
AGT-HAP-1 (lOf.LM) 0.5 0.5 10 min nOc 
AGT-HAP-2 (lOf.LM) 0.5 0.5 
H2O 6.57 14.92 
DNA-template 0 3 
TOTAL 10.0 23 
NEB 3 Buffer 2 ,lira 1= 11.~ 
Eag 1 enzyme 0.1 J'1 [.0 2= ~G 37°C forever 
H2O 7.9 869 3= G(j. 
DNA-template 10 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2 
10 18 26 37 44 63 YY TJ7 IN rI2D u;u 
1 1 2 2 1 1 3 1 3 2 0 2 
B 3 11 lY 27 3~ 
46 65 roY 140 163 172 l~l 
1 2 2 2 1 0 1 2 2 3 0 2 
C 4 12 20 30 3Y 
4Y -77 T!IT 144 TI4 T74 1~4 
2 2 2 1 1 3 1 1 1 0 2 2 
D H2U 13 21 31 40 54 78 105 145 165 175 1~6 
0 1 1 3 1 2 1 2 3 2 2 1 
E 5 14 22 
jj H2U --s5 115 ill 146 H2O 176 l~/ 
3 1 1 2 0 2 3 2 2 0 2 3 
F 7 15 23 34 41 56 87 
rJ(J 147 167 177 l~~ 
1 1 3 1 2 2 1 2 1 3 3 2 
G 11 16 24 35 42 57 Y4 133 156 168 178 lilY 
2 2 2 2 1 2 2 2 1 2 0 2 
H 
y 11 25 36 43 6U Y3 136 158 169 179 IYO 
3 1 1 1 2 1 3 2 1 1 2 0 
FIG 8: 
(See page 152) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 
samples are indicated as water (H20). 









After the digestion with Eag 1 enzyme the peR yielded three products: 75, 176 and 




Mastermix: Dry Liquid Master: For 110 tubes 
Dry Liquid 
Buffer 1 2.3 3 min 94° 
MgCI 0.4 0.75 45 sec 94°C 
dNTP 1.25M 1 1 . 30 sec 56 
Taq 0.03 0.03 45 sec nOc 
AGT-HAP-l (lOf,lM) 0.5 0.5 10 min nOc 
AGT-HAP-2 (10f,lM) 0.5 0.5 
H2O 6.57 14.92 
DNA-template 0 3 
TOTAL 10.0 23 
NEB 3 Buffer 2 
Eag 1 enzyme 0.1 37°C forever 
H2O 7.9 
DNA-template 10 
1 2 3 4 5 6 7 8 9 10 11 
A I 9 17 25 33 4U 415 AUl2 AU15U 
Alll) Al61 
2 2 0 3 1 0 2 2 2 2 2 
B 2 lU 115 26 H2U 41 
4l) AUU~ AUl)15 A I2U AI62 
2 2 1 2 0 1 3 2 1 1 0 
C 3 11 
Il) 27 34 42 5U AUI9 AlU4 A I23 AI66 
1 2 1 3 2 2 3 1 2 1 0 
D 4 12 2U 215 35 43 H2U AU24 AlU6 AI49 AI71 
2 2 2 3 1 2 0 2 3 0 1 
E 5 13 21 2l) 36 44 AU06 B003 A IU15 AISU AlUS 
1 2 2 1 0 3 3 1 1 0 0 
F 6 14 LL 3U 37 45 AUU4 I:lUU4 AI09 AI54 A I7u 
0 1 3 2 3 2 2 1 1 2 1 
G 7 15 23 31 38 46 AUU15 tWUS AllU A l 57 A086 
1 1 0 2 0 1 1 3 2 2 1 
H 15 16 24 32 39 47 Aulu AUM H2U AI6U A006 
1 1 2 1 0 1 1 2 0 0 1 
FIG 9: 
(See page 154) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 




AGT -CORE PROMOTER PCR: 




After the digestion with Eag 1 enzyme the peR yielded three products: 75, 176 and 
251 bp fragments corresponding to GG, AG and AA genotypes respectively. 
AGT-CORE PROMOTER-PCR 










NEB 3 Buffer 




















































For 110 tubes 
3 min 94° 
45 sec 94°C 
30 sec 56 
45 sec nOc 
10 min nOc 
(See page 156) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-4). The molecular weight marker is a 100 bp ladder. Control samples 
are indicated as water (H20). 
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AGT -CORE PROMOTER PCR: 
FIG 10: AGT G6~A CORE PROMOTER PCR: 
PROBANDS AND REPEATS 
After the digestion with Eag 1 enzyme the peR yielded three products: 75, 176 and 




Mastermix: Dry Liquid Master: For 110 tubes 
Dry Liquid 
Buffer 1 ~l;Ol" 1.3 14~ 3 min 94° 
MgCI 0.6 i6'(r 0.9 99 45 sec 94°C 
DNTP 1.25M 1 :[.10 1.3 ·!lr43 30 sec 60°C 
Tag 0.02 f~~<2 0.03 .$'t~ 60 sec nOc 
AT-l (25f!M) 0.1 \bl 0.13 14~~ 10 min nOc 
AT-2 (25f!M) 0.1 1r4 .. , 0.13 14~ 
H2O 7.18 lJJlSt 4.18 \,,¥~$J~~' 
DNA-template 0 3 
TOTAL 10 13 
Dde 1 ()lL) 0.2 0.2 
BufferNr.3 2 2.3 37°C forever 
H2O 7.8 7.8 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2 10 us 26 37 
44 63 99 137 159 H2O 180 
1 1 1 1 1 1 1 1 1 1 0 1 
B 3 11 19 27 38 
46 65 102 140 163 T7L 181 
1 1 1 1 1 1 1 1 1 1 (0) 1 
C 4 12 20 30 39 
49 77 103 144 164 174 T84 
1 1 1 1 2 1 1 1 1 1 1 1 
D H2O 13 21 31 40 54 78 105 145 165 175 186 
0 1 1 1 1 2 1 1 1 1 1 1 
E 5 14 22 33 H2O 55 85 1fT 140 -mrr 176 187 
1 1 1 1 0 1 1 2 1 0 1 1 
F 7 15 23 34 41 56 87 130 147 [67 T77 III 
1 1 1 1 1 2 1 1 1 (1) 1 1 
G 8 16 24 35 42 57 94 133 150 108 178 189 
1 1 1 1 1 1 1 2 1 (1) (0) 1 
H '} 17 25 36 43 60 93 136 1)8' 169 179 190 
1 1 1 2 1 1 2 1 (1) 1 1 1 
FIG 11: 
(See page 158) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 





After digestion with Dde I restriction endonuclease restriction the resulting fragments 
were size fractionated on 2% agarose gels yielding bands corresponding to AA, AC, 














































































































































































































For 140 tubes 
3 min 94° 
45 sec 94°C 
45 sec 60°C 
60 sec nOc 


















(See page 160) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 




FIG 12: ATl PCR: CONTROLS & BFU HETEROZYGOTES 
160 
x100 bp 
After digestion with Dde I restriction endonuclease restriction the resulting fragments 
were size fractionated on 2% agarose gels yielding bands corresponding to AA, AC, 
and CC genotypes. Row 12 shows positive controls for heterozygotes (AC) and the 
rare CC genotypes. 
ATI-PCR 





















































3 min 94° 
45 sec 94°C 
45 sec 60°C 
60 sec nOc 
10 min n Oc 
(See page 162) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-4 above & 1-3 below). The molecular weight marker is a 100 bp 




FIG 13: ATI peR: PROBAND & REPEATS 
Probands (top) and Repeats (below) 
162 
x100 bp 
After digestion with Dde I restriction endonuclease restriction the resulting fragments 
were size fractionated on 2% agarose gels yielding bands corresponding to AA, AC, 




Mastermix: Dry Liquid Master: For 210 tubes 
Dry Liquid 
Buffer 1 2.5 3 min 94° C 
MgCI 0.75 1.8 45 sec 94°C 
DNTP 1.25M 1 2.5 45 sec 52°C 
Taq 0.03 0.03 60 sec nOc 
Primer 171 (5Ol-,M) 0.2 0.5 
Primer 304 (50JlM) 0.2 0.5 10 min nOc 
H2O 6.82 12.17 
DNA-template 0 5 
TOTAL 10 25 
RESTRICTION: 
Neb2 2 t =If'~ 
HAE3 Enzyme 0.1 2= "PE 2 Hrs 37° C 
H2O 7.9 ':II6'S9 ,3=CC 
1 2 3 4 5 6 7 8 9 10 11 12 
A L 10 us L6 37 
44 63 ':1':1 137 15':1 H2O 180 
1 1 3 2 2 2 1 1 2 2 0 2 
B 3 11 1':1 27 38 
46 65 102 140 163 17L 181 
2 2 2 2 2 2 3 1 2 1 2 1 
C 4 12 LU 3U 39 
49 77 1U3 144 164 114 llH 
1 1 2 2 3 2 1 1 1 1 1 3 
D H2O 13 21 31 40 54 7Il 105 145 165 115 186 
0 2 3 2 2 1 2 1 0 1 1 1 
E 5 14 22 33 H2O 55 85 III 146 liLU 116 Itn 
0 1 2 1 0 3 1 1 1 0 2 2 
F 7 15 23 34 41 56 S7 130 147 167 177 -T88 
3 1 2 0 2 1 1 1 2 1 3 3 
G S 16 24 35 42 57 94 Jj3 1)6 161S I llS 189 
2 2 1 2 2 2 2 2 2 2 2 2 
H ':I 11 L) 36 43 60 93 136 ISS Ib,:} 11':1 190 
1 2 2 1 3 3 2 1 1 1 1 1 
FIG 14: 
(See page 164) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 
samples are indicated as water (H20). 
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CYPll~2 PCR: 
FIG 14: CYPllJ}2 PCR for Aldosterone Synthase Polymorphism: PROBANDS 
After digestion with HAE 3 enzyme the reaction yielded three products: 231, 140 and 







Primer 171 (50JlM) 







A I '! 
1 1 
B 2 10 
1 1 
C J 11 
2 3 
D 4 12 
1 2 
E 5 U 
1 2 
F 6 14 
2 2 
G 7 15 
2 2 





























































































































































For 210 tubes 
3 min 94° C 
45 sec 94°C 
45 sec 52°C 
60 sec 72°C 


















(See page 166) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 







FIG 15: CYPll~2 PCR for Aldosterone Synthase Polymorphism: CONTROLS 
After digestion with HAE 3 enzyme the reaction yielded three products: 231 , 140 and 







Primer 171 (50f.!M) 

















































For 50 tubes 
3 min 94° C 
45 sec 94°C 
45 sec 52°C 
60 sec nOc 
(See page 168) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-5). The molecular weight marker is a 100 bp ladder. Control samples 






CYPll~2 peR FOR ALDOSTERONE SYNTHASE 
POLYMORPHISM: PROBANDS & REPEATS 
168 
After digestion with HAE 3 enzyme the reaction yielded three products: 231, 140 and 
91 bp fragments corresponding to the TT, CT and CC genotypes respectively. 
169 
11 p-HSD2 - peR 
DNA: PROBANDS 




DNTP 1.25M 1 
Taq 0.03 '~'Ia ' 
DMSO 1 ·no 
Primer HSD 540A (5J.!M) 0.4 8'4 
2.5 3 min 94° C 
0.75 , 30 sec 94°C 
1 2'10 30 sec 63°C 
0.03 '6.3 30 sec nOc 
1 210 
4 840 10 min nOc 
Primer HSD 870B (5J.!M) 0.4 4 
H2O 14.42 6.n ~ 
DNA-template 0 5 
TOTAL 20 25 
RESTRICTION: 
ALu 1 Enzyme 0.2 
NE Buffer 2 3 
H2O 6.8 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2 tu 18 26 
37 44 63 99 137 TW -mu IW 
1 1 1 1 1 1 1 1 1 1 0 1 
B J I1 19 27 38 
46 65 102 140 163 172 181 
1 1 1 1 1 1 1 1 1 1 1 1 
C 4 12 20 :l0 39 
49 77 -103 144 164 174 184 
1 1 1 1 1 1 1 1 1 1 1 1 
D H2U JJ 21 JI 40 54 78 
-105 145 lO'5" 175 l8b 
0 1 1 1 1 1 1 1 0 1 1 1 
E 5 14 22 33 H2O 55 85 111 146 H2O 176 
-r87 
1 1 1 1 0 1 1 1 1 0 1 1 
F 7 15 23 34 41 56 87 130 147 107 TI7 TI&" 
1 1 1 1 1 1 1 1 0 1 1 1 
G 8 16 24 35 42 57 94 JJ3 156 168 178 lSg 
1 1 1 1 1 1 1 1 1 1 1 1 
H 9 17 25 36 43 60 93 JJ6 158 169 179 lW 
1 1 1 1 1 1 1 2 1 1 1 1 
FIG 17: 
(See page 170) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 
samples are indicated as water (H20). 
170 
11~-HSD2 - peR: 
x100 bp 
GA 
FIG 17: peR For I1Jl-Hydroxysteroid Dehydrogenase Polymorphism: 
PROBANDS 
After digestion with Alu-l enzyme the peR yielded 2 products corresponding to GG 
and AG genotypes. Only one proband coded for the heterozygote (GA No. 136). 
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11 p-HSD2 - peR 






Primer HSD 540A (5f.lM) 





ALu 1 Enzyme 















































For 80 tubes 
3 min 94° C 
30 sec 94°C 
30 sec 63°C 
~i4 . 30 sec n Oc 
!8li 
~ O 10 min n Oc 
~~D 
Stn.6 
4 Hrs 37° C 
(See page 172) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-8). The molecular weight marker is a 100 bp ladder. Control samples 
are indicated as water (H20). 
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11~-HSD2 - peR: 
GG 
GA 
FIG 18: peR for IlJ3-Hydroxysteroid Dehydrogenase Polymorphism: 
PROBANDS & REPEATS & BFU HETEROZYGOTES 
After digestion with Alu-l enzyme the peR yielded 2 products corresponding to GG 
and AG genotypes. Since the rare - 534A allele was not identified the peR reaction 
known from BFU heterozygotes as positive controls (coded yellow) and the results of 
the peR confmned. 
173 
IlB-HSD2 - PCR 
DNA: CONTROLS 
Mastermix: Dry Liquid Master: For 210 tubes 
Dry Liquid 
2.5 " 3 min 94° C Buffer 2 
MgCI 0.75 0.75 
, 30 sec 94°C 
DNTP 1.25M 1 1 
'" 30 sec 63°C 
Taq 0.03 0.03 
, 30 sec nOc 
DMSO 1 1 
Primer HSD 540A (5f.!M) 0.4 4 10 min nOc 
Primer HSD 870B (5f.!M) 0.4 4 
H2O 14.42 6.n 
DNA-template 0 5 
TOTAL 20 25 
RESTRICTION: 
ALu 1 Enzyme 0.2 4"2' 1 == 'l~"G 
NE Buffer 2 3 ~ ='~Q;lA, 4 Hrs 37° C 
H2O 6.8 ' J~~~ . 
1 2 3 4 5 6 7 8 9 10 11 
A I 9 17 25 :53 
40 48 A012 A080 AII9 AI61 
1 1 1 1 1 0 0 1 1 1 1 
B 2 10 18 26 H2O 41 
4lJ f\U05 ~ ATIlJ A10T 
1 1 1 1 0 0 1 1 1 1 0 
C 3 II 19 27 
34 42 50 AOl9 A104 Al23 Al66 
1 1 1 1 1 1 1 1 1 1 1 
D 4 12 2U 2~ 35 43 H2O AlJ24 ArUb Al49" AT7T 
1 1 1 1 1 1 0 1 1 0 1 
E 5 13 21 2lJ 36 44 A006 B003 AI08 Al50 A2lY) 
1 1 1 1 0 1 1 1 1 1 0 
F 6 14 22 30 37 45 A004 8004 A 109 AI 54 AI70 
1 1 1 1 1 1 1 1 1 1 1 
G 7 IS 23 31 3S 46 AUOS B005 AIIO Af57 AU80 
1 1 1 1 0 1 1 1 1 1 1 
H 8 16 24 32 3lJ 47 AUIO A064 H2O ATO(J 6CO 
1 1 1 1 0 1 1 1 0 1 1 
FIG 19: 
(See page 174) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 
samples are indicated as water (H20). 
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11~-HSD2 - peR: 
GG 
FIG 19: PCR for l1~-Hydroxysteroid Dehydrogenase Polymorphism: 
CONTROLS 
After digestion with Alu-l enzyme the peR yielded 2 products corresponding to GG 







TSG ~ 1 (20IlM) 
TSG ~2 (201lM) 









































































































6 7 8 9 
44 63 YY ITI 
1 1 1 1 
46 65 102 140 
1 1 1 1 
49 77 103 144 
1 1 1 1 
54 78 105 145 
1 1 1 0 
55 liS III 146 
1 1 1 1 
56 87 130 14) 
1 1 1 1 
57 ~4 IJj ISo 
1 1 1 1 
60 93 1J0 1515 



















For 220 tubes 
3 min 94° 
45 sec 94°C 
45 sec 68°C 
60 sec nOc 














I III 189 
0 1 
I /~ 190 
1 1 
(See page 176) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 
samples are indicated as water (H20). 
TGF-~l peR: 





Three primers were used in a single reaction mix to yield two products. In the 
presence of Thr 263 a peR product of 150 bp was amplified, whereas a 129 bp 
fragment was amplified in the presence of the Ile 263 variant. Since no individual 
homozygous for the rare allele (lie 263) was identified the peR was repeated using 







TSG 131 (20f.!M) 
TSG 132 (20f.!M) 































4 5 6 
2 0 
177 
For 60 tubes 
3 min 94° 
45 sec 94°C 
45 sec 68°C 
60 sec nOc 
10 min nOc 
(See page 178) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-6). The molecular weight marker is a 100 bp ladder. Control samples 






FIG 21: TGF-J31 PCR: MUTAGENICALLY-SEPARATED PCR ASSAY 
PROBANDS & REPEATS: 
Three primers were used in a single reaction mix to yield two products. In the 
presence of Thr 263 a peR product of 150 bp was amplified, whereas a 129 bp 
fragment was amplified in the presence of the He 263 variant. Since no individual 
homozygous for the rare allele (Ile 263) was identified the peR was repeated using 




Mastermix: Dry For 110 tubes 
Dry 
Buffer 1 3 min 94° 
MgCI(25Mm) 0.6 45 sec 94°C 
dNTP 1.25M 0.25 45 sec 68°C 
Tag 5U/f.l1 0.05 60 sec nOc 
TSG [31 (2Of.lM) 0.05 §~  10 min nOc 
TSG [32 (20f.lM) 0.045 4.~i 
TSG [33 (20f.lM) 0.075 t~~ 
H2O 7.93 f ~ 6 
DNA-template 0 
TOTAL 10 
1 2 3 4 5 6 7 8 9 10 11 
A I ':I 17 25 33 
4U 4l! AUI2 A080 AI19 Am 
1 1 1 1 1 0 1 1 1 1 1 
B 2 IU 18 26 H2O 41 
49 A005 AU':Il! AI2U AI62 
1 1 1 1 0 1 1 1 1 1 0 
C 3 I1 19 27 J4 42 51r AllTII AIU4 AID AI66 
1 1 1 1 1 1 1 1 1 1 1 
D 4 12 20 28 35 43 H2O A024 A106 Al49 AI71 
1 1 1 1 1 1 0 1 1 1 1 
E ~ 13 LT 
--zg- 36 44 A006 BOO3 AlUl! AISU ALUS 
1 1 1 1 0 1 1 1 1 1 1 
F 6 14 22 30 J7 4~ A004 B004 AI 0':1 AIS4 A17TJ 
1 1 1 1 1 1 1 1 1 1 1 
G 7 15 23 31 38 46 AOOl! BOOS AIIO AlS7 AIT80 
1 1 1 1 0 1 1 1 1 1 1 
H 11 16 24 32 3':1 47 AOITJ A064 H2O AI6U 006 CO 
1 1 1 1 0 1 1 1 0 1 1 
FIG 22: 
(See page 180) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 





FIG 22: TGF-JH PCR: MUTAGENICALLY-SEPARATED PCRASSAY: 
CONTROLS 
Three primers were used in a single reaction mix to yield two products. In the 
presence of Thr 263 a peR product of 150 bp was amplified, whereas a 129 bp 
fragment was amplified in the presence of the Ile 263 variant. Since no individual 
homozygous for the rare allele (Ile 263) was identified the peR was repeated using 















A L 10 
1 3 
B 3 II 
1 1 
C 4 12 
2 2 
D HLO U 
0 1 
E 5 14 
1 1 
F 7 15 
1 1 
G 8 16 
1 1 




























































































































































For 220 tubes 
3 min 94° C 
15 sec 94°C 
45 sec 5SoC 


















(See page 182) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 






MTHFR C677T PCR: PROBANDS 
182 
x100 bp 
After digestion with Hinf I restriction endonuclease the PCR yielded three products: 





Mastermix: Dry Liquid Master: For 220 tubes 
Dry Liquid 
Buffer 1 1.3 3 min 94° C 
MgCI 0.6 0.9 15 sec 94°C 
DNTP 1.25M 1.6 1.3 45 sec 58°C ;±t 
45 sec nOc Taq 0.03 0.03 
MTHFR-S (6f.iM) 1 0.13 
MTHFR-AS(6f.iM) 1 0.13 10 min nOc 
H2O 4.77 1.77 
DNA-template 0 
TOTAL 10 13 
RESTRICTION: 
Hinf 1 0.1 0.2 4;:4 
BufferNr.2 2 2.3 'io'(j, 20 Hrs 37° C 
H2O 7.9 7.9 ." .. (~:S~ ~ 
1 2 3 4 5 6 7 8 9 10 11 
A I 9 17 
2) 33 40 48 AOl2 A080 All9 iUOI 
2 1 1 1 1 0 1 1 1 3 1 
B 2 IU 18 
26 H2O 41 49 AOOS A098 AIW AIbL 
2 1 1 1 0 1 1 1 3 1 0 
C 3 1I IY 
27 34 42 SO AOl9 AI04 AI23 AI66 
1 1 1 1 1 1 1 1 1 2 1 
D 4 12 2U 
28 35 43 H2O -AD2'1 AlO6 A149 . Am 
1 1 1 1 2 1 0 1 1 2 1 
E 5 13 21 29 36 
44 A006 B003 AI08 AlSO ALU) 
1 1 1 2 0 1 1 1 1 1 1 
F 6 14 U 30 37 45 AOO4 13004 109 AI54 A170 
1 1 1 2 1 1 1 1 1 1 1 
G 7 15 n 31 38 46 A008 BOOS AIIO A157 AG&o 
1 2 1 2 0 2 2 2 1 1 1 
H IS 16 24 32 39 47 AOIO A064 H2O AI60 6CO 
1 1 2 1 0 1 1 1 0 1 1 
FIG 24: 
(See page 184) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 






MTHFR C677T PCR: CONTROLS 
184 
After digestion with Hinf I restriction endonuclease the PCR yielded three products: 
246, 175, 71 bp fragments corresponding to the CC, CT and TT genotypes 
respectively. 
MTHFR-PCR 




























































For 50 tubes 
3 min 94° C 
j' 15 sec 94°C 
I 45 sec 58°C 
" ° 45 sec 72 C 
" ° 10 min 72 C 
20 Hrs 37° C 
(See page 186) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-5). The molecular weight marker is a 100 bp ladder. Control samples 








MTHFR C677T PCR: PROBAND REPEATS 
After digestion with Hinf I restriction endonuclease the PCR yielded three products: 








DNTP 1.25M 1 
Tag 0.02 




DSE D 1 (~L) 0.6 
Buffer Nr.Y 1.8 
BSA 1: 10 1 
H2O 6.6 
1 2 3 4 5 
A 2 tu I~ 26 37 
2 3 2 2 2 
B 3 11 1':1 n ,;~ 
3 2 2 2 3 
C 4 12 20 30 3Y 
2 2 2 3 3 
D H2U 13 21 31 40 
0 3 2 2 3 
E 5 14 22 33 H2U 
3 2 1 3 0 
F 7 15 23 34 41 
2 3 3 2 2 
G II 16 24 35 42 
2 2 3 2 3 
H 
') 17 25 ';0 43 















6 7 8 
44 63 YY 
2 0 2 
46 65 102 
3 1 3 
49 77 103 
3 3 2 
54 711 105 
3 2 3 
55 85 III 
2 2 2 
56 87 UO 
0 3 2 
57 94 UJ 
2 3 3 
00 YJ 136 










































For 110 tubes 
3 min 94° 
45 sec 94°C 
45 sec 60°C 
60 sec nOc 


















(See page 188) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-12). The molecular weight marker is a 100 bp ladder. Control 









After digestion with BSE DI restriction endonuclease the PCR yielded 3 products: 
268, 152 116 bp fragments corresponding to the TT, TC and CC genotypes 
respectively. 
G-PROTEIN-PCR 
DNA:PROBANDS & REPEAT CONTROLS 
Mastermix: Dry Liquid 
Dry 
Buffer 1 ~O 1.5 
MgCI 0.75 3.~;$ 1.2 
DNTP 1.25M 1 .$0) 1.5 
Taq 0.02 1 0.03 
GPROT 1+2 (20f.!M) 0.26 l~~ 0.4 
H2O 6.97 . ,cl~J!Slf$~5 ..... 5.37 
DNA-template 0 5 
TOTAL 10 15 
DSE D 1 (f.!L) 0.6 0.6 
BufferNr.Y 1.8 2.2 
BSA 1: 10 1 1.0 




















For 110 tubes 
3 min 94° 
45 sec 94°C 
45 sec 60°C 
60 sec nOc 
2 Hrs 60° C 
(See page 190) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-6). The molecular weight marker is a 100 bp ladder. Control samples 




FIG 27: G-PROTEIN: 
G-PROTEIN peR: 
PROBANDS & REPEATS 
190 
x100 bp 
After digestion with BSE DJ restriction endonuclease the PCR yielded 3 products: 





Mastermix: Dry Liquid Master: For 110 tubes 
Dry Liquid 
Buffer 1 1.5 3 min 94° 
MgCI 0.75 1.2 45 sec 94°C 
DNTP 1.25M 1 1.5 45 sec 60°C 
Taq 0.02 0.03 60 sec nOc 
GPROT 1 +2 (20f.lM) 0.26 0.4 10 min nOc 
H2O 6.97 5.37 
DNA-template 0 5 
TOTAL 10 15 
DSE D 1 (f.lL) 0.6 0.6 
BufferNr.Y 1.8 2.2 2 Hrs 60° C 
BSA 1: 10 1 1.0 
H2O 6.6 6.2 
1 2 3 4 5 6 7 8 9 10 11 
A I Y 
17 L5 33 40 41! AolL AOI!O A1l9 AI61 
3 2 3 3 3 0 3 2 2 3 3 
B 2 10 III 
L6 HLU 41 49 A005 AOYI! Auo AI6L 
3 3 0 3 0 2 3 3 3 3 3 
C 3 
II IY L7 34 42 50 AOIY AI04 AIL) AIM 
2 2 2 2 3 3 2 1 3 3 1 
D 4 IL LU 2ll 35 
4J H:lU AO:l4 AI06 AI4Y AI71 
2 2 1 2 3 2 0 2 3 3 2 
E 5 1J Lt 29 36 44 A006 BOOJ AlUl! AlSo AL05 
2 2 3 3 0 3 3 2 3 2 0 
F 6 14 u 30 37 45 A004 B004 AI09 AI54 AI70 
0 2 3 3 3 2 2 2 2 3 3 
G 7 IS 23 31 3ll 46 AOOll BOOS AllO AI57 AOll6 
2 2 0 1 0 2 1 3 3 2 2 
H 8 16 24 32 39 47 AOlU A064 HLU A I 6U AUU6 
3 3 3 1 0 3 3 3 0 0 3 
FIG 28: 
(See page 192) - 2% Agarose gel electrophoresis showing DNA profile as per table 
above (lanes 1-11). The molecular weight marker is a 100 bp ladder. Control 









After digestion with BSE DI restriction endonuclease the PCR yielded 3 products: 
268, 152 116 bp fragments corresponding to the TT, TC and CC genotypes 
respectively. 
Chi2ace 193 
ACE controls (0) cases (0) sum 
11 25 44 69 
ID 34 55 89 
DD 17 16 33 
76 115 191 
controls (E) cases (E) cont (0-EY2 cas (O-E)A2 co (O-E)A2/E ca (O-E)A2/E 
11 27.46 41.54 6.03 6.03 0.22 0.15 
ID 35.41 53.59 2.00 2.00 0.06 0.04 
DD 13.13 19.87 14.97 14.97 1.14 0.75 
76.00 115.00 23.00 23.00 1.42 0.94 
X 2= 2.35 DF=2 
Hardy-Weinberg Equilibrium? 
controls cases 
observed expected XA2 observed expected XA2 
11 25 23 0.14 11 44 44 0.00 
ID 34 38 0.34 ID 55 54 0.02 
DD 17 15 0.21 DD 16 16 0.01 
n= 76 76 0.69 n= 115 115 0.03 
fl 0.55 f1 0.62 
fD 0.45 f3 0.38 
I D 
cases 143 87 230 
controls 84 68 152 
227 155 382 X2= 1.81 DF = 1 
Chi2agt 194 
AGT controls (0) cases (0) sum 
1 ':I') 44 76 .. Uoo 
2 32 50 82 
3 11 18 29 
75 112 187 
controls (E) cases (E) cant (O-EY2 cas (O-E)I'2 co (O-E)I'2/E ca (O-EY\2/E 
1 30.48 45.52 2.31 2.31 0.08 0.05 
2 32.89 49.11 0.79 0.79 0.02 0.02 
3 11.63 17.37 0.40 0.40 0.03 0.02 
75.00 112.00 3.49 3.49 0.13 0.09 
X 2= 0.22 DF=2 
Hardy-Weinberg Equilibrium? 
controls cases 
observed expected XA2 ob-served expected XA2 
1 32 31 0.05 1 44 43 0.05 
2 32 35 0.19 2 50 53 0.17 
3 11 10 0.17 3 18 17 0.13 
n= 75 75 0.41 n= 112 112 0.35 
f1 0.64 f1 0.62 
f3 0.36 f3 0.38 
1 3 
cases 138 86 224 
controls 96 54 150 
234 140 374 X2= 0.22 DF = 1 
CHI2tgfb 195 
TGF-B controls (0) cases (0) sum 
1 78 114 192 
2 1 1 2 
3 1 1 2 
80 116 196 
controls (E) cases (E) cont (0-E)A2 cas (0-E)A2 co (O-E)A2fE ca (O-E)A2/E 
1 78.37 113.63 0.13 0.13 0.00 0.00 
2 0.82 1.18 0.03 0.03 0.04 0.03 
3 0.82 1.18 0.03 0.03 0.04 0.03 
80.00 116.00 0.20 0.20 0.08 0.06 
X 2= 0.14 DF==2 
Hardy-Weinberg Equilibr:ium? 
controls cases 
observed expected XA2 observed expected XA2 
1 78 77 0.01 1 114 113 0.01 
2 1 3 1.28 2 1 3 1.30 
3 1 1 0.00 3 1 1 0.00 
n= 80 81 1.30 n= 116 117 1.31 
f1 = 0.98 f1 = 0.99 
f3 = 0.02 f3 = 0.01 
1 3 
cases 229 3 232 
controls 157 3 160 
386 6 392 X2 = 0.21 DF = 1 
Fisher's exact (number of cells < 5) 
P = 0.69 
For the purposes of the Hardy-Weinberg calculation, the 0 value for the CC and the 
TT genotype was replaced by 1. The allelic frequencies remained the same 
Chi2atl 196 
AT1 controls (0) cases (0) sum 
1 65 100 165 
2 15 16 31 
3 0 0 0 
80 116 196 
controls (E) cases (E) cont (0-E)1I.2 cas (0-E)A2 co (0-E)1I.2/E ca (0-E)A2/E 
1 67.35 97.65 5.51 5.51 0.08 0.06 
2 12.65 18.35 5.51 5.51 0.44 0.30 
3 0.00 0.00 0.00 0.00 
80.00 116.00 11 .02 11.0? 
X 2 = 0.88 DF=2 
Hardy-Weinberg Equilibrium? 
controls cases 
observed expected XII.2 observed expected XII.2 
1 65 66 0.01 1 100 101 0.00 
2 15 14 0.15 2 16 15 0.08 
3 0 1 0.70 3 0 1 0.55 
n= 80 80 0.86 n= 116 116 0.64 
f1 = 0.91 f1 = 0.93 
f3 = 0.09 I f3 = 0.07 
1 3 
cases 216 16 232 
controls 145 15 160 
361 31 392 X2= 0.80 DF = 1 
For the purposes of the Hardy-Weinberg calculation, the 0 value for the CC genotype 
was replaced by 1 . The statistical significance for the allelic frequencies was kept the 
same. 
CHI2CYPllB2 197 
CYP11B2 controls (0) cases (0) sum 
1 31 48 79 
2 42 54 96 
3 7 15 22 
80 117 197 
controls (E) cases (E) cant (0-E)A2 cas (0-E)A2 co (O-E)A2IE ca (0-E)A2/E 
1 32.08 46.92 1.17 1.17 0.04 0.02 
2 38.98 57.02 9.09 9.09 0.23 0.16 
3 8.93 13.07 3.74 3.74 0.42 0.29 
80.00 117.00 14.00 14.00 0.69 0.47 
X 2= 1.16 DF=2 
Hardy-Weinberg Equiiibrium? 
controls cases 
observed expected XA2 observed expected XA2 
1 31 36 0.71 1 48 48 0.00 
2 42 32 3.20 2 54 54 0.00 
3 2 1 1.00 3 15 1 0.02 
n= 75 69 4.91 n = 117 103 0.02 
f1 = 0.69 f1 = 0.64 
f3 = 0.31 f3 = 0.36 
1 3 
cases 150 84 234 
controls 104 56 160 
254 140 394 X 2= 0.03 DF = 1 
p= 0.97 
CHI211 BHSD2 198 
11BHSD2 controls (0) cases (0) sum 
1 7t;!;. 11 ~ 191 , IV , '''' 
2 1 1 2 
3 1 1 2 
78 117 195 
controls (E) cases (E) cont (0-E)A2 cas (0-E)A2 co (0-E)A2/E ca (0-E)A2/E 
1 76.40 114.60 0.16 0.16 0.00 0.00 
2 0.80 1.20 0.04 0.04 0.05 0.03 
3 0.80 1.20 0.04 0.04 0.05 0.03 
78.00 117.00 0.24 0.24 0.10 0.07 
X 2 = 0.17 DF=2 
Hardy-Weinberg Equiiibrium? 
controls cases 
observed expected XA2 observed expected XA2 
1 76 75 0.01 1 115 114 0.01 
2 1 3 1.28 2 1 3 1.30 
3 1 1 0.00 3 1 1 0.00 
n= 78 79 1.29 n= 117 118 1.31 
f1 = 0.98 f1 = 0.99 
f3 = 0.02 f3 = 0.01 
1 3 
cases 231 3 234 
controls 153 3 156 
384 6 390 X2= 0.25 DF = 1 
Fisher's exact (number of cells < 5) 
P = 0.69 
CHI2MTHFR 199 
MTHFR controls (0) cases (0) sum 
1 64 94 158 
2 14 21 35 
3 2 1 3 
80 116 196 
controls (E) cases (E) cant (O-E)A2 cas (0-E)A2 co (O-E)A2fE ca (0-E)A2!E 
1 64.49 93.51 0.24 0.24 0.00 0.00 
2 14.29 20.71 0.08 0.08 0.01 0.00 
3 1.22 1.78 0.60 0.60 0.49 0.34 
80.00 116.00 0.92 0.92 0.50 0.35 
X 2= 0.85 DF=2 
Hardy-Weinberg Equilibrium? 
controls cases 
observed expected XA2 observed expected XA2 
1 64 63 0.02 1 94 94 0.00 
2 14 16 0.24 2 21 21 0.00 
3 2 1 1.00 3 1 1 0.02 
n= SO SO 1.26 n= 116 116 0.02 
f1 = 0.89 f1 = 0.90 
f3 = 0.11 f3 = 0.10 
1 3 
cases 209 23 232 
controls 142 18 160 




G-PROT controls (0) cases (0) sum 
1 6 9 15 
2 32 47 79 
3 42 61 103 
80 117 197 
controls (E) cases (E) cont (0-EY'2 cas (O-E)1I2 co (O-E)1I2!E ca (O-E)1I2/E 
1 6.09 8.91 0.01 0.01 0.00 0.00 
2 32.08 46.92 0.01 0.01 0.00 0.00 
3 41.83 61.17 0.03 0.03 0.00 0.00 
80.00 117.00 0.04 0.04 0.00 0.00 
X 2= 0.00 OF=2 
Hardy-Weinberg Equilibrium? 
controls cases 
observed expected XII2 observed expected XII2 
1 6 6 0.00 1 9 9 0.00 
2 32 32 0.00 2 47 47 0.00 
3 42 42 0.00 3 61 61 0.00 
n= 80 80 0.00 n= 117 117 0.00 
f1= 0.28 f1 = 0.28 
f3= 0.73 f3 = 0.72 
1 3 
cases 65 169 234 
controls 44 116 160 
109 285 394 X2 = 0.00 OF -1 
